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                                            Abstract 
 
  The current study aimed to gain an in-depth understanding of the lived 
experience of liver transplant patients with Hepatitis C Virus (HCV) recurrence. 
The semi-structured interviews with seven male participants were audio-
recorded, transcribed verbatim and then analysed using Interpretative 
Phenomenological Analysis (IPA). Three master themes were identified: 1) the 
experience of encountering HCV; 2) managing the diagnosis of HCV; and 3) the 
experience of treatment. The first theme highlighted the psychosocial 
consequences of being diagnosed with HCV including fears of contaminating 
others, a fear of disclosing the condition to others and stigma. The second theme 
revealed participants’ resilient coping strategies such as optimism, acceptance, 
and adaptation that helped them to better manage the diagnosis. Participants 
also reported their need for support from both their loved ones and professional 
care providers. Finally, the third master theme focused on the experience of 
receiving treatment, including both the pre-and post-transplant period. 
Participants reflected on their participation in a number of medical trials that made 
them feel like “a guinea pig”. Participants were found to be aware of the risk of 
post-transplant virus recurrence and expressed uncertainty for their futures 
following re-diagnosis. A new cure evoked hope for the future, fuelled a strong 
determination to fight the virus, and generated a lively discussion on the need for 
information provision. The clinical implications of this study lie, in particular, in the 
potential for the improvement in quality of life for patients with a current diagnosis 
of HCV and in those with virus recurrence that are awaiting the new treatment.  
Keywords: Interpretative Phenomenological Analysis (IPA), Hepatitis C Virus 
(HCV), liver transplant, virus recurrence. 
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Glossary of Terms 
 
Alanine aminotransferase (ALT) –enzyme mainly found in the liver. Its level is 
measured to test if liver is damaged or diseased. 
Hepatitis C Virus (HCV) – was initially called non-A non-B before it was identified 
(1989). Hepatitis C is a blood-borne virus that predominantly infects the cells of 
the liver. This can result in inflammation and significant damage to the liver. 
Hepatocellular carcinoma (HCC) - is a primary malignancy of the liver and 
occurs predominantly in patients with underlying chronic liver disease and 
cirrhosis. 
Interferon α (IFN-α) –a family of naturally occurring glycoproteins that have both 
direct antiviral and immunomodulatory activities. 
Master theme- main themes that result from identifying patterns between sub-
ordinate themes. They capture most accurately participant’s views on the 
particular phenomenon under investigation.  
Resilience- individual differences or life experiences that help people to cope 
positively with adversity, make them able to deal with stress and protect them 
from the consequences of adverse experiences.    
Ribavirin (RBV)-is a synthetic nucleoside (guanosine) analogue with a broad 
spectrum of antiviral activity. RBV has been shown to be active in combination 
with interferon (IFN) among patients with chronic HCV.   
Sofosbuvir (also known as Sovaldi) is a nucleotide analog used in combination 
with other drugs for the treatment of hepatitis C virus (HCV) infection. 
Subordinate theme- concise statements that are produced by condensating 
initial exploratory comments attached to a fragment of transcript.                             
Sustained viral response (SVR)- lack of virus in the blood plasma 24 weeks 
after completion of antiviral therapy for chronic hepatitis C virus (HCV) infection.  
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Epigraph 
 
“I do as much as I can, but still learn at the end of the day, when you go to your 
bed at night, it (HCV recurrence) comes back to haunt you, it really does.” (Jimmy) 
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Chapter One: Introduction 
   The following chapter will first commence with an overview of the prevalence 
of Hepatitis C Virus (HCV), ways how the virus can be transmitted and brief 
symptomatology of the illness. As most participants in this study referred to the 
socio-political context of HCV contraction, introducing a short reference to the 
events leading up to contraction will be presented to contextualise participants’ 
accounts. Then, both within the UK and worldwide, changing epidemiological 
patterns of HCV will be described. With a basic knowledge of the virus history 
and prevalence, the reader can next learn about available HCV early treatment, 
liver transplantation and post-transplant therapy after virus recurrence.     
  1.1. Hepatitis C Virus (HCV): Prevalence, Contraction & Symptomatology 
of HCV 
  HCV continues to be a major health care burden worldwide, with incidence 
rates of about 3% and some 170 million people affected by the virus (World 
Health Organisation, WHO, 2014). However, prevalence rates throughout the 
world have reduced following increased awareness within developed countries 
of blood transfusion as the major risk factor associated with spread of the virus 
(Sy & Mazen Jamal, 2006). After 1990, when HCV blood screening was 
introduced, transfusion-related Hepatitis C has virtually disappeared (Poynard, 
2005). In England, infectious donations were attributed to 1 in 520,000 during 
1993-98 and this subsequently decreased to 1 in 30 million during 1999-2001 
(Soldan, Barbara, Ramsay, & Hall, 2003). Within the UK, it is estimated that 
214.000 individuals are infected with HCV, of which approximately 37.000 
reside in Scotland (Public Health England, 2014) including approximately 4.500 
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HCV antibody positive individuals in Edinburgh and Lothian (Health Protection 
Agency, 2011). At present, the prevalence of HCV among intravenous drug 
users (IVDU) can reach even 90% if they are HIV-infected (Sulkowski & 
Thomas, 2003).  
  HCV can lead to both acute and chronic hepatitis infection. For some individuals, 
acute HCV infection is a short-term disease that can be spontaneously cleared 
within weeks after an individual has been exposed to the virus (Poynard, 2005). 
However, the acute form of the virus can, if more severe and untreated, often 
develop into chronic infection. In fact, chronic HCV virus occurs in the vast 
majority of individuals infected (>80%) (Seeff, 2002), because most HCV cases 
are unrecognized until many years after the acute episode. The reason for this is 
typically the paucity of symptoms. The progression of the disease is also mostly 
asymptomatic and silent, therefore, the infection is usually identified only on 
routine biochemical screening or during the course of blood donation. In that 
sense, a vast number of Hepatitis C cases remain both undetected and 
undiagnosed and as such, the progression of the disease cannot be easily 
predicted. 
  Research has shown that progression from acute HCV infection to severe end-
stage liver disease and liver-related death clearly can occur (i.e., Seef, Miller, 
Rabkin, Buskell-Bales, et al., 2000). Usually, it is suggested that HCV becomes 
terminal only when it leads to cirrhosis, the final stage of liver fibrosis (liver 
scarring) (Poynard, Raziu, Charlotte, Goodman, et al., 2001). However, 
developing complications such as hepatocellular carcinoma (HCC) or other 
hepatic dysfunction may also accelerate the progression rates. Thus, hepatitis C 
constitutes an important risk factor leading to increased morbidity and mortality. 
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For that reason, the end-stage chronic disease caused by HCV is currently a 
leading indication for liver transplantation both in Europe and the United States 
(Feray, Gigou, Samuel, Paradis, et al., 1994).  
  1.1.1 Socio-political context of HCV in the UK. 
  Before 1990, when HCV blood screening was introduced and transfusion-
related HCV had been systematically eliminated as a major source of infection 
(Poynard, 2005), thousands of people with HCV were infected through blood 
transfusions and blood products in Scotland, in the 1970s and 1980s. During this 
time, developing post-transfusion non-A non-B hepatitis (NANBH) multiplied 
amongst blood product recipients who underwent transfusions of blood that was 
generated from the USA paid blood donations (Taintedblood, 2011). Most of the 
patients being treated for haemophilia in the 1970s (who were given 
contaminated blood derived from difficult to trace sources) contracted HCV and 
about 20% of them were also infected with HIV (Department of Health, 2007; 
Sabin  et al., 2005). 
  It has been estimated that more than 4500 patients contracted HCV and/or HIV 
through blood transfusion, of whom approximately 2000 have died to date (House 
of Lords Debate, 2011). This public health disaster led to lengthy legal claims of 
patient groups (such as The Hepatitis C Trust and Tainted Blood) for 
compensation for infected individuals and their families, and a public inquiry 
(Department of Health, 2006). Despite resistance of ongoing UK Governments to 
accept those public calls, three government-funded organisations were 
established to financially support the victims of medically acquired HCV.   
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  Further, two Department of Health inquiries were initiated in order to investigate 
the contaminated blood issue. However, ongoing UK Governments continue to 
argue that at the time when the contaminated blood was provided to the patients 
in the course of NHS treatment, there had been no wrongdoing considering 
available knowledge and understanding of HCV and HIV (Department of Health, 
2006). In response, in January 2009 Lord Penrose established a public inquiry 
requiring an investigation into HCV/HIV acquired infection from NHS treatment in 
Scotland. The Penrose Inquiry has published a preliminary (2010) and a final 
report (2015) that summarizes evidence related to the contaminated blood issue 
in Scotland to date.  
  An echo of the circumstances around the HCV infection contraction in the 70s 
and 80s can be found in five accounts within this study. This particular group of 
participants is seldom a consideration within the HCV literature, although they are 
confronted with exceptional social challenges, including stigma and social 
exclusion. The lived experience of people who were infected with HCV through 
blood transfusions extends far beyond the personal experience. The 
consequences of contracting the virus through blood products supplied by the 
NHS over thirty years ago affect also the significant others and the whole social 
environment of the individuals living with HCV. 
  1.2 Treatment of HCV 
  Therapeutic decisions in chronic HCV infection have been made difficult by the 
clinical nature of most acute and chronic infections. This is because, in many 
cases, infections are not even detected unless anti-HCV or HCV RNA tests are 
performed. This does not lessen the danger of chronic HCV, which often does 
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not become symptomatic until the development of cirrhosis some 20 years 
following infection (Thein, Yi, Dore, & Krahn, 2008). Given these considerations, 
HCV is often not diagnosed for a long period after virus exposure, since patients 
are relatively healthy and do not seek medical help. This represents one of the 
major challenges in treating HCV. 
  However, once the disease is diagnosed, patients are offered a variety of anti-
viral treatments, including interferon α (IFN-α) therapy. In the first large-scale, 
controlled trials when INF-α was used for treating Non-A and non-B Hepatitis 
(NANBH), it was shown that the therapy was well tolerated and alanine 
aminotransferase (ALT) levels declined shortly after the trial started (Hoofnagle, 
Davis, Pappas, Hanson, Peters, et al., 1986). Subsequent clinical trials confirmed 
a decreased ALT in about a half of participants, however, the effects of reduced 
levels of ALT did last in only one-fourth of patients when the therapy ended (Tine, 
Magrin, Craxi, & Pagliaro, 1991). The fact that only a small percentage of 
individuals experienced sustained benefits from this type of treatment indicated 
that there was a need for more effective and adequate therapy. 
  Moreover, IFN treatment was found to have several side effects. These include 
‘flu-like’ symptoms, fatigue and depression (Di Bisceglie, Conjeevaram, Fried, 
Sallie, et al., 1989). These side effects that have often an extremely debilitating 
impact on patients’ well-being, indicate that therapy with IFN should be carefully 
administered and that psychological support should be offered to treated 
individuals and their loved ones (Feitelson, 2002).  
  An alternative for Interferon monotherapy is its combination with ribavirin (RBV). 
HCV genotype is used to predict after-effects of this antiviral treatment. In this 
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sense, about 82% of patients with genotype 2 and 3 were found to derive 
sustained benefits from this treatment, whereas only around half of patients with 
genotype 1 showed the sustained virologic response (Manns, McHutchison, 
Gordon, Rustgi, et al., 2001; Hadziyannis, Sette, Morgan, Balan, et al, 2004). A 
number of side effects accompanying administration of IFN and RBV result in 
frequent dose reduction and low adherence to the treatment. Some studies also 
demonstrated that the combined therapy of IFN/RBV can unlikely lead to HCV 
clearance when specific preventing factors are involved (e.g. high baseline viral 
loads or advanced fibrosis) (Backus, Boothroyd, Phillips, & Mole, 2007) 
  1.3 Diagnosis of recurrent HCV after liver transplantation 
  As previously stated, as the disease is typically asymptomatic until many years 
after the acute episode, progression to severe end stage liver failure can occur. 
Orthotropic liver transplantation (OLT) is a life-prolonging option for many 
patients with hepatitis C infection. However, postoperative recurrence of infection 
occurs invariably in all HCV-infected liver transplant patients and constitutes a 
great burden on patients and the whole healthcare system. The severity of post-
transplant inflammation may vary, ranging from a mild form to an accelerated 
recurrence of cirrhosis associated with poor outcomes (Satapathy, Sclair, Fiel, 
Del Rio, et al., 2011). The reinfection is usually identified in half of post-operative 
patients within a year after transplantation and in the majority of OLT recipients 
within five years of surgery (Kia, Matkowskyj, & Levitsky, 2013). Of those ‘re-
diagnosed’ with HCV, only 10% to 30% of patients progress to liver cirrhosis, 
developing graft failure. However, once HCV cirrhosis recurs, patients only 
survive up to five years after transplant (Berenguer, Prieto, & Rayon, 2000).  
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  1.4 Treatment of HCV recurrence 
  To increase survival rates of post-transplant patients and prevent HCV 
recurrence, antiviral therapy is used. This prophylactic treatment involves using 
pegylated interferon (PEG-IFN) and ribavirin (RBV) to achieve sustained viral 
response (SVR). Data suggests that applying the antiviral therapy may 
significantly reduce or slow disease progression (Chalasani, Manzarbeitia, 
Ferenci, Vogel, et al., 2005). However, only a small percentage of patients are 
considered suitable candidates for treatment within the first couple of weeks after 
liver transplantation (Shergill, Khalili, Straley, Bollinger, et al., 2005). The reason 
is reduced tolerability in OLT recipients, who are still recovering from surgery and 
require immunosuppression. Many patients terminate antiviral treatment even 
after one dose of interferon due to side effects and the risk of acute rejection. 
Thus, overall success of prophylactic treatment (20%-30%) in post-transplant 
patients is rather limited and associated with a high percentage of potentially 
detrimental effects leading to therapy discontinuation.   
  The pegylated interferon and ribavirin therapy is continued after virus recurrence 
and as in the case of the prophylactic trials, it was shown that this treatment is at 
least modestly cost-effective. Further, an overall survival rate was only 
demonstrated in patients who were able to attain an SVR, but the percentage of 
these responders ranged from only 25% to 45% of all post-transplant patients 
receiving the same treatment (Sharma, Marrero, Fontana, Greenson, et al., 
2007). In summary, only a small percentage of patients benefit from antiviral 
therapy, while the majority of treated recurrent HCV patients appear to be 
unresponsive to the only available treatment.  
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  The low effectiveness of antiviral post-transplant treatment or lack of an 
alternative therapy for unresponsive recipients does not seem to be, however, an 
existing problem anymore. A new therapeutic drug, sofosbuvir (SOF), has been 
approved by the National Institute for Health and Care Excellence (NICE, 2015) 
and was launched in the UK in February 2015. SOF-based therapy constitutes a 
breakthrough treatment of HCV that has demonstrated a sustained viral response 
rate of over 90% (i.e. Lawitz, Lalezari, Hassanein, Kowdley, et al., 2013). The 
new therapeutic class in combination with ribavirin, or peginterferon plus ribavirin 
can be used in HCV patients with genotypes 1 to 6, where genotypes 1 and 3 
constitute ~90% of all HCV cases. This treatment is also a solution for the pre-
existing problem with low tolerability to the peginterferon alfa that is now the only 
option in the course of treatment.  
  Patients who stayed untreated because of a number of side effects and relative 
contraindications associated with use of interferon, currently receive a 
combination of sofosbuvir with ribavirin (RBV) without including peginterferon 
(PEGINF). According to findings in three studies conducted by Lawitz et al. 
(2013), previously untreated patients with genotype 1 to 4 infection who were 
receiving SOF+RBV+PEGINF or SOF+RBV indicated a high Genotype 1,2 & 4) 
or moderate (genotype 3) sustained virologic response at twelve weeks of 
treatment. In the SOF+ RBV+PEGINF study, 90% recipients with genotype 1 or 
4 infection were found to have a SVR at twelve weeks. In a randomised study 
(Bouliere, Wendt, Fontaine, Hezode, et al. , 2013)., where patients with genotype 
2 and 3 receiving SOF+ RBV, those with genotype 2 demonstrated higher SVR 
rates than the group of patients with genotype 3, 97% to 56%, respectively. A 
high (81%) response rate was also identified in the third study with patients with 
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genotype 1 who were diagnosed with cirrhosis. The results did vary between 
patients with different genotypes or between patients with and without cirrhosis, 
however, overall rates of SVR observed in the research were still the highest that 
have been shown to date for the HCV population. 
  In sum, this chapter has introduced the reader to prevalence of HCV, ways it 
can be transmitted and symptomatology of the illness. Treatment at different 
stages of disease progression was also described. Chapter 2 will now summarise 
HCV literature describing biopsychosocial impact of HCV and its treatment on 
individuals’ quality of life. This chapter will also introduce to the reader a 
theoretical framework that was related to the previous literature and current 
research. 
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Chapter Two: Literature review 
   This chapter aims to explore the wider HCV literature, focussing specifically on: 
1) psychological burden associated with diagnosis of HCV; 2)the biopsychosocial 
impact of HCV on individuals’ quality of life; 3) typical physical and psychological 
signs and symptoms of HCV; 4) impact of HCV on significant others; and 5) 
coping with HCV. Then, based on the previous research and in accordance with 
current findings two theoretical frameworks will be introduced and related to the 
context of HCV.  
  2.1 The biopsychosocial impact of HCV on quality of life 
   Symptoms of a chronic illness such as hepatitis C can have an enormous 
impact on both the mental and physical functioning of the infected person. 
Several studies have demonstrated a significant decrease in the health-related 
quality of life of HCV patients when compared to the general population or other 
control groups (e.g., Ware, Bayliss, Mannocchia, Davis, & The International 
Hepatitis Interventional Therapy Group, 1999; Davies, Balart, Schiff, Lindsay, et 
al., 1994). The most common clinical manifestations of chronic HCV infection 
include fatigue, depression, nausea, musculoskeletal pain or jaundice and these 
can significantly impair patients’ vitality, social functioning and mental well-being 
(Shiffman, 2011; Harris & Richters, 2006). These symptoms can also be the result 
of antiviral treatment that patients undergo or a consequence of post-
transplantation physiological imbalance.  
However, before the HCV symptoms become a burden, and the anti-viral 
treatments and their seriously debilitating side-effects commence, patients have 
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to deal with the diagnosis itself. The personal impacts of a diagnosis of HCV are 
significant. Patients’ lifestyle and the degree of social participation change 
depending on how they approach the diagnosis and how their community 
responds to their ‘new social identity’.    
  2.1.1 Diagnosis and its impact on quality of life 
  Rodger, Jolley, Thompson, Lanigan and others (1999) explored the impact of 
diagnosis by comparing three groups of participants: individuals unaware of their 
HCV serostatus, those aware of their diagnosis and healthy controls. The results 
demonstrated that patients who were aware of their HCV serostatus indicated a 
significant impairment in quality of life scores in seven of eight scales: 1) vitality; 
2) role limitation; 3) physical, bodily pain; 4) general health; 5) social functioning; 
6) role limitation; and 7) emotional and mental health, when compared with 
healthy population norms. They subjectively perceived their health as being 
extremely poor and that this, in consequence, led to a reduction in social 
functioning and emotional difficulties. Individuals who were not informed about 
their HCV serostatus and who were sociodemographically and clinically matched 
with the aware group, scored significantly worse in only three measures (general 
health, mental health and vitality). These results clearly indicate the effect of 
labelling associated with diagnosis and that the diagnosis of HCV may affect (at 
least partially) people’s quality of life. These findings have also been reported by 
other authors (Carithers, Sugano, & Bayliss, 1996; Bonkovsky, Woolley, & the 
Consensus Interferon Study Group, 1999; Koff, 1999). 
   Thus, receiving a diagnosis can significantly influence patients’ perception of 
their health status, which in turn may have negative social and emotional 
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implications. Further, as individuals with HCV are largely marginalised within 
society because of a common association of infection with injection drug users, 
the diagnosis can evoke in them strong emotional responses. 
   2.1.1.1 Burden of diagnosis and stigma 
   The diagnosis can raise various negative emotions, which patients can 
internalise (e.g. self-disgust, regret and personal shame); or externalise (e.g. 
blame, anger and violent outbursts) (Tompkins, Wright, & Jones, 2005). Disbelief 
and shock are also common reactions at the time of diagnosis that can, 
consequently, evolve into enduring anxiety and depression. These responses to 
diagnosis can also lead to long-term psychosocial effects identified via patients’ 
concerns about the health and well-being of their partners and children 
(Chapman, & McManus, 2012). Some people also fear the negative effect the 
diagnosis might have on their social relationships with others, their sexual 
relationships and within familial relationships in the future (Tompkins et al., 2005). 
Thus, the stress associated with a diagnosis of HCV affects all aspects of 
patients’ functioning; psychological, social and physical. In fact, Castera et al. 
(2006) found that the emotional and psychological burden associated with HCV 
diagnosis was comparable to the impact of highly stressful life events such as 
divorce, losing one’s home or being dismissed from one’s job.  
  In this sense, patients’ perception of the burden seems, to a great extent, to be 
determined by their beliefs about the illness and their attitudes towards it, rather 
than by the physical presence of significant liver disease itself. Cordoba, Reyes, 
Esteban and Hernandez (2003) claimed that labelling and stigma related to the 
diagnosis of HCV may be the major causes of the high degree of distress 
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experienced by infected patients. In support of these findings, Rodger et al. 
(1999) demonstrated that participants with HCV showed more depressive 
symptoms than did individuals who were unaware of their health condition. 
  The profound impact of diagnosis is also related to the social stigma and 
discrimination associated with this chronic disease. As it is the case with other 
blood-borne diseases such as HIV, experiences of being stigmatised because of 
having HCV may be related to the predominant social view that the infection is 
rife amongst intravenous drug users. In developed countries, the majority of 
people with HCV have acquired the disease via intravenous drug use (IDU) and 
by sharing or re-using contaminated syringes and needles (Remis, 2004). The 
resultant social opinion is, therefore, that individuals with hepatitis C should be 
blamed for contracting the virus and are seen as being a source of contagion 
(Herek, Capitanio, & Widaman, 2003).  
  This arbitrary social view often causes stigmatisation, regardless of the mode of 
virus transmission (Zickmund, Ho, Masuda, Ippolito, & LaBrecque, 2003). A 
common response of infected individuals towards stigmatisation of HCV is 
concealment of their diagnosis, which often leads to changes in lifestyle, work 
and social commitments (Butt, Paterson, & McGuinness, 2008). Shafer, 
Scheurlen, Felten and Kraus (2005) found that one-third of one hundred and 
three individuals with HCV chose not to reveal their diagnosis to their family, 
friends or even physicians for fear of rejection. Disclosure of the diagnosis to 
loved ones or friends can evoke mixed responses in patients themselves. Many 
of them perceive this act as a moral obligation towards everyone they encounter, 
whereas others are anxious about the unpredictable consequences of disclosure, 
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fearing negative reactions from loved ones or even from other drug users 
(Tompkins et al., 2005). 
   Unpredictable reactions to a diagnosis of hepatitis C have also been reported 
by health care providers. In their cross-sectional study of 504 people with HCV, 
Hopwood et al. (2006) demonstrated that 64.7% (n=326) of participants reported 
having experienced discrimination within health care services. In addition, higher 
levels of reported discrimination were found to be associated with patients’ 
pessimism regarding the prognosis about their future and their disrupted 
interaction with family, friends and other social groups. These findings may 
suggest that reported pessimism can be related to individuals’ previous 
experiences of healthcare discrimination. According to other studies and reports 
(e.g., Anti-Discrimination Board of New South Wales, 2001; Hopwood & Treloar, 
2004), patients with HCV tend to avoid any interactions with medical services in 
order to prevent further discrimination.  
  Perceived discrimination in the healthcare sector can include delaying access 
to blood and liver testing, or even refusal of treatment (Butt, et al., 2008). These 
attitudes towards patients not only dictate the quality of the health care provided, 
but also shape perceptions of the illness in the affected individuals and their self-
care management of the disease (Paterson, Butt, McGuinness, & Moffat, 2006). 
Moreover, stigma and discrimination that are prevalent within communities and 
healthcare services can not only influence patients’ management of the illness 
and the quality of care offered, but also feed into their self-concept and biography. 
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  2.1.2 Biographical disruption and diagnosis of HCV  
  According to Mike Bury’s (1982, p.169) concept of ‘biographical disruption’, a 
diagnosis of chronic illness has the potential to disrupt the structure of everyday 
life, including people’s future plans and requires a major re-evaluating of life 
experiences and self-perception. An important aspect of the process of 
biographical disruption involves the problem of uncertainty. Seeking and 
receiving information about the illness can alleviate some aspects of uncertainty. 
  Gaining knowledge is important in terms of an individual’s ability to cope with 
chronic disease, his or her ability to disclose having the disease, and access to 
social support. However, it can also lead to stigma (Suarez, 2010). Thus, the 
results of acquiring sufficient knowledge about HCV have positive and negative 
aspects. In other words, having a good understanding of the disease can, on one 
hand, lead to self-labelling and attunement but, on the other hand, to a greater 
feeling of stigmatization. According to Suarez (2010), there is also a clear 
correlation between a high level of knowledge, a high level of disclosure and 
various social support groups (e.g. work and significant others).  
   According to Suarez (2010), accurate and more detailed knowledge can 
promote patients’ practice of self-care, minimize the likelihood of infecting others 
and lead to an overall improvement in health status. Conversely, a lack of 
knowledge regarding the transmission of HCV or available HCV treatment 
(Heimer, Clair, Grau, & Bluthenthal, 2002) can cause anxiety (Davis, Rhodes, & 
Martin, 2004). A sense of fear and uncertainty can be enhanced by HCV’s 
unpredictable course and limited access to medical knowledge. Therefore, 
chronically ill individuals often incorporate their own biographical experiences into 
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expert knowledge, and develop their own interpretations of the course of the 
illness (Williams, 1984). This approach prevents them from experiencing 
confusion caused by a lack of medical advice.  
   In her study of people who had been diagnosed with HCV, Magdalena Harris 
(2009), demonstrated that biographical disruption could also be contextual. She 
showed that the process can be dependent on previous experience of disease, 
marginalization or the perception of HCV within given communities. Harris (2009) 
indicated that contextual factors could also provide an explanation of what she 
described as ‘narratives of unconcern’. She found that almost the same number 
of patients in her study described diagnosis of HCV as either a burden or as “no 
big deal”’ (2009, p.1028).   
  A group of ‘unconcerned’ participants was also mentioned by Olsen, Banwell, & 
Dance (2013), who argued that HCV caused no specific concerns amongst the 
IDUs. In their study, most of the participants did not perceive HCV as being 
disruptive, but rather as an inevitable element of their lifestyle, incorporated in 
their identity as drug users and people living in poverty. In the case of these 
individuals, reactions and attitudes to a diagnosis of HCV constituted evidence of 
biographical reinforcement rather than of biographical disruption. 
  However, the majority of the current literature exploring the lived experience of 
HCV has emphasized the disruptive character of diagnosis. According to 
Hepworth and Krug (1999), disclosing a positive status and confusion regarding 
its implications for work and the family environment can lead to social withdrawal. 
They found that individuals with HCV were often re-positioned outside of family, 
friends and work relationships. Uncertainty about the future and social isolation 
17 
 
were identified in the responses of HCV patients (Hepworth & Krug, 1999; 
Burrows & Bassett, 1996).  
   Sladden, Hickey, Dunn, and Beard (1998) observed distinct reactions to HCV 
infection. Some of their participants reported no changes in their lifestyle following 
diagnosis. However, others, as in the studies mentioned above, reported a 
significant change in their lifestyle after receiving a diagnosis. They showed a 
significant decline in their general health, which affected their work performance 
and other daily commitments. In this regard, participants’ concerns were mainly 
related to their occupational future as well as to commencing personal and sexual 
relationships. Disclosure of diagnosis often resulted in the experience of 
discrimination at work and isolation (Sladden, et al., 1998), and in individuals’ fear 
of transmitting the virus to partners and children (Lowe and Cotton, 1999). 
  In summary, a diagnosis of HCV may affect people’s personal and work 
commitments, their future plans and emotional stability. It disrupts their 
biographical continuity and requires emotional adjustment and rethinking their 
role in the social context. Further, diagnosis with HCV can be perceived as a 
highly challenging and life changing event that may influence dramatically 
patients’ quality of life. Experiences of diagnosis are not, however, the only 
disruptions that are reported by patients with HCV. The recognition and 
acceptance of a new ill identity result in further biographical disruption, requiring 
management of symptoms and pursuing a healthy status. Therefore, patients 
with HCV decide to undertake antiviral treatments expecting improvements in 
their condition and quality of life. 
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  2.1.3 Quality of life and the course of treatment 
  The dramatic decline in the self-reported health-related quality of life (HRQOL) 
appears to be related to the course of HCV treatment that poses a six- to twelve- 
month challenge for chronically ill patients. Physical and/or mental side effects of 
anti-viral treatment were found to reduce the quality of life of patients and this, in 
turn, reduced patients’ adherence to medication (Rodis & Kibbe, 2010). 
  Evidence for the association between quality of life and the course of interferon 
therapy has been provided by several studies, which have reported a consistent 
oscillation from considerable decrements in HRQOL during the treatment to 
significant improvements in HRQOL six months after treatment, in patients with 
a sustained virologic response (Ware et al., 2003; Hunt, Dominitz, Bute, Waters, 
Blasi, et al., 1997). The pattern of improvements in measurements (e.g. social 
functioning, general health or health distress) was not, however, identified in 
patients who failed to respond to treatment regimes. Virologic non-responders 
declined significantly in eight of twelve health-related quality of life scales, as 
compared to the general health scores of patients who responded successfully 
to the treatment. 
  As therapeutic options for HCV population were quite limited until 2015 (when 
new, sofosbuvir treatment have been introduced) and patients had to undergo 
quite invasive procedures (interferon and ribavirin treatment) that were at that 
time widely applicable. Commonly experienced side effects with interferon 
monotherapy were fever, headache, muscle aches, and fatigue (McHutchison & 
Hoofnagle, 2000). These side effects were usually intermittent and somewhat 
unpredictable. The number and severity of side effects of interferon varied greatly 
from patient to patient, but they were more frequent when higher doses of 
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interferon were given to patients. In turn, experiences of more frequent side 
effects determined higher rates of discontinuation of therapy and decrease in 
health-related quality of life (Renault, Hoofnagle, Park, et al., 1987). 
  2.1.3.1 Fatigue   
  Fatigue constitutes the most frequent and most debilitating symptom that affects 
HCV patients’ quality of life (Sarkar, Jiang, Evon, Wahed, & Hoofnagle, 2012). 
Fatigue remains a common complaint in the majority of HCV patients both before 
and during the antiviral treatment. However, the severity of fatigue increases and 
becomes more troublesome during the course of antiviral therapy (Hassoun, 
Willems, Deslauriers, Nguyen, & Huet, 2002). Patients’ perceptions of fatigue as 
a highly detrimental side-effect of treatment can lead to the termination and/or 
failure of antiviral intervention (Hassanein, Cooksley, Sulkowski, Smith, et al., 
2004). However, if patients are able to withstand the severity of interferon therapy 
and clearance of the virus is observed, the severity of the fatigue also declines. 
However, a clear association between specific changes in symptoms and 
improvements in the quality of life have not yet been demonstrated in the HCV 
population. Existing evidence (Hassanein et al., 2004; McHutchison, Ware, 
Bayliss, Pianko, et al., 2001) of correlations between successful outcomes of 
treatment and improvements in the quality of life, which encompasses physical 
functioning (i.e. fatigue), may suggest that the eradication of HCV can in turn, 
cause the eradication of symptoms.   
   2.1.3.2 Depression 
   The course of antiviral treatment is also associated with an increased risk of 
depression, which is another predominant symptom of HCV (Schaefer, Capuron, 
20 
 
Friebe, Diez-Quevedo, et al., 2012). In general, the prevalence of depression in 
HCV patients significantly exceeds the incidence of depression identified in 
healthy individuals at 59% versus 21% (Quelhas & Lopes, 2009; Constant, 
Castera, Quintard, Bernard, et al., 2005). Depressive symptoms in response to 
interferon treatment were found in 60% of patients receiving the antiviral therapy 
(Ong, & Younossi, 2004), and in some cases, they were related to suicidal 
intentions and self-harming episodes (Janssen, Brouwer, van der Mast, & 
Schalm, 1994). The association between antiviral therapy and depression is a 
critical predictor for patients’ reduced compliance with treatment regimes. 
Therefore, some studies have posited that early detection and the management 
of the symptoms before and during therapy can increase adherence to the 
treatment (Dwight, Kowdley, Russo, Ciechanowski, et al., 2000).   
  2.1.4 Post-transplant quality of life   
  An impaired QoL and restricted progression to independent living have also 
been reported by HCV patients after receiving liver transplants. Poorer physical 
functioning (Singh, Gayowski, Wagener & Marino, 1999; Feurer, Kelly Wright, 
Payne, et al., 2002), higher rates of depression and anxiety (De Bona, Ponton, 
Ermani, Iemmolo, et al., 2000), and increased levels of fatigue are common 
(Paterson, Gayowski, Wannstedt, Wagener, et al., 2000). However, no research 
has provided a causal relationship between quality of life and several post-
transplant symptoms. For example, it is not clear whether quality of life after liver 
transplantation causes the deterioration of mental and physical functioning or vice 
versa.  
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  2.1.5 Quality of life and virus recurrence  
  Studies that aimed to assess the QoL in individuals with HCV after receiving a 
transplant have demonstrated that participants with recurrent HCV had a 
significantly impaired QoL and more depressive symptoms than did those without 
recurrent infection (Singh et al., 1999) and those who received transplants for 
other reasons (Peterson et al., 2000). In their longitudinal study, Singh et al. 
(1999) examined 59 transplant recipients pre-transplant, and at six and twelve 
months post-surgery. They found that at six months posttransplant, participants 
with diagnosis of HCV recurrence reported significantly lower functional status 
and a reduction in physical functioning from the baseline (the pre-transplant 
scores) than did the other patients in the control group. The HCV patients did, 
however, demonstrate an increase in their QoL after transplantation when 
compared to their pre-transplant results. No difference was recognized in the QoL 
scores when participants with recurrent HCV were compared with those without 
virus recurrence. Furthermore, a tendency towards greater psychological distress 
was also identified in the HCV- recurrent group at six months posttransplant. They 
were found to report greater levels of anger, tension, anxiety and hostility than 
did the control groups. The differences in the quality of life, physical functioning 
and psychological distress between patients with HCV and all the other patients 
became significantly greater at twelve months after receiving the transplant. 
Patients with recurrent HCV continued to score very low with regard to functional 
status and experienced more severe depression when compared to the results 
at the baseline and at six months posttransplant. 
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  Conversely, in their longitudinal investigation (followed up after four years), 
Paterson et al. (2000) demonstrated that only physical functioning declined 
significantly in patients with HCV recurrence. These results suggested that 
individuals with recurrent HCV might gradually adjust to the highly stressful 
circumstances associated with being diagnosed with HCV posttransplant and 
improve in terms of mental well-being, whereas they become more physically 
disabling over time. However, although mental health was not as impaired as was 
physical functioning, other factors such as depression and mood disturbances 
were found to be important contributors to poor QoL in patients with diagnosis of 
HCV recurrence.  
  Lower mental and physical functioning scores at twelve months post-OLT 
reported by patients in the Singh et al.’s study (1999) can be related with negative 
impact of the diagnosis of recurrent HCV. As studies (Roger et al., 1999; 
Younossi et al., 2007) show, patients informed of disease recurrence score lower 
on quality of life surveys than those who do not know about their positive 
serostatus. Thus, patients’ concerns and attitudes to knowledge of the diagnosis 
of HCV recurrence can determine lower mental well-being or HRQOL scores 
despite no physical manifestations of physical decreases (Singh et al., 1999; 
Paterson et al., 2000). As the diagnosis of HCV recurrence is mainly received 
within a year after transplant, patients investigated by Paterson et al. (2000) four 
years posttransplant could adapt to knowledge of the diagnosis and their low 
mood disturbance scores might reflect this shift in their attitude to their illness. 
 Higher psychological distress reported by patients in the Singh et al.’s (1999) 
study can also be influenced by another factor, such as HCV genotype, that was 
not assessed in this research. Paterson et al. (2000) found that HCV recurrent 
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patients with genotype 1b scored significantly lower on psychological variables 
when compared with those with genotype 1a. In this sense, there is a possibility 
that majority of patients recruited by Singh et al.’s (1999) might have represented 
HCV population with genotype 1b, and therefore, scored higher on psychological 
distress. In the Paterson et al.’s (2000) study, the number of patients with 
genotype 1b was scarce that could determine low mood disturbance scores, 
which stands in contradiction to Singh et al.’s (1999) findings. Thus, the 
discrepancy between those two studies regarding the degree of psychological 
impairment can be identified with regard to HCV genotype, reactions to the 
diagnosis of recurrent HCV, as well as, indirectly, by the specific timing of 
collecting HRQOL and psychological distress scores (12 months and 4 years 
post-transplant).  
 However, despite some differences between these two longitudinal 
investigations, both Singh et al. (1999) and Paterson et al. (2000), showed that 
HRQOL scores and self-reported physical functioning do not correlate with 
physical sequelae of liver disease. This is consistent with studies that reported 
slow progression of liver disease and small per cent of patients with cirrhosis (5-
10%) at 2 years post-OLT (e.g., Younossi, et al., 1999; De Bona et al., 1998). 
Furthermore, post-transplant patients with recurrent HCV can be unaffected with 
cirrhosis for approximately seven to twelve years (M=9.5 years) (Gane, 2003). 
This small per cent of patients progressing to liver failure or cirrhosis, makes it 
difficult to explain, why patients in Singh et al.’s (1999) and Paterson et al. (2000) 
studies reported a significant decrease in HRQOL after twelve months and four 
years post-transplant.  
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   The lower HRQOL scores in post-OLT patients might have been assessed 
more effectively and conclusively if current, generic HRQOL questionnaires (e.g., 
the SF-36) were replaced with transplant- and disease recurrence-specific 
HRQOL instruments. These new, sensitive measures that would relate to a 
particular stage of disease progression could provide researchers with more 
adequate explanations of the nuances of transplantation and HCV recurrence.  
  The generic HRQOL instruments that were used in studies with HCV post-OLT 
patients so far were designed to be applicable to a wide range of types and 
severities of health conditions. However, most of these HRQOL measures were 
not patient-centred as the criteria having been evaluated might have not been of 
crucial importance to the participants, or participants’ response options might 
have been limited (Unruh, Weisbord, & Kimmel, 2005; Kalantar-Zadeh & Unruh, 
2005). Thiis information-reducing approach can be changed by allowing 
participants themselves to define the QoL dimensions that are most important to 
them. These patient-specific criteria might, in turn, be elaborated through 
qualitative interviewing, which could give HCV researchers more in-depth and 
conclusive results. This instrument might identify HRQOL criteria often not 
captured in health surveys as being relevant for patients such as, for example, 
relationships, spirituality, or sexuality. (Kalantar-Zadeh & Unruh, 2005). 
  In this sense, spirituality and family were found to be of great importance for 
HCV patients in terms of the development of resilient coping and improvement of 
their mental well-being (Hopwood & Treloar, 2008; see the following themes of 
this chapter). These domains of patients’ functioning after transplantation were 
not identified in any of the studies using generic HRQOL instruments. Thus, by 
extending quantitative measures to semi-structured interviewing researchers 
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could possibly provide more in-depth and clear explanations of, for instance, 
patients’ decrease in mental and physical functioning, beginning a year post-
transplant (Singh et al., 1999). 
  In summary, researchers who used quantitative instruments for measuring 
HRQOL in patients with recurrent HCV mainly focused on identifying and 
quantifying some mental (e.g., emotional problems, psychological distress, 
depression) and physical components (e.g., physical health, bodily pain). Their 
results were comparably consistent in indicating decreased overall health scores, 
very low physical functioning scores, as well as higher levels of depression and 
fatigue (Singh et al., 1999; Paterson et al., 2000). However, they could not 
provide an explanation of causal relationship between scores from each 
dimension. Furthermore, HRQOL instruments used in OLT recipients did not 
include a cognitive function domain and psychosocial dimensions that could 
clarify decreased levels of depression and emotional distress recognized in 
patients after twelve-month post-transplant (Sing et al., 1999; Gayowski et al., 
1999).  
  Psychosocial dimensions have been introduced in qualitative research on 
HRQOL. Dudley et al. (2007) revealed that stigma and disease uncertainty 
experienced after liver transplantation might have an adverse impact on quality 
of life in HCV patients. These findings are consistent with other qualitative studies 
with HCV patients that identified a sense of uncertainty related to future health 
and life expectancy, as well as to a fear of organ rejection (Forsberg et al., 2000). 
The sense of uncertainty regarding the posttransplant unpredictability of patients’ 
lives and the prospect of death seem to explain Sing et al.’s (1999) findings of 
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increased psychological stress and depression in persons with HCV recurrence, 
reported twelve months posttransplant.  
  This ongoing disease uncertainty, mental distress and feelings of stigma appear 
to accompany all stages of HCV progression and treatment. However, their 
impact on a patient’s quality of life is shifting and is likely to change as he comes 
into contact with other individuals such as family members (Hopwood & Treloar, 
2003).   
 
   2.1.6 Impact of HCV on loved ones 
   Despite experiencing fear and uncertainty, many patients decide to disclose 
their illness to others. This difficult step appears to be vital in order for individuals 
with HCV to learn to accept their condition and to deal with it effectively. For 
example, it is important in terms of receiving physical, emotional and financial 
support when their lives become strongly influenced by the treatment and its side 
effects (Sgorbini, O’Brien, & Jackson, 2009). However, family members of 
chronically ill individuals are not only caregivers, they also share the experience 
of the disease and losses associated with it with their partners/parents, such as 
the loss of independence, the loss of freedom or the loss of a former lifestyle 
(Eriksson & Svedlund, 2006). These losses and stresses in everyday life that 
accumulate in partners over weeks or even years might change the structure of 
their relationships dramatically. Accumulated anxieties and anger that are not 
communicated well or at all can create a distance between partners. However, 
despite the difficulties, frustration and anger, some relationships become stronger 
and the experience of hepatitis C brings them even closer (Sgorbini et al., 2009).   
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  Individuals who live in these strong and stable relationships may rely on their 
partners in terms of moral support, as well as their help in coping with diagnosis 
and treatment regimens. Thus, these positive family relationships can be defined 
as protective factors that build resilience in relation to coping with HCV (Hopwood 
& Treloar, 2008). Caring and competent adults in the family are, however, only 
one of many adaptive and protective factors that enhance a person’s ability to 
cope with a serious threat. I will now introduce some factors and processes that 
can contribute to positive outcomes in spite of exposure to severe adversity such 
as HCV.  
 
  2.2 Coping with HCV 
  According to Sachs (1991), coping strategies have an important impact on 
disease outcomes. They constitute a defence mechanism against either: 1) the 
physical and psychological stress, or 2) an enhanced stress response that 
interferes with the likelihood of recovery. Effective coping can reduce the stress 
of illness and maintain a positive self-concept and emotional balance (Ogden, 
2004). It is also important to acknowledge an idiosyncratic perception of the 
disease amongst affected individuals and the variation in the application of coping 
strategies despite the identical symptomatology. 
  There is a paucity of research focusing on HCV and coping strategies. The 
impact of different psychosocial determinants (such as stigma and feelings of 
contamination) that add to the psychological distress of HCV is a major issue that 
is being investigated (Moore, Howley, D., & Bradley, 2008; Conrad, Garrett, 
Cooksley, Dunne, & MacDonald, 2006; Fraser & Treloar, 2006), whereas 
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research demonstrating what HCV patients do when they are confronted with 
psychosocial adversity is somewhat rare (Stewart, Mikocka-Walus, Morgan, 
Colman, et al., 2012). Furthermore, most of the small number of studies 
(Hopwood et al., 2006) investigating coping strategies in the HCV population refer 
to the resilient style of coping as the most adaptive and widely applied form of 
responding to stress-evoking adversity amongst affected individuals.   
   2.2.1 Resilient coping 
   Individuals cope with stressful life events in a resilient way when they 
endeavour to overcome adversity by invoking protective factors (e.g., optimism, 
psycho-spiritual factors) and previous life experiences (Richardson, 2002). For 
adults, the preservation of health and adapting successfully to acute stress in the 
face of chronic adversity provides key resilience outcomes (Charney, 2004). 
Resilient responses to stress can be perceived as potential protective factors that 
promote positive cognitive reappraisal and the application of active problem-
focused coping strategies. In this sense, individuals facing adverse life situations 
tend to re-evaluate what they experience in ways that are more acceptable and 
positive. This reframing of adverse experiences allows them to identify alternative 
ways to maintain their well-being (Seligman, Steen, Park, & Peterson, 2005). 
Meaning-making processes utilised by resilient individuals in order to decrease 
stress reactivity and to promote recovery often involve religious and spiritual 
practices (Pargament, Smith, Koenig, & Perez, 1998). Religious strategies were 
found to be perceived by a few HCV patients as a method of healing (Stoller, 
Webster, Blixen, McCormick, et al., 2009). Many patients used prayers as a form 
of fighting HCV and interpreting the virus as part of God’s plan. When certain 
aspects of HCV appeared to be overwhelming and difficult to manage on their 
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own, religious patients turned the illness over to God, shifting the responsibility 
for a possible cure or restricting the progression of the disease to a higher power. 
Patients’ beliefs and trust in God’s decisions regarding their health and well-being 
have been learned from past experiences when God challenged them but never 
failed to rescue them in the end (Stroller et al., 2009).  
  In their study on resilient coping amongst patients with HCV, Hopwood and 
Treloar (2008) found that adaptive coping strategies drawn from past experience 
could be used to facilitate patients’ adherence to treatment and to manage the 
diagnosis. The establishment of a healthy lifestyle, identifying supportive social 
networks, staying occupied with reduced working hours, and exploring prior 
experiences of having been treated for chronic illness shaped patients’ resilience 
when they were routinely confronted by treatment challenges. Hopwood and 
Treloar (2008) also recognised and confirmed previous findings that spirituality, 
determination and optimism can enhance the development of resilient coping 
(Bonanno, 2004; Tedeschi & Kilmer, 2005), particularly in relation to the side-
effects of the treatment.  
   2.2.2 Side effects and coping 
   A detailed report by Hopwood, Treloar and Redsull (2006), reflecting on 
experiences of HCV treatment and its management, indicated a number of coping 
strategies such as planning, seeking support, remaining occupied, adopting a 
positive attitude and a healthy lifestyle, play an important role in reducing the side 
effects of highly invasive antiviral treatment. Patients’ reactions to antiviral 
treatment and their coping strategies to reduce the effects of the treatment can 
be often idiosyncratic.  
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  According to patients’ accounts published by Hopwood et al. (2006), particularly 
important factors for maintaining mental well-being during the prolonged 
treatment appeared to be work or any form of activity that helped patients to stay 
occupied. Being occupied, even by engaging in small projects, provided patients 
with a sense of achievement and accomplishment. Patients who remained 
employed despite antiviral therapy, reported that giving up work would deprive 
them of the opportunity to escape from the reality of treatment, and from 
necessary distraction and stimulation. This approach to treatment and its 
consequences seems to be consistent with the findings of the study by Kausar 
and Yusuf (2011), which revealed avoidant coping strategies in post-treatment 
patients. In this regard, HCV patients seem to choose to remain occupied during 
the course of antiviral therapy in order to distance themselves from the stressor 
and to increase feelings of self-efficacy.  
  A sense of competence and control over the situation while receiving on the 
antiviral treatment can be also achieved by maintaining a healthy lifestyle. HCV 
patients tend to adopt healthy dietary practices such as drinking more water and 
ensuring good nutrition, while avoiding certain types of food (i.e. salt, ‘spicy’ food 
and foods containing little protein), drugs and alcohol (Stoller, et al., 2009; 
Hopwood et al., 2006). Some respondents in Stoller et al.’s (2009) study also 
emphasised the importance of eating specific foods (i.e. spinach, calf liver) and 
drinking specific liquids (e.g., green tea, freshly squeezed juices) because they 
believe in their cleansing and liver-strengthening effects.  
  2.2.3 Supporting relationships 
  Support from partners, families and support groups was found to be an 
important social variable in managing the physical and psychiatric side effects of 
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HCV treatment, particularly depression (Hopwood et al., 2006). Significant others 
help HCV patients to maintain their QoL during lengthy and repetitive  
treatment periods, and are perceived as a major non-medical factor influencing  
patients’ decisions to begin the treatment in the first place (McNally et al., 2004). 
Patients’ mood swings and symptoms of depression that result from the interferon  
treatment often make it difficult for them to remain supportive of their partners 
and children (Hopwood et al., 2006).  
  Therefore, this is the time when their partners need to take over responsibility 
for the children and the household. The entire family has to cope with the frequent 
outbursts of anger, hostility and irritability that accompany interferon treatment 
(Kraus, Schäfer, Faller, Csef, & Scheurlen, 2003), and which often disturb the 
harmony of family life. Thus, partners and children have to adjust sensitively to 
constantly changing circumstances and the needs of their ill partners/parents to 
balance their need for care and their need for private space (Hopwood et al., 
2006).  
  The role of spouses and children also becomes extremely important in the 
patients’ early recovery after receiving a liver transplant. They bring the family 
together and provide stability that can balance the emotional chaos experienced 
by people following surgery (Forsberg, Backman, & Moller, 2000). According to 
the lived experience of liver transplant recipients, family members sharing and 
explaining medical information to them post-transplant is of particular importance. 
Having explored the extant psychosocial literature on HCV, I will now turn to the 
theoretical perspectives that underpin and inform the current study. 
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  2.3 Theoretical perspectives on HCV in the current study. 
  Whilst existing literature on psychosocial consequences of HCV on patients’ 
quality of life has been often focused on biographical disruption and stigma 
(Suarez, 2010; Harris, 2009), this is also an aim of the theoretical exploration in 
the current research. The theory of stigma and social identity that will be 
presented in this section resonates with the previously identified perspective of 
HCV patients and the researcher’s interest in how participants’ lives were affected 
by the diagnosis of HCV, the treatment and the recurrence of the virus. 
Furthermore, the secondary objective of this research is to explore the coping 
strategies that individuals with HCV use in order to deal with the biopsychosocial 
impact of HCV. According to the extant literature presented previously in this 
study, a coping strategy that was predominantly adopted by individuals with HCV 
when facing the adversity caused by illness appeared to be related to resilience. 
Therefore, another theoretical perspective chosen for the current study is 
resilience theory. 
   2.3.1 Resilience theory 
   Resilience refers to a phenomenon or a dynamic process involving adaptive 
coping and adjustment in the face of significant changes in life circumstances and 
the experience of adverse situations (Bonanno, 2004). An emerging body of 
evidence shows that even when confronted with highly disruptive and 
traumatising life events, people are able to use both their internal and external 
resources as protective factors in order to cope with adversity successfully 
(Rutter, 1990). The concept of resilience consists of two critical conditions: 
 
33 
 
Fig.1. The two-component construct of resilience (Luthar, Cicchetti, & Becker, 2000). 
 
 
 
    
  
 
   Thus, resilience can be perceived as a form of effective and successful coping 
and adaptation applied appropriately with regard to adversity (Zautra, Davis, 
Reich, & Nicassario, 2008). Resilient coping requires applying various supportive 
strategies and mechanisms that can be identified within individuals and 
communities. In this sense, people who more likely use resilience in response to 
exposure to a potentially traumatic event, have multiple social (e.g., supportive 
relationships, community resources) and personal (e.g., temperament) resources 
that help them to cope with stress and achieve positive outcomes (Hobfoll, 2002).  
The adaptive and supportive factors can also include individual differences or life 
experiences that help people to deal with stress in the future, and which constitute 
protection from the development of mental health problems under stress-evoking 
circumstances (Richardson, 2002). Self-efficacy is essential for resilience (Rutter, 
1987). A resilient person is optimistic and hopeful about the outcome of even the 
most difficult situations, such as chronic physical illness (Peterson, 2000). 
Resilient people have also good social competence and communication skills. 
Therefore, when they are challenged by adverse events, they also have access 
to more social support, an important aspect of resilience, even though they are 
still capable of managing life challenges on their own.  
Resilience 
(1) Exposure to 
significant threat or 
severe adversity 
(2) The achievement of 
positive adaptation 
despite adversities 
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 Resilience might also influence an individual’s appraisal of a situation as stressful 
or harmless and impact his or hers coping response to it (Skodol, 2010). Resilient 
individuals that score high on optimism and self-esteem have been found to be 
more likely to engage with a problem and be action orientated in their coping 
strategies (Holahan & Moos, 1991). This approach results from their belief that 
they are capable to change the outcomes of an adverse life event for the better 
(Taylor, Kemeny, Aspinwall, & Schneider, 1992).  
 Living with a chronic illness such as HCV means resilient coping with an 
accumulation of stressors that can ultimately give rise to depression and anxiety 
(Alonzo, 2000; Chalfant, Bryant, & Fulcher, 2004). Diagnosis of HCV is generally 
the point at which the cascade of stressors associated with chronic illness begins 
to build. Receiving a diagnosis of HCV is likely to be one of the most stressful life 
adversities an individual experiences. However, the diagnosis does not inevitably 
lead to adverse mental outcomes if an affected individual demonstrates a resilient 
pattern with little perturbation in levels of psychological and physical well-being 
(Fife, 2005; Valle & Levy, 2008). Maintaining prosocial contact, having a caring 
family, spirituality, self-confidence and optimism can enhance individuals’ 
resilient responses to diagnosis and their ability to cope with an ongoing adversity 
(Bonanno, 2004; Tedeschi & Kilmer, 2005). 
The two-component construct of resilience (Luthar, Cicchetti, & Becker, 2000) 
can be used not only to illustrate positive responses to diagnosis of HCV but also 
to explain adaptive outcomes in a therapeutic context. There are several 
indications for the construct of resilience being relevant to the experience of 
receiving HCV treatment. To begin with, this regimen is long, either 24 or 48 
weeks depending on factors like viral genotype. Second, the treatment drugs 
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interferon and ribavirin are associated with severe and sustained physical and 
psychiatric side-effects (Hopwood & Treloar, 2005). Finally, individuals with HCV 
who had undergone liver transplantation and had been diagnosed with HCV 
recurrence are now exposed to new challenges and burdens related to their 
chronic condition. Drawing on pre-transplant experience of living with HCV, they 
might or might not employ the factors and processes that facilitated coping during 
the initial treatment. Therefore, this thesis aims to explore the socio-contextual 
factors that enhance participants’ ability to adapt to both pre-transplant and post-
transplant circumstances and maintain stable level of physical and psychological 
well-being. 
   2.3.2 Social identity and stigma 
   Chronic illness can cause major disruption to core components of identity, such 
as social roles and relationships. It has the potential to reconfigure one’s very 
social identity and cause a disruption of the expected and the ‘usual’ that 
establish people’s daily routine (e.g. physical activities, work) and the self-
concept (Mattingly & Garro, 2000). Anything can alter one of these, and then this 
alteration might very likely lead to creating a stigma (Markowitz, 1998). 
  The concept of stigma is a significant factor in many chronic illnesses and 
disabilities. When people do not meet social expectations because of features 
that are atypical or unwelcome, they are depreciated from being just members of 
society to being ostracized. Stigmatised individuals respond to societal exclusion 
and devaluation in a variety of ways. They often act as if the illness or disability 
has not affected them and can even pretend they have no impairment or less of 
a stigmatized identity (Joachim & Acorn, 2000). This form of reaction, however, 
is only possible when stigmatizing attribute is not visible.    
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   Psychologists and sociologists have distinguished two concepts of stigma, 
namely felt stigma and enacted stigma (Scambler, 2004). The former refers to 
the way how the person who is affected perceives and internalizes the 
devaluating circumstances. One of the components of felt stigma is the fear of 
being labelled by others, even though the reason for stigmatization is not 
particularly evident or even visible to others. Enacted stigma, on the other hand, 
is related to specific responses from others towards the stigmatized individual. 
This type of stigma is usually associated with visible manifestations of individual’s 
differentness.  
  The cultural invisibility of HCV can suggest that stigma and the social identity of 
affected individuals may be different from those who have visible attributes that 
make their disability evident and easy to target. The felt stigma might also not be 
clearly established when infected individuals remain asymptomatic and are not 
even aware that their health and well-being are at risk of deterioration. Their 
stigmatized identity is then exclusively defined by diagnostic experience or their 
interaction with medical professionals and others (Brown, 1995).  
  As society expects from its members to classify individuals by commonly 
acceptable features, illness may contribute to creating a new social identity of 
incapability (Goffman, 1963). In this sense, individuals who have an attribute 
categorized as socially unwanted (e.g., chronic illness) develop ‘a spoiled identity’ 
that leads, in turn, to intolerance and aversion. However, the extent of 
discrimination and the content of stigma may vary depending on how the same 
illness is perceived within different societies and cultures. Thus, as HCV infection 
occurs mainly, in developed countries, in people who inject drugs, a strong 
association between injection and infection can be found in the ubiquitous, 
stigmatising responses towards individuals with HCV (Harris, 2005).   
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  Stigmatized individuals can also respond to stigma with resistance and rejection 
(Dudley, 1983). These strategies promote changes in an existing societal order 
and have the power to preserve positive self-identity (Stuenkel, & Wong, 2009). 
Finally, isolation can also be a common reaction to stigma. Individuals might limit 
their social circles to small numbers of people who enhance their feelings of 
normality and who are often afflicted in the same way (Camp, Finlay, & Lyons, 
2002). These two forms of reactions to stigma can potentially be related to HCV 
individuals. Participants who contracted HCV through blood transfusion and who 
could, therefore, perceive themselves as innocent ‘victims’ of the socio-political 
system might adopt a pro-active approach to stigmatisation by, for example, 
speaking out against existing regulations (The Penrose Inquiry preliminary 
Report, 2010). Conversely, they might isolate themselves out of fear of infecting 
others and fear of disclosure (Lowe & Cotton, 1999).     
      
  2.4 Research objectives 
  This study aims to make a substantial contribution to previous research on liver 
transplant as a result of HCV by addressing the psychosocial consequences of 
HCV recurrence post-transplantation and the consequences of a new HCV 
treatment. It will focus chronologically on the lived experience of HCV beginning 
at the point of diagnosis and continue through receiving a transplant, post-
transplant treatment and being offered a new cure. The psychosocial challenges 
accompanying this long journey of living with HCV will also be explored from the 
patients’ perspective. This particular population was chosen for the current 
project as it was found to be under-researched in terms of patients’ perspectives 
on living with virus recurrence and their coping strategies. Thus, the current study 
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is the first of its kind to explore HCV patients’ responses towards post-transplant 
virus recurrence and aims to identify the factors described by the participants 
themselves that may influence their psychological wellbeing after having had a 
liver transplant and experiencing recurrence of the virus.  
  2.5 Aims and research questions 
  Much of the research to date on the outcomes of liver transplantation in patients 
with hepatitis C virus has approached the problem from either the perspective of 
the medical provider or the healthcare system (e.g. Satapathy, 2011). The current 
study aims to gain an in-depth understanding of experiences of HCV for patients 
diagnosed with infection recurrence after liver transplantation, using an 
Interpretative Phenomenological Analysis (IPA) (Smith & Osborn, 2004; Smith, 
Flowers & Larkin, 2009). The primary research question is therefore: 
 
To explore the psychosocial experience of living with recurrent HCV 
following a liver transplant. 
 
   In addition, there are a number of secondary research questions:  
1) How do the participants’ attitudes and life expectations change (if at all) after 
an initial diagnosis of HCV, and after being diagnosed with virus recurrence? 
2) What does it mean to live with recurrent HCV?  
3) In what ways is the quality of life of participants affected by liver transplant and 
virus recurrence?  
4) How do the participants cope with their chronic condition? 
5) In what ways did the new HCV cure change participants’ expectations and 
attitudes to life? 
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  In summary, this chapter has reviewed the extant literature in relation to the 
biopsychosocial impact of living with HCV, considering both the diagnosis and 
treatment of HCV. Studies that have been discussed in this chapter indicated that 
patients with HCV had a poorer generic and disease specific HRQOL than the 
healthy control groups and other clinical populations. Further, their self-reported 
impairments of quality of life have been shown not to be related to the degree or 
severity of the liver disease, but to other effects, such as the impact of diagnosis, 
stigmatization of HCV, treatment and its side effects. This chapter has also 
explored resilient coping employed by the HCV population to deal with the side 
effects of pre-transplant antiviral therapy, as well as with post-transplant health 
challenges. Patients with HCV were found to establish healthy lifestyle, engage 
in spiritual practices, seek social support and stayed occupationally active in 
order to reduce adverse experiences of diagnosis and treatment.  
 This chapter has also introduced two theoretical perspectives on resilience and 
stigma in order to provide an insightful framework for understanding participants’ 
accounts in the current study. The concept of stigma was approached as a major 
disruptive factor in a chronic illness, such as HCV, that could lead to social 
isolation and rejection of affected individuals. It was also recognized that 
stigmatized people could respond actively to stigma with resistance. Therefore, 
resilience as a dynamic process involving adaptive coping and adjustment in the 
face of adverse situations was discussed in the context of HCV. The chapter 
closes with an overview of the current study’s aims and objectives. Chapter 3 will 
now detail the research methodology applied for this investigation.  
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Chapter Three: Methodology 
  3.1. Introduction 
  This chapter aims to provide an overview of qualitative methodology as well as 
those approaches which were considered as potential approaches to data 
analysis in the current study.  First, however, a rationale for the chosen approach 
(IPA) will be provided and discussed in terms of fit with the aims and objectives 
of the study. The process of recruitment, data collection and data analysis will 
follow along with ethical considerations.  
 
  3.2 Overview of Qualitative Research 
  Qualitative research has established itself in many social sciences, for instance 
psychology and nursing. There is a great variety of qualitative methodological 
approaches that can be used by both novices and experienced researchers and 
that can reflect different premises and aims of particular research. These different 
methods might be described as interpretative positions represented by qualitative 
researchers in order to engage in specific socially organized settings that they 
explore, describe and analyse (Miller & Dingwall, 1997).  
  Unlike quantitative researchers who aim to produce a set of theoretically defined 
generalisations derived from the critical shifting of data, qualitative researchers 
are not interested in identifying objectives and facts in the world, but in peoples’ 
perceptions and experiences of their ‘subjective’ realities. Further, qualitative 
researchers do not intend to recognize any cause-effect relationships between 
several aspects of participants’ behaviour, because they are more concerned 
with how individuals make sense of their behaviour and how they manage 
relationships within it.   
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   In this sense, qualitative interpretation of data is not focused on finding 
correlations between particular variables that can be measured and observed. 
Thus it is not something that positivists would describe as a subject worthy of 
scientific study. The qualitative approach rejects a realistic view on research that 
assumes there is a single reality that should be investigated by scientists (using 
as objective and unbiased methods as possible). The qualitative researcher aims 
to ‘see through the eyes’ of participants instead (Bryman, 1988), and favours a 
subjectivist aim to a positivist, fact-based objectivity of context-isolated social 
investigation. Qualitative data are not a set of facts but are an outcome of an 
interaction between the researcher and participant, influenced by the 
researcher’s own interpretations of data and biases.  
  Although qualitative data is to some extent biased by the researcher’s 
descriptions and analysis, it is- for the most part- situated in participants’ own 
interpretations as the most central data. This process allows the author to validate 
in-depth material that is provided by those people being studied and not by the 
researcher’s analysis only. Qualitative data that is determined by the participants’ 
perspective reflects the complexity of a study’s subject and can be used to 
confirm or disconfirm existing theories, or to develop new empirically grounded 
theories. Most qualitative research tends to discover new information and moves 
from single cases to a wider understanding of a specific phenomenon under study. 
However, qualitative research does not seek to make excessive generalisations 
about investigated situations or human thoughts and behaviours. Rather, it builds 
a frame of reference for future investigations and offers a conclusive 
interpretation of a subject in its everyday context.   
 
 
42 
 
  3.3 Qualitative Research Approaches 
   3.3.1 Grounded theory  
   Grounded theory is one of the qualitative research methods that is used both 
within and outside of social sciences. Glaser and Strauss (1967) who proposed 
this method, argued that theories developed using their model could be applied 
in practice situations. In this sense, grounded theory is of particular value for 
social work and theory-based interventions that can be tested in practice settings. 
Thus, if a primary aim of this study was to recognize possible implications for 
intervention for patients with recurrent HCV and test those in practice, grounded 
theory would be considered as a potential methodology to apply. Nonetheless, 
this research aims to capture the meaning people ascribe to HCV, and not to 
immerse in data and deductively test it.  
   Grounded theory in its design is used to build a novel theory about unknown or 
little-known phenomenon (Willig, 2008). It was considered as not being suitable 
for this Master’s degree project which requires a considerable review of previous 
research preceding collecting data.  Moreover, a major objective of this project 
was to understand what patients’ experiences of recurrent HCV after liver 
transplant and not to produce a theory based on the gathered data. Therefore, 
this approach was deemed unsuitable both in terms of interpretation and 
explanation. In addition, the method of data gathering in grounded theory does 
not require the use of pre-structured interview schedules or does not recommend 
any specific preparations for data collection. Accordingly, the researcher is 
encouraged to proceed freely with interviews that should result in genuine 
interactive data (Glaser, 1992). This approach would perhaps be appropriate for 
an experienced qualitative researcher, however for me as a novice, a pre-
formulated interview schedule was necessary to facilitate a comfortable 
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interaction with participants. In addition, using semi-structured interviews for the 
purpose of this research giving the patients an opportunity to direct the content 
and for the researcher to capture an inductive, idiographic perspective of the 
interviewees.  
   Grounded theory can also overwhelm with methods being used for data 
gathering that may include observation, interviews or diaries. This kind of variety 
of methods produce a large amount of data that then need to be organized into 
categories and groupings of categories. Constant comparative analysis is used 
to undo emergent patterns and transform them into other networks of categories, 
until new data reaches its ‘saturation’ (Charmaz, 2006). In order to achieve a 
point of saturation, which is where no new categories emerge, grounded theory 
requires a large amount of data and considerable time spent on its analysis. 
Considering time constraints and the limited size of the Master thesis, I 
questioned whether it was feasible to define a complete, well-defined ‘grounded’ 
theory that would not reveal signs of premature theory generation.  
    
   3.3.2 Thematic analysis 
   Thematic analysis (TA) can be considered as the most accessible approach for 
a student who is new to qualitative analysis (Braun & Clarke, 2006). It contains 
core elements of the data analysis procedure (i.e., familiarizing with the data, 
generating initial coding, searching for themes) that can be found in many other 
qualitative approaches (e.g., IPA, Grounded Theory) and, therefore, it may be 
ideal for students who then should not be obliged to give their analytical approach 
a label. However, despite the grounded stance of the TA’s supporters (Braun & 
Clarke, 2006), who gave a full account of this approach and its application, for 
others (Dempster, 2011; McCorry, Demster, Clarke & Doyle, 2009) TA represents 
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a technique employed in the analysis of qualitative data rather than a 
methodological approach per se. 
   TA, unlike other qualitative research methods, is not allied to a specific 
epistemological position. This on one hand gives a researcher a form of analytical 
freedom, but on the other, it may be problematic for them to clearly explain that 
the method they used was thorough and rigorous. Consequently, thematic 
analyses can vary considerably, depending on which of the previous research 
and theory the recent findings are most likely to be related to. In summary, TA’s 
lack of allegiance to the specific theoretical or ideological principles makes it 
difficult to progress from text analysis to meaningful results that can support 
researcher’s theoretical predictions.  
   In this study, a more generic phenomenological approach was required to 
gather and make sense of data. It was my intention, as a researcher, to focus 
upon patients’ experiences of a particular phenomenon that is clearly defined in 
the research question and grounded in an epistemological position. It was 
important for me to give to the reader an exact account of the method I used and 
the research aims I chose for my study. In this sense, TA, if understood as a 
specific approach that is free from theoretical and ideological background, seems 
to be insufficient to give a clear account of what a researcher hopes to achieve 
from the analytical procedure and how exactly they intend to accomplish their 
aims.  
   
   3.3.3 Phenomenology 
   Phenomenology, as a philosophical approach posits that there is a reality that 
can be studied, but it also states that this reality is perceived by individuals in 
different ways and it is these perceptions which are the focus of phenomenology. 
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In other words, a phenomenological stance views a person’s own perception of 
the world as primary and every attempt to report on the individuals’ experiences 
will result in distortion of their stories by the phenomenology of the person 
reporting.  
   Phenomenology by allowing this hermeneutic distortion formalizes the 
possibility of doing qualitative research, where subjectivity of the researcher’s 
interpretation of the participant’s words is approved. It rests on the premise that 
human experience is situational, contextual and the way people look at it depends 
on their particular point of view on the world. However, the authentication and 
enhancement of the original meaning contained in people’s experience can be 
preserved if we, as researchers, lay aside the predominant understandings of the 
explored phenomena and reconsider our immediate experience of them (Crotty, 
1996).    
    Human experience is never to be perceived in isolation, but is always based 
on intentionality: that is people’s thoughts, actions, expectations, or feelings are 
always related to particular objects. Intentionality bespeaks the relationship 
between human beings and their world. Therefore, people cannot be described 
apart from their world, as their world cannot be described apart from them. In this 
sense, phenomenology invites us to make sense of the world that was described 
by us or to us, immediately and directly. The understandings that we have already 
ascribed to the given phenomena should then ‘bracket’ to the best of our ability 
in order to let the experience of phenomena speak to us as first (Crotty, 1996). 
   According to Husserl ([1936]1970, p. 258), ‘bracketing off’ personal bias and 
assumptions from interfering with the lived experience, was possible. Further, he 
argued that it was possible to transcend our subjectivity and reveal the world as 
it really is.  It didn’t mean pretending not to have these assumptions, but rather to 
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be aware of these assumptions and reflect on the extent to which they interfere 
with the analysis of the phenomenon. Conversely, Heidegger (1967) and Ricoeur 
(1981) argued that even when attempting to bracket our preconceptions, there is 
always an ideological position we represent while discussing the meaning of an 
experience, even if we are unaware of it.  
  Following Heidegger (1967) and Gadamer (1976) who questioned the possibility 
of setting aside all preconceptions and biases in one’s contemplation of a 
phenomenon, I decided that ‘bracketing’ in this study would not be desirable. I 
believe that it is not possible to stand outside of lived experience to see things as 
they really are, by denying my own subjective position. Further, in accordance 
with a hermeneutic version of phenomenology, the interpretation and analysis 
that I brought to the original text, were also acknowledged as an integral part of 
phenomenological analysis. In this sense, I went beyond the strictly descriptive 
approach to phenomenological research that requires the researcher to adopt a 
specific attitude in which past knowledge and expertise can be bracketed off and 
the scientific attention can be re-focused on interpretation that lies in 
“phenomenological purity” (Husserl, 1931, p. 262).  
 
  3.4 Interpretative Phenomenological Analysis 
  In the present study, the use of interpretative phenomenological analysis (IPA) 
was chosen. The main focus of this method is to examine participants’ subjective 
perception of their lived experiences and not to endeavour to create an objective 
description of the world (Smith, et al., 2009). Accordingly, the essence of 
phenomenological philosophy is the individual’s experiences that comprise the 
world and its underlying empirical meanings (Colaizzi, 1978).  
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   Access to these experiences depends on what participants tell the researcher 
about them. IPA emphasizes that the researcher needs to interpret given 
phenomena based on participant’s account of them in order to understand their 
experience. The researcher’s sense-making of what is happening to the 
participant is second order, it is participant’s understanding and interpretation of 
their own account regarding the given phenomenon which are of primary 
importance. Thus, a two-stage interpretation process, or double hermeneutics, is 
involved in the IPA approach (Smith, 2008). 
    
   3.4.1 History of IPA 
   IPA has a relatively short history. As a new qualitative methodology, it was first 
introduced by Jonathan Smith (1996) who made a claim for an approach that 
could be both experiential and qualitative, and that would be a strictly psychology-
centred methodology. At first, IPA was predominantly applied in health 
psychology research due to its early concerns with health and illness, but its 
application soon expanded to different disciplines of psychology that 
demonstrated its importance.  
   One of the major foundations of IPA is the philosophical approach of 
phenomenology, the study of experience. Edmund Husserl (1900/2001),a 
phenomenological theorist, argued that in order to be able to explore essential 
qualities of human experience, the focus should be redirected from an individual’s 
perception of objects (as part of the outside world) to their personal reflection of 
those objects. Thus, Husserl’s philosophical approach equipped IPA researchers 
to focus on the process of reflection and its meaning in identifying the real nature 
of experience. The founder of phenomenological philosophy recognized the aim 
of the phenomenological approach as a “return to the things themselves” (Sachen 
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selbst, Husserl, 1900/2001, p. 36) and claimed to set aside all that belongs to the 
world of prejudice and preconceptions, and what is alien to the given phenomena.  
   The process of going “back to the ‘things themselves’” (Husserl, 1900/2001, 
p.168), meaning making, gaining understanding of our experience of the given 
phenomenon enable us three phases of contemplation: epoché, 
phenomenological reduction, and imaginative variation. Epoché requires 
‘bracketing off’ of pre-existing judgments and assumptions in order to be fully 
aware of the subject of our consideration. Phenomenological reduction continues 
the process initiated with the epoché. Thus, once we start to see things as they 
really are, beyond our preconceptions, we have to describe what we see, 
according to our perception and consciousness. The reduction aims to identify 
what makes the experience what it is, in other words, what elements or factors 
constitute the experiential entity. Imaginative variation, the last phase of 
phenomenological contemplation, attempts to answer the question: How the 
experience was possible to appear, thus what circumstances or dimensions 
should be considered as directly involved in shaping the phenomenon? At last, 
when both the phenomenological reduction and imaginative variation are 
integrated, we then obtain a complete description of the experience, the essence 
of the phenomenon. 
   The other major theoretical foundation of IPA is hermeneutics,the theory of 
interpretation.According to Heidegger’s (1927/1962) early work, people live in an 
interpreted world and in consequence they are themselves hermeneutic, 
interpreters. He also identified an obstacle to interpretation in the form of 
preconceptions or assumptions people bring with them to the process. However, 
Heidegger also defined how they can avoid the situation when their own fore-
conceptions blur the interpretation of the world. The way in which people prioritize 
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phenomena in their interpretations may have an impact on whether or not they 
will allow preconceptions to affect their perception of those phenomena. In other 
words, if preconception dominates one’s understanding of the world, then any 
encounter with a new concept must be subordinate to previous assumptions. The 
importance of the phenomena can, however, be also shifted from prior 
experience towards new things, and in that case, preconceptions are drawn from 
the new concepts. Concluding, the hermeneutic approach provides the qualitative 
research with an important perspective on the process of interpreting participant’s 
views of the world and on perceptual obstacles that are inevitable in interpretative 
sense-making.   
 
   3.4.2 Ontology and epistemology 
   Epistemology is one of the philosophical stances that lies behind my chosen 
methodology. Maynard (1994, p.10) emphasized the importance of choosing an 
epistemological stance, in other words philosophical grounding, that will justify 
what knowledge is possible and if it is “adequate and legitimate”. Hence I needed 
to identify and justify the epistemological stance that would be adopted in the 
current research and which reflected my research approach. In IPA, the 
researcher’s epistemological stance can be largely determined by a person’s 
need to explore and make sense of observations made in the ‘health-illness’ 
world. A researcher in response to this need can generate knowledge that can 
be either a reflection of his epistemological stance, the interviewee’s 
epistemological stance or something in between the two. It seems to be 
impossible to separate those parallel perspectives that complement each other. 
   This shared reality is understood in terms of definitions, images and stereotypes 
(Rothe, 2007). We can play a role in the reality that will reflect our preconceptions 
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about it or discover and ask questions about the nature and sense of the reality. 
By asking questions, a researcher can identify multiple dynamic realities that may 
remain beyond our interpretations of them (Searle, 1995). We can formulate 
these interpretations in a number of contexts, but there will be never just one that 
can be generalized to all possible settings. 
 
   3.4.3 Validity in IPA 
   As quantitative research is evaluated according to the specific criteria for 
validity and reliability, the same procedure might be expected to be followed by 
researchers conducting qualitative research, respectively. Yardley (2000), writing 
in the context of health psychology, has produced guidelines for examining the 
validity of qualitative research, which were derived from different methodologies. 
She emphasizes four broad topics likely to be addressed by any research 
approach, although the ways in which these principles are applied differ widely 
between the various quantitative and qualitative methods. I will describe the 
principles in reference to IPA, as a method of choice in the current study, as well 
as general procedural assumptions that can be applied to other qualitative 
research approaches.         
   The first principle indicated by Yardley is sensitivity to context. The qualitative 
researcher can demonstrate this form of sensitivity in a variety of different ways, 
that is, by acknowledging the theoretical context, relevant literature background 
or socio-cultural factors that are relevant to the topic being studied. Research that 
ignores the importance of all these factors and processes influencing the object 
under investigation posits itself at risk of replicating what is already known (Marks 
& Yardley, 2004). In reference to IPA, sensitivity to context can be shown through 
demonstrating and taking into account the existing theoretical and empirical 
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literature that has been already established in the subject under investigation, as 
well as in terms of the methodology chosen for the research.  
   Marks and Yardley (2004) claim also that the quality of research is related to 
the rigour and commitment with which the research process is carried out. This 
principle can be again demonstrated in the various ways and at different stages 
of the investigation. Thus, in order to conduct a high quality IPA study, I initially 
recruited an appropriate sample that allowed me to provide a rich and in-depth 
data, supporting the study’s topic. My commitment was also demonstrated by my 
personal engagement in the process of data collection, that is, when and where 
the interviews took place. Rigour and commitment was also demonstrated in my 
attentive listening to what participants had to say, and careful reflections on the 
participants’ statements, by consistent probing and responding to relevant cues 
in the stories. 
   The third of Yardley’s (2000) principles, transparency and coherence, can be 
directly related to the IPA paradigm and the means to apply it systematically and 
consistently. In accordance with IPA requirements (Smith et al., 2012), I was 
focused on idiographic engagement in data analysis, illustrating particularities of 
individual cases by using appropriate quotes, but I did also emphasize the 
importance of shared experiences in formulating the major themes. I used 
participants’ extracts to support the emergent themes and my interpretation of 
them. Finally, it was essential for this study to communicate clearly to the reader 
how coherence between research aims dictated by IPA and the procedures that 
were used to guarantee validity of the findings, was established.   
    The last broad principle defined by Yardley (2000) refers to impact and 
importance of the research. In other words, the real validity of the conducted 
piece of research depends on its ultimate value for the public or the discipline that 
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it represents. Thus, in case of the current study, it is assumed that the findings 
will have a practical value for post-transplant patients with recurrent HCV, whose 
personal perspective on living with HCV and on professional health care was 
demonstrated in the form of direct quotes and in the author’s analysis. This 
research aims to provide both the public and health professional with information 
about challenges that are a part of patients’ everyday reality, and their needs and 
future expectations.  
 
   3.4.4 Rationale for Interpretative Phenomenological Analysis (IPA) 
   IPA that was chosen for this research foregrounds the experience of the 
individual, and hence provides a ‘voice’ for the lived experiences of a given 
clinical population, which is not adequately represented or evaluated by 
quantitative methods which target large samples. 
    An aim of this study was to understand how individuals with HCV interpret their 
experience of being diagnosed with the virus, of receiving treatment, undergoing 
a liver transplant and finally being diagnosed with HCV recurrence. I was 
interested in how participants construct their worlds, their coping system, and 
what meanings they attribute to their experiences. I chose IPA over any other 
qualitative approaches as it was concerned with the interpretation of meaning 
and the detailed exploration of lived experiences that were reflecting my 
exploratory orientation.  
 
   3.4.5 Data Collection 
   IPA requires rich, detailed data that could help the researcher to explore the 
participant’s understanding and interpretation of the phenomenon under 
investigation. Therefore, the most suitable instrument for data collection in this 
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approach should be flexible in its structure. Thus, the semi-structured interview 
became the most popular form of exploring the participant’s personal experiences 
of a given phenomenon. An interview schedule in this type of interviewing is 
formulated before the actual data collection begins and constitutes a guideline to 
a dialogue between participant and interviewer rather than a rigid structure that 
has to be consistently followed. In this method, the interviewee is given an 
opportunity to discuss in-depth his views, thoughts and feelings. 
   The researcher as an active listener should give the participant space to think 
and reflect fully on concerns that emerge during the interview. Questions that are 
asked by the interviewer should be open-ended in order to invite the individuals 
to provide deeper and richer disclosure. During the course of the interview, the 
researcher does not have to follow the order of questions included in the schedule 
or ask the questions each time in exactly the same manner. The way the 
questions are phrased or re-phrased may depend on the content of the 
participant’s previous answers or on the way he or she responds to the questions 
in general. The flexible structure of the semi-structured interviewing allows also 
the interviewer to explore the arising important concerns in more detail by using 
probing. In this sense, the participant is naturally encouraged to reflect at length 
on issues that were mentioned by him only briefly or that were simply 
overgeneralised. It is essential here to be attentive to certain points in the 
participant’s stories that can help the researcher to identify some causal links 
between phenomena and actions. In respect to the inductive principles of 
phenomenological approach, the interviewer should acknowledge that the flow 
and style of interviewing are means to build explanations based upon the 
participant’s perception of the world (Katz, 2001).  
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  3.4.6 Sampling 
   The logic of sampling size in qualitative research is different from the logic of 
the sample size used and recommended for the quantitative data collection, the 
same way they vary regarding the way of selecting the sample. In quantitative 
investigation the aim is to present probable generalization of the phenomenon. In 
this sense, the quantitative study needs a significant number of participants in 
order to build a valid argument that can be generalized from the small to a larger 
population, whereas qualitative research focuses on the richness of individual 
cases, and whether or not the information given reflects the experiences of the 
individual participants.  
    As qualitative approaches follow purposeful strategies rather than statistical 
formulas, this purposiveness is clearly applied in the matter of sample size. Smith 
et al. (2009) suggested that for a Masters research a sample of between three 
and six participants can be considered as reasonable. In this way, data collected 
and analysed would not become problematic in terms of amount of information 
generated. Moreover, a small sample size is typical and recommended for IPA 
(Smith et al., 2009) as larger samples can result in a loss of subtle inflection of 
meaning and subtle interaction processes in particular contexts.  
 
   3.4.7 Procedure of Analysis 
   IPA approach employs an in-depth qualitative analysis. Unlike quantitative and 
experimental methodologies, this method focuses on making sense of a given 
phenomenon rather than on the quantified evaluation of people’s views of the 
phenomenon. IPA investigates an individual’s personal experience while allowing 
both the participant and the researcher to be involved in the interpretation. When 
interpreting the given phenomenon, the participant can reflect freely on his or her 
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experiences and identify the meanings attached to them. The researcher, on the 
other hand, needs to be aware of his or her own preconceptions and prejudices 
that can interfere with sense-making from the perspective of the participants. Two 
aspects of the interpretation process need to be acknowledged when analysing 
qualitative data, namely empathic hermeneutics and understanding as an attempt 
to make sense of someone else’s experience (Smith, 2008).  
    To embrace the complexity of interpretation, Smith et al. (2009) distinguished 
six basic stages of the process (reading and re-reading, initial noting, formulating 
subthemes, looking for associated emergent themes, interpreting the next 
interview, identifying patterns across cases) that facilitate the development of 
analysis and help the researcher to realize the underlying significance of those 
steps. Each of these steps will be discussed later in the chapter with examples of 
each step highlighted and supported by data. 
 
  3.5 Design and methods in the current study 
   3.5.1 Sample  
In accordance with the qualitative paradigm, the sample in this study was chosen 
purposively. On my behalf, a transplant research nurse carefully selected a 
sample that met my inclusion criteria and constituted ‘information-rich cases’ 
(Patton, 1990, p.169) in order to explore the experiences of patients with HCV 
recurrence after liver transplantation. It was not my intention to generalise the 
findings to the entire population of HCV post-liver transplant individuals, but to 
understand the perspective of a small number of patients whose stories could be 
representative of the research question under investigation in depth. Moreover, 
a homogenous sample was selected for this study in order to present an in-depth 
interpretation of the given phenomenon in a small subgroup of post-transplant 
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patients with recurrent HCV. The homogeneity of the sampling in this study was 
dictated by practical issues such as selecting patients: 1) whose attendance at 
the clinics was relatively frequent; 2) while considering their safety and risk at any 
stage of the investigation; 3) whose challenging behaviour could have been of a 
risk to myself as a researcher; and 4) the possibility of contacting them within the 
time specified for the study. This study is also homogenous in terms of the gender 
of the research participants. Lack of a response to the study from female patients 
resulted in a male patients’ only focus on regarding the research question, which 
can be presumed to have reduced the variation in patients’ perspectives and to 
have simplified the analysis of the studied phenomenon.  
   When deciding about on the selection of post-transplant patients, I had to 
consider a number of aspects associated with both their mental and physical 
health that could impact on their ability to discuss the phenomenon being studied. 
As they are extremely physically and psychologically vulnerable shortly after liver 
transplantation (for example, participants might experience pain, exhaustion and 
depressive thoughts), I decided to interview patients at least six months after they 
had undergone surgery. The six months period post-transplant was considered 
sufficient time to have recovered with regard to every aspect of their functioning 
and for having overcome possible complications. The inclusion criterion of a time 
interval of between six and 18 months was dictated by an approximate period 
during which over 50% of patients were typically diagnosed with virus recurrence 
(Teixeira, Pastacaldi, Davis, Dhillon, et al., 2000; Toso, Cader, Mentha-Dugerdil, 
Meeberg, et al., 2013). 
   Furthermore, with regard to the inclusion criteria, all the participants in this study 
were over 18 years of age and were fluent in English. This was to ensure that 
participants were able to give written consent prior to the interviews.  As advised 
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by the Head Hepatologist, potential participants invited to take part in this study 
were those who had been seen routinely at the Royal Infirmary of Edinburgh and 
who were not currently receiving methadone treatment. In terms of exclusion 
criteria, patients who had received more than one liver transplant or who had 
been diagnosed with other serious liver-related health conditions were not invited 
to part take in the study. As the aim of the study was to recruit as homogenous a 
sample as possible, including patients with comorbid conditions or those who had 
received multiple transplants could have biased the data. Further exclusion 
criteria included imprisonment (to protect researcher’s safety), those considered 
by the Head Hepatologist to be too emotionally frail to partake and those 
possessing a current psychosis or mental health condition (all the patients who 
had received liver transplants had undergone a full psychiatric assessment at the 
unit). Adhering to these inclusion/exclusion criteria resulted in twenty-eight 
patients meeting the criteria for possible inclusion this study. 
 
   3.5.1.1 Participants  
  Seven patients took part in this study. Participants were all male with an age 
range from 53-68 years (M=57.3). The response rate to this study was 25%. 
Reasons for the small sample size obtained for this study can be related to both 
the time constraint on the study and the size of the population under investigation 
that was available during the recruitment period. 75% of potential participants did 
not respond to the invitation letter sent to them by transplant co-ordinators. Small 
sample sizes are, however, exemplary for IPA. The table below provides further 
information on the participants.               
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Table 1. Demographic data. 
Pseudonym Gender Age Time since transplant 
Gus Male 68 12 months 
Harry  Male 56 10 months  
Jimmy Male 54 9 months 
Eric Male 53 11 months 
Ted  Male 54 12 months 
Steve Male 63 23 months 
Chris Male 53 20 months 
 
 
   3.5.2 Recruitment Procedure 
   The seven patients with recurrent HCV who decided to participate in this study 
were recruited through the Out-Patients Department (OPD4) for Gastro-Intestinal 
and Liver Disorders at the Royal Infirmary of Edinburgh (RIE). In order to protect 
patient confidentiality and anonymity, the transplant research nurse at the RIE 
identified suitable patients based on the inclusion and exclusion criteria with 
which she was provided and distributed recruitment packs to potential 
participants on my behalf. The recruitment packs were either sent to patients via 
post (n=18) or distributed to them by the transplant co-ordinators during their 
routine appointments at the Out-Patients Clinics (n=10). Patients to whom the 
transplant research nurse sent the invitation packs via mail were expected to 
appear at the clinics in at least four months from the start of the recruitment 
process. In summary, four of the participants were invited via face-to-face 
recruitment and three participants responded to the Invitation Letter (see 
Appendix 4) sent to them via mail. The method of approaching the potential 
participants depended on the dates of their next appointments at the Out-Patient 
Clinics. Thus, patients who had visits scheduled within the next two-three months 
were introduced to the aim of the study personally by the co-ordinators and 
received their invitation letter during their appointments.  
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The Letter of Invitation and the Participant Information Sheet (see Appendix 5) 
included in the recruitment pack explained the nature of the project in detail and 
what was involved in participation. My contact details (e-mail) were also provided 
in the letter so that interested patients could express their willingness to take part 
or find out more about the study. Participants could also contact me via a reply-
slip sent to Edinburgh Napier University, care of the Director of Studies. The RIE 
did also included a letter saying that they supported the research (see Appendix 
3). Participants did opt in by returning a reply slip, which was attached to their 
letters in a pre-paid envelop, to me via the Director of Studies at Edinburgh Napier 
University. Once the potential participant had expressed an interest in 
participating in the study, I provided further information about the study, explained 
what involvement would entail and provided an opportunity to ask questions. I 
then advised the potential participant to take a further 24 hours to consider 
whether he would like to take part. After 24 hours, I then contacted the participant 
to determine if he was still willing to partake. I then contacted the participants’ 
General Practitioners via post (see Appendix 2) in order to seek confirmation that 
their patients could participate in my study considering their current psychological 
and physical health. Once I had received a response from the GPs, I contacted 
potential participants to arrange a date for the interview to take place at the 
Scottish Transplant Unit at the Royal Infirmary of Edinburgh.  
   3.5.3 Interview design and procedure 
   The theoretical approach of IPA favours the use of a semi-structured interview 
procedure as outlined by Smith (1995). An interview schedule (Appendix 8) was 
prepared prior to the interviews and outlined the areas of interest to be discussed.  
This included asking HCV patients about the following:  
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1) Their personal experiences of HCV;  
2) The impact of having had a transplant on quality of life and self-perceptions; 
3) Expectations pre-surgery and how they changed after the transplant;  
4) The experience of HCV recurrence post-transplant, and  
5) The impact of re-diagnosis on their attitudes.  
 However, my aim was not to follow this interview schedule in any strict or rigid 
way. Instead, a process of reflecting (e.g., “you said there that…”) and probing 
(“tell me more about that”) was adopted. This allowed the participant to direct the 
content of the interview and prioritise issues that he felt were central to the topic 
under investigation.  
  Interviews were carried out at the Welcome Clinical Research Facility (WCRF) 
at the RIE where I booked private, confidential rooms in an environment with 
which the patients were comfortable and familiar. It was my initial intention to 
arrange the interviews for Tuesdays or Thursdays when the patients were 
attending follow-up clinics in order to save the participants’ time and travel 
expenses. However, most of the patients who expressed a willingness to 
participate were not scheduled for their visits within a couple of months from the 
point time of receiving the letters. Therefore, the interviews were scheduled on 
the days and times that were most convenient for them, outside of their clinic 
appointments. Five of the seven participants were interviewed at the WCRF at 
the RIE, while one participant was interviewed at another hospital facility and the 
other in his own household; both venues were outside of Edinburgh. With regard 
to the two interviews that were not carried out at the WCRF, and in adherence to 
the agreed lone working arrangements, I informed one of the supervisors about 
the visits in advance, including their location and nature, and when I expected to 
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arrive and leave. Afterwards, I telephoned the supervisor to report that I had 
arrived back safely. 
  Each interview was expected to last approximately one to two hours. The seven 
interviews that I conducted for the purpose of this study lasted between 32 and 
68 minutes. Participants were once again given/had the Participant Information 
Sheet read to them by the researcher prior to the Participant Consent Form (see 
Appendix 6) being signed. An opportunity to ask questions was again provided at 
this point. I then asked all the potential participants three screening questions. 
These questions were: 
1) Have you had any thoughts about harming yourself in anyway during the last 
2 weeks? 
2) If yes, have you had any thoughts about how you would harm yourself? 
3) Have you ever tried to harm yourself in the past? 
If the participant answered "Yes" to Questions 1 and 2, he would be considered 
"high risk" and would be excluded from the project at this stage. I would then have 
contacted an experienced member (a named individual) of the liver transplant 
team (the transplant coordinator) to deal with the situation. This individual would 
have been called to stay with the participant while the NHS protocol for suicidal 
patients was implemented. Participants would be made aware of this prior to 
contacting anyone. 
  If there was no indication of risk to a participant’s well-being and all the 
screening questions were answered “No”, I then proceeded with the first question 
on the interview schedule. Participants were given time to answer questions 
without being prompted by me or being introduced to my perspective concerning 
the given phenomena. The answers to the first few questions in the interview 
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provided me with information-rich accounts that often covered more matters that 
were included on the schedule. Therefore, I used the interview schedule flexibly 
and as a guide rather than a pre-defined and required construct.  
  After completing the interview procedure, each of the participants received a 
Debrief Sheet (see Appendix 7) including contact details of for myself (e-mail), 
the Director of this Study, the Independent Advisor, the Clinical Consultant and a 
list of support organisations that participants could contact in the event of further 
questions or other issues related to the current study.     
 
   3.5.4 Analysis 
   In this study interviews of seven participants were analysed case by case. Each 
transcript of the interview was examined and described in detail following the 
idiographic approach to analysis (see Fig.2). In this sense, my analyses unfolded 
unique recollections of each participant constituting a particular example of 
phenomenon under investigation. 
Fig. 2. Steps of an IPA analysis. 
 
step 1
• reading and re-reading the transcript
step 2
• initial noting and descriptive comments
step 3
• initial notes are transformed into emergent themes
step 4
• Searching for connections between emergent themes and developing 
master themes
step 5
• Moving to the next interview and repeating all the steps of analysis
step 6
• Searching for connections across the cases and defining the master 
themes for the whole group under investigation 
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   According to IPA guidelines, in the first step, I familiarized and actively engaged 
with the original transcript, while reading and re-reading the data. This phase 
allowed me to develop chronological accounts into a consistent and easy-to-
follow structure of an interview. I was also coming back to listening to the audio-
recordings whilst studying the transcripts. I could then recall vividly the dynamic 
of the interview and make some initial notes based on how the stories were told 
to me in person. This first stage of analysis gave me an opportunity to notice 
sensations and thoughts that were evoked while reading and listening to the 
participants’ accounts simultaneously. These first impressions were captured in 
the initial notes and facilitated my engagement with the text. Repeated reading 
allowed me then to recognize how a number of relatively generic and loose 
patterns of explanations can lead to more in-depth and chronological descriptions 
of specific events. 
   Then, I proceeded to make descriptive and comprehensive notes that led to 
dividing transcript into ‘meaning units’ (Giorgi & Giorgi, 2003, p.23). My comments 
that were made to these distinguished units, with a constant phenomenological 
focus, reflected closely true meanings underlying participants’ stories. Comments 
that were related to people, objects or events of great importance for the 
participant were indicated in the initial coding. Semantic content of these 
reflections and language use constituted important clues that helped me to 
understand reasons and consequences of the participant’s thoughts, feelings and 
concerns. The second stage involved developing exploratory comments based 
on semantic content and language used in the transcript (Table 2, see below). 
Analysing line by line, I was focused on identifying relationships, processes and 
events that were of great significance for participants and that mattered for 
understanding their lived experience of HCV. This initial step of analysis helped 
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me to grow further the familiarity with participants’ accounts and recognize 
specific patterns of meaning in their narratives.  
   The third stage in my analysis comprised identifying emergent themes from the 
transcript and initial notes. In the search for themes I attempted to condense the 
content of transcript and produce more concise statements from previous notes. 
These statements had a form of phrases that posed conceptual generalisations 
and psychological meaning of the most crucial points in the text (Table 2). 
Meaning units identified in the second stage of initial noting now underwent 
linguistic transformations that moved the analysis towards psychological 
interpretation and understanding. At that stage, the emerged themes started to 
capture and reflect the sense-making from both the participant’s and my own 
perspective. Therefore, the themes are also meant, according to the hermeneutic 
circle, to be both interpretations of the researcher’s text and a reflection of the 
transcript as a whole. 
 
Table 2. Developing explanatory comments and emergent themes. 
Emergent themes Original Transcript Explanatory 
comments 
 
 
 
 
Uncertainty 
 
 
Fear of unknown 
R: Gus, could you please tell me how you 
were diagnosed with Hepatitis C? What were 
you thoughts and feelings about the 
diagnosis? 
 
G: I was in, getting a blood sample taken and 
I think I was in Eastern General Hospital for 
something else and I don’t even really know 
why they wanted the blood sample. It had 
nothing to do with what I was in for. Then, 
about maybe a week or two weeks later, I got 
a call and I think it was a letter, I can’t 
remember. It’s a long time ago, saying that 
are an abnormality in you liver, and could you 
come in on certain day. And of course the first 
thing you think of a liver oh my God, you 
know, because you can do without a kidney 
or this and that, you can eh...but liver, you 
 
 
 
He found himself in a 
highly unclear medical 
situation.  
Obscure circumstances 
of medical testing. Not 
being told what they 
were investigating 
 
Recognition this is 
serious 
Fear of what symptoms 
may indicate 
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Worries 
 
Source of the 
infection 
 
 
 
 
 
 
Lack of knowledge 
know, “what's the abnormality?”... I had to 
wait the eight days till I had the interview or 
the meeting, appointment to find out what it 
was and they came up and said this thing 
about Hep C which I'd never heard of before 
and had a chat with them and realize how I 
got Hep C which was from a transfusion 1986 
and eh… here I was a bit concerned about it, 
you know, just because it was just suddenly 
out of the blue. And eh… another 
appointment was made for me, you know, 
going in to the hospital to sit down. I had a 
chat and I was told something like, “you 
maybe have got 15 years to live” (laughter). 
At that time I was, you know, they didn't really 
know a lot of this. So, it was a bit 
disconcerting… yes, when I did come here, 
oh my goodness, eh as anything good. 
Serious concerns that 
accompanying the initial  
diagnosis received from 
the hospital 
 
 
Trying to identify the 
sources of infection 
 
 
 
Surprised by diagnosis 
and life expectancy 
approximation given to 
him in the hospital 
Initial perplexity after 
receiving the diagnosis 
 
   The fourth stage involved a more analytical ordering of themes. I aimed to 
establish a mapping of previously identified and chronologically ordered themes. 
I was here relatively selective in terms of themes I wanted to include into final set 
of super-ordinate themes and into the presentation of results. The decision 
whether to merge particular themes or exclude from further consideration 
depended to some extent on my research question, but it was also based on the 
re-evaluation the significance of comments from initial stages of analysis. Some 
of the emergent themes that were recognized in the previous stage clustered 
together, whereas some emerged as super-ordinate themes. Abstraction as a 
process of clustering was used for identifying patterns and connections between 
the emergent themes. The themes were usually grouped around chronologically 
occurring events in the patient’s life. Thus, the diagnosis of HCV, liver 
transplantation, and virus recurrence constituted as a frame of reference for many 
emergent themes and did also help to define super-ordinate themes (see Fig. 3).  
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Fig.3. Abstraction leading to the development of a super-ordinate theme. 
 
   In the next, fifth step of the analysis involved moving to the next participant’s 
account. The same four stages of the explanatory process that were applied in 
the previous case, were repeated in the subsequent analysis. This stage required 
treating the new transcript as a separate and unique entity and bracketing off the 
themes that emerged in the previous analysis. It was inevitable that some of the 
concepts that were recognized and articulated in the first case, influenced to 
some extent my search for patterns of meaning in the following accounts. 
However, a conscious recognition of similarities with the previous analysis did not 
prevent my search for new themes and meanings that emerged in the next 
participant’s transcript.  
   The last stage of the analysis involved identifying patterns between all the 
cases under investigation. New chains of connections between people’s 
idiosyncratic emotional states, ways of thinking and feeling were established in 
respect to the given phenomenon they reflected on. The final outcomes of the 
analysis organized around the super-ordinate themes based on all cases 
Psychosocial 
impact of HCV
Fear of 
contaminating 
others
Fear of 
disclosure
Plans 
on hold
Stigma
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provided me with a conclusive explanation of various aspects and quality of the 
individual’s experience of diagnosis of HCV, liver transplant, virus recurrence and 
pre-and post-transplant treatment. I approached that stage of analysis by 
assessing the key super-ordinate themes for the whole group (see Table 3). 
Although, according to Smith et al. (2009), the procedure is mainly applied for 
larger samples, I chose it as it made the process more manageable for me as a 
novice. The themes were classified as recurrent when they were identified in at 
least three of the participant interviews. Counting like this indicated a high 
prevalence of particular themes across the group and it was also considered as 
a way to facilitate the validity of the results.    
 
Table 3. A sample of recurrent themes.  
Super-ordinate 
themes 
Eric Steve Gus Ted Jamie Chris Harry Present in 
one third of 
the sample? 
Seeking 
information 
YES YES YES YES YES NO YES YES 
Side effects YES YES YES YES YES NO YES YES 
Stigma YES NO YES NO YES NO YES NO 
Physical 
deterioration 
NO NO YES YES NO NO NO NO 
Disclosure NO NO YES YES YES YES NO YES 
 
   The completed analyses of the seven interviews listed in this thesis provided 
information-rich account on the experience and attitudes of patients with HCV 
recurrence after liver transplantation.  
 
   3.6 Ethical Approval 
   This study was reviewed by two independent ethics committees. First, ethical 
approval was granted by the Faculty of Health, Life and Social Sciences 
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Research Ethics and Governance Approvals Group at Edinburgh Napier 
University in January 2014. I also sought ethical approval from the NHS Research 
Ethics Committee 3 (REC 3; Ref: 14/WS/0122; see Appendix 1), West of 
Scotland, in February 2014. A favourable ethical decision was received from the 
NHS Ethics Committee in June 2014 after attending two Committee meetings 
and addressing several issues that were raised by the members of each of the 
two committee. The major amendments that were carried out in respect of REC 
3 guidelines were related to the inclusion and exclusion criteria, preventing 
screening for suicidal intention, formulating lone working protocol between 
supervisors and myself, and establishing a communication between participants’ 
GPs and the researcher. 
  3.7 General ethical considerations 
  In the current study, the potentially sensitive nature of the interview questions 
could result in some individuals experiencing a degree of distress. In the unlikely 
event that participants could become upset/distressed as a consequence of the 
interview, they have been encouraged to discuss any upsetting issues with the 
resident Clinical Psychologist at the Royal Infirmary of Edinburgh or had to be 
immediately contacted with the transplant co-ordinator who was ‘on-call’ on the 
day of the interview taking place. Additionally, in order to address a possible 
occurrence of distress after the interview was completed, each participant was 
provided with a Debrief Sheet detailing the contact details of the Director of 
Studies and the Clinical Psychologist at the RIE whom they could contact. 
Participants were also advised that they could withdraw from the research at any 
time and that they did not have to answer any questions that they did not wish to. 
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  Considering possible risks that could result from conducting this study, it was 
also acknowledged during the second sitting of REC3 that conducting interviews 
beyond the safe hospital setting, might involve risk to myself as a researcher. 
Although the Welcome Clinical Research Facility at the RIE was offered to 
potential participants as a familiar and convenient environment for the interview 
to take place, they might express an intention that their interview was carried out 
in a place of their choice. Therefore, lone working arrangements has been 
developed in order to protect the researcher from the risks of violence and 
aggression. According to the agreed operating procedures, I as the lone worker 
should have always ensured that someone else (e.g., my supervisors) were 
aware of my movements. I was obliged to tell my supervisors about any visit in 
advance, including its location and nature, and specify when I expected to arrive 
and leave. Afterwards, I let my supervisors know that I was safe.  
A reasonable time was always set by my supervisors for contact. My supervisors 
were also updated by me if my arrival or visit was delayed or when I had to cancel 
an appointment. In the event of no contact from me, supervisors did in the first 
instance attempt to make contact directly, then to make contact to a participant 
whose contact details had been given to them in a sealed envelope by me. 
Should contact with myself and the participant still not have been established, the 
police would be informed followed by the university ‘on call’ supervisor.  
  3.8 Confidentiality and data handling 
  Participation in this study was confidential. However, confidentiality might have 
been limited if I deemed during conducting the interviews that there to be a risk 
to any of the participants. In relation to someone becoming distressed or making 
a statement which could give me a cause for concern to harm themselves or 
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others (i.e. suicidal tendencies), I, as a certified Mental Health First Aider would 
provide initial help and reassurance to the person. The participant would then be 
informed that I was obliged to contact an experienced member of staff within the 
liver transplant team (a transplant coordinator) in order to report the occurred 
situation. This individual would be contacted immediately and I would be allied in 
to remain with the patient while NHS protocol for suicidal patients was adhered 
to (e.g. contacting GP, contacting the liaison Psychiatry team, etc.). This would 
be discussed with the participant prior to the disclosure of information. All 
potential participants would be informed of this in the Participant Information 
Sheet and Consent Form. This procedure adheres to Section 7.1 of the British 
Psychological Society's Code of Conduct, Ethical Principle & Guidelines (2006). 
All data that was collected was stored on a password protected computer. Only I 
and the Director of Studies had access to the data. All participants were also 
asked to select a pseudonym to which they were referred to throughout the study. 
Data stored on the researcher’s computer for the purpose of analysis was 
anonymised in this way and additionally was password protected. 
 
 
 
 
 
 
 
71 
 
Chapter Four: Results 
 An interpretative phenomenological analysis of seven semi-structured interviews 
revealed three inter-related Master themes: 1) The experience of encountering 
HCV 2) Managing the diagnosis of HCV and 3) The experience of treatment. 
Each of the Master themes will be explored together with their constituent 
subordinate themes and in vivo coding (see Table 4, below).  The themes reflect 
a chronological trajectory of HCV: initial diagnosis, undergoing liver transplant, 
post-transplant transition, virus recurrence and the most recent period of awaiting 
new treatment. For the purpose of the reader, it is noteworthy that the symbol 
(…) indicates that some text in the extracts has been omitted. The extracts 
presented herein have been selected as they represent the most powerful or 
insightful quotes and capture the essence of the theme.   
Table 4.  Table of Master themes and related sub-themes. 
Master themes Subordinate themes In vivo coding 
1. The experience of encountering 
HCV 
Learning about the 
infected self 
 
Identifying the source of infection 
A lack of information provision 
Psychosocial impact of 
HCV 
Fear of contaminating others 
Fear of disclosure 
Stigma 
2. Managing the diagnosis of HCV Coping with HCV: 
Resilience and supporting 
relationships 
Keeping occupied 
Adopting a healthy life style 
“I wouldn’t have managed without them”: 
necessity for practical support 
“They are part of it”: impact on the family 
Optimism 
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Experience of medical and 
social support 
Mistrust in health care 
Self-sufficient approach  
Importance of social support 
“We still need to be looked after”: 
negotiating health care  
2 The experience of treatment Trial and error circle 
 
 
Feeling “like a guinea pig”: trial and error 
approach to treatment 
Concerns about the side effects 
Living with uncertainty “I was going downhill pretty quickly”: 
being aware of impaired physical 
functioning 
“It’s still there”: facing virus recurrence 
Living with uncertainty 
  New cure Determined to ‘get rid of it’ 
Hope 
 
Theme 1: Experience of encountering HCV 
Life with HCV began at the point of diagnosis, an experience which for some 
participants was inconceivable and life interfering, but for others caused no 
reportable or substantial life change or disruption. Despite the initial impact of the 
diagnosis on participants’ lives, the sense of uncertainty about the ‘dormant’ and 
unknown nature of HCV, emerged throughout all participants’ narratives. First, 
they described their concerns about encountering the diagnosis that was, at the 
time they were diagnosed, vaguely understood and defined. Thus, participants 
found themselves in a position of ‘limbo’- with no information provision by medical 
professionals. Consequently, with a desperate need to understand what was 
happening to them, they began their journey to search for meaning. The process 
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of learning about the illness first initiated an attempt to identify potential sources 
of HCV. This appeared to be an important step in making sense of why this had 
“happened to them”. Following on from this was a process of self-seeking for 
more knowledge and information. Participants search for understanding only 
further highlighted their sense of isolation and of being let down by the very 
people who diagnosed their condition. The “not knowing” how to live with HCV 
coupled with an awareness of the potential stigma associated with the condition, 
caused patients a dilemma about disclosure, a fear of contaminating others and 
interfered with their anticipated futures. What follows will highlight the 
psychosocial journey of the participants and the impact that HCV had on their 
lives.  
Learning about the infected self 
  Participants reported receiving a diagnosis of HCV in either primary care or in 
hospital after routine blood tests. They were poorly prepared for receiving the 
diagnosis and reported a lack of any essential advice or support provision. All 
were previously unaware of their condition and were not informed about the 
purpose of taking a blood sample, which was for HCV serology. The high level of 
uncertainty that accompanied the medical procedure raised in the participants’ 
suspicion and confusion. For them it seemed to be an indicator that something 
was wrong: 
“I think I was in hospital for something else and I don’t even 
really know why they wanted the blood sample. It had 
nothing to do with what I was in for.”(Gus) 
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For many, there was a sense of ‘shock’, they were completely unprepared for 
their diagnosis which came ‘suddenly out of the blue’ (Gus). They were taken for 
tests in obscure circumstances or while being treated for different conditions, but 
in neither of these situations they were informed of the nature of tests. Awaiting 
the blood test results one of the participants was not even aware that he was 
sitting in an HCV clinic (Jimmy). The not knowing why the blood samples were 
taken evoked initial feelings of puzzlement, amazement, and fear that were 
enhanced by the unexpected news of a diagnosis. Jimmy seemed to dissociate 
in response to the diagnosis by redirecting his thoughts and shutting the news 
out by building the imaginary wall around the self: 
“When they took me in, and when they told me I thought 
of bricks, because I had no idea how, or where I’d got this.”  
(Jimmy) 
 Considering the lack of knowledge about the virus at the time when they all 
received the diagnosis of HCV, participants could have been infected for years 
and only the presence of some HCV symptoms such as jaundice (Ted), or liver 
pains (Harry) became a reason for their health concerns. Thus, while for many, 
the blood test was perhaps the first indication that ‘there’s something not right’ 
(Jimmy), for others, the occurrence of symptoms was already a cause for 
concern: 
“(…) it was the jaundice, that's what they say, because my 
skin all went yellow.  But I found out it was Hep, but I didn't 
know whether it was Hep C or what, because they didn't 
know a lot about Hep C in these days.” (Ted)  
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For all, however, regardless of the occurrence of symptoms, the diagnosis 
highlighted the ‘silent’, ‘dormant’ nature of their condition. Even those, who could 
have prepared themselves for the possibility of the diagnosis by noticing the 
physical indicators, were oblivious to what was happening within their bodies: 
“I thought it was lying dormant.  I thought – and then when 
the doctor said, no, it was there.  It was just eating away, 
all the time, at your liver.” (Ted)  
This view of the virus being temporarily inactive and not affecting the system, was 
abruptly demystified, when the doctor revealed the destructing impact of it on 
Ted’s liver functioning. For Ted, there was a sense that the virus was consuming 
him, corroding his liver in- it was a silent killer. The fact that many patients were 
not affected by the virus until diagnosis, heightened their initial shock and the 
sense of bewilderment of the virus occurrence. The virus seemed not to interfere 
with patients daily functioning until they started treatment for it. Treatment was 
considered to bring it ‘back out’ from the dormant state. For Ted, treatment 
became a trigger of virus activation that threatened his life stability and 
anticipated future: 
“I thought it was just lying there and hadn't been disturbed 
until I got treated for it. And then when I got treated for it, 
that's when it came back out again.”(Ted) 
Given the lack of knowledge about the effectiveness of HCV treatment, patients 
became easily confused by their asymptomatic health condition and arrived at 
mistaken conclusions, such as:  
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“I actually thought my hepatitis went away. As I say, after 
a week in hospital and then, as I say, I just got on.  I 
thought I was done, because I never had any trouble.” 
(Ted) 
Ted seemed to hold expectations of moving on with his life, leaving HCV behind 
him after hospitalisation period. Attending treatment appeared to be associated 
by participants with a successful cure. Therefore, when the virus turned out not 
to be cleared, they seemed to experience disappointment and frustration. Many 
others, who have never experienced any drawbacks that could have been 
associated with a given diagnosis, and lived with the virus ‘lying dormant’ for 
years not knowing of it, never perceived the illness as a challenge or burden that 
they had to struggle with. For them, discovering a condition that had persevered 
in their bodies for so many years gave them a sense of helplessness, a feeling 
that ‘there was nothing’ they could do about it and that the control over their life 
was lost. Living with HCV appeared to be a permanent state with no perspective 
for a change even after a part of their body, infected organ was removed and 
replaced with the healthy one: 
“When I got told I had the virus there was nothing I could 
do because I’d had it for years and years, and I didn’t even 
know I had it. But once I got the liver transplant, I says, 
“I’ve got that and I’ve still got this virus.”  And that probably 
preyed on my mind a bit, but there’s nothing I could have 
done about that. [] There’s nothing you can do, you know.” 
(Steve) 
77 
 
Difficulty in accepting the initial diagnosis resulted from the fact that many 
participants were diagnosed in the 70s when there was still a lack of knowledge 
about the virus and its consequences. As a relatively unknown condition, HCV 
was not properly explained or defined to the patients, therefore, they could only 
acknowledge the diagnosis that was given to them, and hope for treatment in the 
future. However, the reactions to this factual uncertainty fluctuated from 
acceptance to perplexity when threatening diagnosis-related predictions were 
made by professionals: 
“I had a chat and I was told something like, “you maybe 
have got 15 years to live” (laughter). At that time I was, you 
know, they didn't really know a lot of this. So, it was a bit 
disconcerting…” (Gus) 
Thus, the impact of the informational gap seemed to unsettle and bewilder 
participants who were suddenly faced with a diagnosis for life that was not 
sufficiently explained by medical evidence. The lack of knowledge made 
participants also feel that the diagnosis was all they could be given. They were 
informed that they were ill and ‘were dissed’ with the burden of uncertainty. 
Consequently, the initial fear and shock experienced after receiving the diagnosis 
was amplified by a sense of isolation, of being on their own with an unknown 
disease, and an overwhelming uncertainty about their future. Participants found 
themselves in ‘limbo’ where nobody could tell them ‘this is what was going to 
happen in the future’ (Eric). 
According to participants’ accounts, ‘no information at all’ and no professional 
care was provided to them in the 70s and 80s when most of them received their 
diagnosis. Possible medical interventions were anticipated in the future, but 
78 
 
nothing was applied at the time of diagnosis. Being left in this zone of 
nothingness, participants tried to identify their own sources of information. They 
were trying to take control of a situation that seemed to be unmanageable:  
“(…) When I first got diagnosed the first thing I did was I 
contacted the haemophiliac Society and I still have all the 
papers away back to that time. (…) they were the only 
people I could think of. There was no Hep C Trust or 
anything.” (Gus) 
There was a determination to recognize any possible sources of information and 
seek answers that could not be obtained from health providers. Participants were 
searching newspapers and found out that some ‘studies were on and they were 
funding what they could do’. Sources of information were not always official and 
validated, and they could be simply ‘from word of mouth’, from other people 
affected by HCV or involved in the process such as Haemophilia Scotland.  
   After the initial shock and consternation of receiving the diagnosis, participants 
then began to ponder the source of the infection. Many were relatively certain in 
identifying circumstances and ways in which they contracted the virus. Two of the 
participants (Ted, Steve) recalled in their youth sporadic injecting drug use 
incidents, which they believed were the cause of their HCV positivity. A single 
drug use from the past made Steve sure about how and when he had contracted 
the virus. Ted, in turn, did not mention just a single episode of injecting himself 
and struggled to be more exact about the time when he could have gotten the 
virus. However, they both accepted personal responsibility for contracting the 
virus as a result of ‘totally naive’ early life experiences of heroin use. There is a 
sense of remorse, guilt and shame in Steve’s account where he confessed that 
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he ‘never took drugs’ in his life and ‘never even touched it’, apart from this one 
time when he was 21 years of age. Genuine regret peppers his account: 
“It was the worst thing in my life I’ve ever done.”(Steve) 
For others, the source of infection was considered to be: either sexually 
transmitted (Jimmy) or transmitted through blood transfusion (Eric, Gus, Harry, 
Chris). Although the source of the infection here was still the subject of ‘dispute’, 
all five participants could easily trace the infection to a time when a major 
operation took place in their lives or to a specific treatment involving blood 
transfusion. For these participants, the situation was considered unjust and 
undeserved: 
“I contracted Hep C through contaminated blood given to 
me for treatment for my haemophilia.”[] “You’ve got it.” [] 
“Somebody gave it to me.  I didn’t go out there and stick a 
needle in me…” (Eric) 
Thus, unlike for Steve and Ted who contracted the virus through their own risk 
behaviours, the others’ reports were peppered with a sense of anger and blame. 
They had received ‘dirty blood’, ‘contaminated blood’ and, therefore, the virus 
occurrence was not perceived by them as being their fault. They expressed a real 
need to escape personal blame for something that was “done to them” by others 
and not by themselves. Identifying culprits for their situation seemed to absolve 
them of all responsibility. Eric who was also contracted with the virus at the time 
when no blood screening was in place, blamed both political and health sectors 
that were responsible for providing the infected blood: 
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“(…) it shouldn’t have happened, that is basically it.” [] All 
these thousands of people that have been affected by the 
Hep C they shouldn’t have happened and that’s why we 
are fighting at the moment.”[…] we try to get answers 
because nobody is saying, “It was me that did it.”  All we 
want is somebody to say, “It was the national health’s 
problem, the government did it and then let’s do something 
about it.””(Eric) 
Eric appeared to use the plural pronoun ‘we’ to emphasize the shared experience 
of injustice and enhance the gravity of the situation. Like Eric, many other 
participants reported a need for someone to take responsibility for the situation 
and for that situation to be rectified via effective treatment: 
“ (…) because I am not into the blame culture and as I say 
I didn’t like the Prime Minister and all that and I will never 
forgive her that but I am not getting into the blame culture 
and living my life that way. I just feel we need to get on and 
get these drugs developed and see where we can go from 
there. That’s basically where I am. (Gus) 
Participants’ responses to the diagnosis seemed to depend how they contracted 
the virus. Patients who had the infection transmitted through injecting themselves 
showed a tendency to self-blame and to adopt avoidant thinking (e.g. Ted who 
‘never really thought too much of it’ or Steve who accepted his helpless stance 
that ‘there’s nothing’ he ‘could have done about that’). On the other hand 
participants who received contaminated blood through transfusion, took a more 
pro-active approach to the situation they were forced into. They accepted their 
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right to blame other people who were responsible for “giving them” the virus and 
the right to claim treatment in a form of compensation for the terrible mistakes 
from the past. The past was still on Gus’s mind and it was something he would 
‘never forgive’ but like others, he recognized the need to ‘use it as a means for 
improvements for the future’ and ‘get on and get a cure for it’. 
While most of the participants speculated the source of infection and had varying 
degrees of certainty as to how it was contracted, for others (Eric, Chris) there was 
no such source of certainty. Jimmy seemed to feel lost and constantly worried 
because of his unsuccessful search for clear explanations of receiving the virus:  
“Still to this day I’m out of my mind where, and how I could’ve got that.”(Jimmy)   
Jimmy’s complete lack of certainty regarding the source of his infection caused 
that he, unlike other participants, as the only one put no blame on anyone and 
not on himself, in particular.     
In summary, a number of potential sources for contracting the virus are 
recognized: sexual transmission, blood transfusion during two major operations, 
or contact with an infected relative. All seem to be feasible explanations for 
infection occurrence, but none of them seemed to give a definite answer. This 
uncertainty caused participants unresolved distress and a feeling of mental 
unsettlement. 
Psychosocial impact of HCV 
The initial diagnosis of HCV affected all the participants despite some assertions 
of ‘no thoughts given’ (Ted). Participants were all aware that a positive HCV 
status had a considerable psychosocial impact. For example, as participants 
revealed their accounts, it was clear how the diagnosis led them to a number of 
82 
 
personal sacrifices, such as a decision of not getting involved in romantic 
relationships. An awareness of the infectious nature of HCV caused distress 
when interacting with others. Stigma, often associated with HCV resulted in a fear 
of disclosing HCV to others and a fear of contaminating others consequently 
resulted in social withdrawal. Fear of disclosure seemed not to depend on how 
participants contracted HCV but on stereotypical views accompanying the 
diagnosis. A risk of being perceived as a drug addict or as an untouchable outcast 
preyed on participants’ minds.   
 Participants felt strongly about the preconceptions people held about HCV. Eric 
was aware of places “where a lot of people see the stigma where a lot of Hep C 
is a bad word.” Those preconceptions led to the shift in an attitude towards the 
infected person: 
“Like people’s attitude towards me changed like I was a 
leper sort of thing.” (Chris) 
Chris’ extract demonstrated how HCV, a potentially treatable viral infection that 
is wrongly perceived by the society, could distort a way the infected person 
perceived his condition and himself. A status of being HCV positive degraded the 
patient to the rank of an outcast that was rejected by his environment. In this 
sense, stigmatizing evoked and deepened the sense of participants’ social 
exclusion, both amongst family members and friends:  
“(…) it has changed a lot I don’t see people as much, and 
I never get invited to their house and they seem to think 
that they’ll catch something off of me, but I’ve told them 
you cannot catch it. (Chris)  
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Chris’ account revealed that people were ignorant about the virus and his modes 
of transmission. This reminded him of “the AIDS virus when it first came up’. Any 
attempts to rationally explain to his friends the risks of contamination were made 
in vain because “they’re still wary and it’s a bit of a downer”. Chris expressed a 
strong need for people to understand his situation and how his body was affected 
by their unfair reactions. He wished that they could feel what he felt, that they 
“look inside to how my body felt at being excluded”. This marginalisation occurred 
not only within the wider social network but also within close family relations. 
Contact often became limited to phone calls and visits became even more 
restricted:  
 “I’ll speak to them on the phone or they’ll text me as 
regards to them visiting or getting invited to their house 
(…)” (Chris)  
While for Chris not seeing friends and relatives was a sacrifice that was imposed 
on him causing a feeling of exclusion, for Harry keeping his cousins and friends 
away from his household, was a conscious decision made by himself in order to 
protect them from receiving the virus: 
“So I told them not come to our house, not to bring their 
kids to our house… Even my friends stopped coming (…) 
the first three months I completely ignored all the people.” 
(Harry) 
The disappointment and frustration from not seeing friends and relatives, and in 
relation to reactions to their condition, were enhanced when Jimmy recognized 
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that people who hold these preconceptions possessed the knowledge necessary 
to avoid this kind of stereotypical thinking: 
“There was a couple of times where my niece was there 
(…) and wanted something for the kids and it was in my 
mum’s house and I said to her, “Oh I’m going to the kitchen 
I’ll get you it.”  And her mother, who is a nurse herself, 
jumped up and shouted, “No, you’ll not bother, I’ll get it.”  I 
thought, that’s a big one, she’s a nurse, she should know.” 
(Jimmy) 
Disclosure, therefore, could be an anxiety-provoking act where participants 
feared unpredictable and disappointing reactions from others. For Jimmy, fears 
to disclose HCV extended to potential partners:  
“After I was diagnosed I was scared to go into a 
relationship (…) something I don’t think I will, ever have 
another one, because I don’t think I can turn around and 
say to a female, I’m sorry but I’ve got Hep C, or I’ve had 
Hep C.  Because I think they’d just about turnabout and 
walk out the door on you.  So, it’s kind of, it’s sad in a way 
knowing that – I don’t think I could get into a relationship 
knowing that, to have to tell somebody that and then 
knowing they might just walk through the door, reject you, 
and just walk out the door altogether.”(Jimmy) 
The burden of living with HCV awaked the reality of a lack of any positive future 
intimate romantic relationships in Jimmy’s life. His despair seemed to be endless 
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and even a possibility of clearing the virus would not give him sufficient 
confidence to enter a romantic relationship. The diagnosis in this sense, 
appeared to be a life-long sentence characterised by a fear of rejection and 
isolation. 
The decision of disclosure appeared to be not only embedded in fear of potential 
negative responses to the diagnosis, but depended also on the recognized 
source of the infection. Steve who expressed regret for injecting himself in his 
youth and who seemed to be ashamed of how he contracted the virus, decided 
not to disclose his HCV even to his closest family. His significant others were only 
informed about liver cirrhosis as an official reason for his need for liver 
transplantation: 
“(…) none of my family knows [] When I found out about 
the cancer they didn’t know from where it was.” (Steve)  
A sense of being responsible for contracting HCV through injecting himself 
seemed to determine his decision of avoiding disclosure. Conversely, disclosure 
did not constitute an issue when participants contracted their virus through blood 
transfusion and when they void of any personal responsibility of contracting HCV: 
“I know a lot of people have a stigma about Hep C but I’ve 
got no – I’ll tell everybody that I’ve got it because it wasn’t 
my fault.”(Eric) 
As a consequence of perceiving oneself as a victim in the whole situation, 
participants had great ease in sharing the diagnosis with “anybody that wants to 
know”, in particular with those who showed interest and support. There seemed 
to be no stigma and instead, unconditional family and friends’ support where 
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participants were clear and honest about their past and regretted nothing about 
what had happened to them. However, the ease in the way they perceived their 
health condition did not mean that HCV had no impact on their lives. Diagnosis 
evoked a lot concerns about the health and well-being of their partners and 
children. 
 Thus, disclosure could be perceived as an act of courage but also as an act of 
caring for others. Participants disclosed themselves to make their family and 
friends aware of their condition and to give them an opportunity to protect 
themselves. In participants’ reports, there was a clear indication of several 
precautions they had undertaken out of concerns for others, especially members 
of their families and friends. A fear of contaminating others with the virus caused 
them to make difficult decisions about limiting their participation in community 
living and when meeting with friends and family to be “very careful from the other 
people children are not to catch an infection” (Harry).  
The precautions that had a clear purpose of protecting the vulnerable others 
could, however, also have a form of self-limiting and self-controlling thoughts and 
behaviours:    
“Even if you’re, if I’m in my mother’s and I’m maybe cutting 
something, careful not to cut yourself, it’s weird.” (Jimmy)  
The fear of contaminating others could lead the participant to a state of constant 
alertness and precaution that became part of his daily routine: 
“As soon as you open your eyes here, you’re conscious, 
right be careful.” (Jimmy) 
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Jimmy’s life seemed to be characterised by excessive acts of precaution to 
prevent others from contracting the virus. Jimmy tended to anticipate potentially 
hazardous situations that could possibly increase risk of infecting others. A simple 
situation, such as cutting himself shaving, was perceived as a high-risk incident 
that would prevent him from leaving the house until the wound “dries up”, making 
it safe for him to be in the company of others.    
Participants also reported disruption in terms of avoiding holidays:  
“What happens if something happens on your holiday and 
you’re taken to hospital, and you’re unconscious, and 
they start tampering about with you, and there’s blood 
everywhere. You don’t want to go on holiday.“ (Jimmy) 
Thus, HCV constrained peoples’ everyday existence and made them carefully 
judge every step they took in life. The diagnosis appeared to prevent participants 
from making any future plans. Uncertainty regarding how their condition could 
change within days or what could happen when on holiday stopped them from 
making any definite decisions. In this way their holidays were postponed for 
months or years out of fear of an organ rejection that “could kick in” suddenly or 
unpredictable medical circumstances that “could happen at any time” and in any 
place.  
The participants’ former lives seemed to be gone forever. However, they 
appeared to hold on to the hope of regaining the active life that was taken from 
them with the diagnosis. Their accounts revealed how they envisaged 
themselves engaging in former activities without living in fear of putting others at 
risk. This was, however, dependent on whether or not the virus would be 
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‘cleared’. Being ‘cured’ brought hope for the future and the possibility of regaining 
freedom, but participants were also sceptical of this ever being a realistic 
possibility:  
“I’ll get rid of the Hep C and then I can start thinking about 
going on holidays, and I can go this, and I can do that.  But, 
it doesn’t work that way, does it?” (Jimmy) 
As with the disclosure issue in terms of building a new romantic relationship, the 
diagnosis of HCV seemed to be a constant and unresolved obstacle for Jimmy. 
The perspective of clearing the virus brought no relief or certainty in his 
reflections. For others, plans seemed not be on hold until the moment of clearing 
the virus, Gus made plans despite his current health concerns, and difficulties 
attaining travel insurance. He clearly expressed determination in that he was “not 
going to stop going on holiday” or he was not going to stop fulfilling his idea of 
pro-active living. His determination could have his source in the fact that he 
contracted HCV through no fault of his own. Therefore, when confronted with 
inevitable HCV consequences, he decided to appreciate the unpredictability of 
life and became determined to make the most of his  
Theme 2: Managing the diagnosis 
Participants in the current study reported a number of coping strategies that 
allowed them to live life despite the adversities related to HCV diagnosis. These 
strategies ranged from various resilient forms of coping, to seeking medical 
support and relying on the support of their significant others. Participants 
appeared to incorporate all of these coping mechanisms in their treatment 
regime, but also used them to deal with any consequences of living with a chronic 
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illness. Resilient coping (e.g. keeping occupied, optimism, adapting health 
lifestyle) allowed them to maintain a relatively balanced and healthy level of 
functioning, despite the often detrimental effects of HCV treatment and its side 
effects. Social support also appeared to be important, although the extent to 
which this support was required varied amongst participants. In particular, 
participants emphasized the invaluable contribution made by family and friends 
to their recovery and their ongoing support was considered central for 
improvement in their quality of life.  
Coping with HCV: resilience and supporting relationships 
Patients with HCV experienced a number of side effects of HCV treatment and a 
continuous deterioration caused by the illness itself. In response they had to 
develop and apply adaptive coping strategies. These strategies appeared to be 
beneficial in improving adherence to treatment and in facilitating adaption to a 
change in social circumstances. Participants in this study tended to manage the 
challenges of their condition by keeping occupied, adjusting their former lifestyle 
to current health requirements, spirituality or simply by accepting their situation. 
Participants also emphasized the need for family and friends support in coping 
with the daily challenges of living with HCV.  
Support from loved ones ranged from emotional support to physical assistance 
before, during and after the antiviral treatments. All participants described the role 
of family as not only necessary but as crucial for their recovery and survival. Their 
attendance and adherence to the treatment seemed to be completely dependent 
on support from the family. There is a sense of an enormous debt of gratitude to 
their loved ones: 
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“They were the main support.  Just travelling, even 
travelling, when I was in they could visit us every day from 
Glasgow in the mornings.  Some of them were here in the 
afternoon, some at night, they split it up so that I had a visit 
all time.  And when I got out I had to come here once a 
week for two weeks, and then it was twice a month, so 
obviously I had to rely on family for coming here, which 
was great, you know, I wouldn’t have made.  I would 
definitely not have made it.” (Steve) 
 Although participants’ attempts to adapt to the reality of ongoing infection and a 
series of treatments appeared to be dependent on the help from others, they also 
tried to manage their lives on their own by, for example, adopting a healthy 
lifestyle. Common strategies they used included refraining from alcohol, 
cigarettes, and some foods that made them ill and caused liver irritation. They did 
not only adhere to dietary advice from the medical team, but they changed their 
eating habits based on their own bodily reactions. Implementing a healthier 
lifestyle, allowed participants to develop a sense of control over their illness and 
made them realize that they themselves could change the way they felt: 
“The most important thing is to refrain from such foods 
which is not good for the Hep C or the liver. And also 
alcohol and the… What’s called the thing is… The smoke. 
I don’t smoke. I don’t drink. And even refrain from the 
foods. I am taking Warfarin now but I want to… And that 
morning before the surgery... Before the surgery also ten 
years before when I ate some grapes and felt something 
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is different. I stopped the grapes. Why I have the grapes 
when it’s not good for my liver. So I feel something 
different.” (Harry) 
Self-management and change in health behaviours seemed to be facilitated by 
participants’ positive mental attitude. Despite adversities such as unsuccessful 
treatment outcomes and virus recurrence, participants reported very optimistic 
view that ‘things can only improve’. Their optimism, although it might seem to be 
unrealistic, was based on rational expectations for future cures, they learned to 
anticipate these over the years. They also seemed to be focused more on the 
present experience of health improvement rather than on the ongoing infection: 
“I would just say to people, just advise, try and stay 
positive. It’s something that you’ve got. The only cure there 
is if it’s not cured, and you’ve got to go for it. You’ve got to 
go for it. Try and keep yourself fit, do what they tell you, 
you’ll come out the other end, and just get on with your life 
after that.”(Gus) 
Getting a new liver appeared to be for many of the participants a milestone in 
rediscovering their lives and was pivotal for attitudinal change. Post-surgery, 
nothing seemed to limit their lives (as it had in the pre-transplant period) and their 
expanded optimistic view gave them an impression that they had ‘everything to 
look forward to’. Many of the participants emphasized that they had learned to 
live for the present moment and to accept ‘every day as it comes’.  
For two participants (Steve, Harry), a positive attitude and acceptance of living 
with HCV seemed to be grounded in their religious practices. Harry used prayer, 
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first, to decrease stress when waiting on the decision as to whether he would be 
on the transplant waiting list and second, when awaiting the transplant itself. The 
fear of possible negative outcomes of the surgery and of death itself seemed to 
be overwhelming and difficult to manage. However, prayer and fatalism appeared 
to ease this distress: 
When it (liver transplant) was coming I just prayed to God and at that moment I 
prayed for a while, which we pray regularly and that’s it. My wife as well and so 
all the family and some of our friends came and they prayed to Allah, (Harry) 
After a long, uncertain and stressful wait to receive a transplant, a challenging 
period of post-transplant recovery then ensued. Participants seemed to be aware 
that without the emotional and physical support from their family members they 
would have had to stay in hospital and rely on medical care alone. They 
emphasized the huge psychological burden that was caused by their poor 
physical condition after transplant. They reported physical weakness and 
depressive thoughts that would not be possible to overcome without constant 
encouragement from their family: 
“I wouldn’t say suicidal thoughts, but just stupid thoughts 
going through your head.  As I say, if you stayed yourself, 
you would need help because it does play on your mind, 
you know what I mean?  Just stupid things.  What am I 
really doing because I'm just lying here, I'm doing nothing, 
because you can't do nothing. [] But no, if you didn't have 
a family round about you, you'd need to stay in hospital.  
You'd need help from a psychiatrist to say, "Look, that's 
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normal for you to have all these daft things running through 
your head."  But my family were there for me.”(Ted) 
Great importance of family support in recovery was often emphasized by 
participants. They also revealed a sense of responsibility and protecting mode 
towards their loved ones, who sacrificed their lives to look after them. They 
seemed to stay ‘strong’ and well for their family knowing how ‘hard’ and 
‘disappointing’ the journey through HCV treatment was for them as well. In a 
reciprocal manner, they appeared to perceive their families need for support as 
being just important as the help they required themselves. Participants were fully 
aware of the burden that their illness brought upon their partners and that they 
were considered an integral ‘part’ of the HCV situation. Participants seemed to 
feel a responsibility for their families who were in a way fated to share their lives 
and destiny with them:   
“They need to get a little bit more I think.  There should 
be somebody there I think supporting them. Okay, fair 
enough, maybe a nurse or something popped in just to 
say ‘everything is going well’ but that’s it.  I think they 
should get a little bit more I think. [] They are part of it.  
Even though I’m going through it they are dealing with it 
just as much as I am.  They’ve got to live with me.”(Eric) 
After a long period of recovery from liver transplant, participants reported that 
staying employed was an important form of coping that helped them to maintain 
a sense of stability and achievement. For Gus the decision to get back to work 
after his liver transplantation seemed to be a triumph over illness, a way of 
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regaining control over his life and a reminder of what a ‘normal’ life might be. His 
goal to return to work motivated him to stay active, despite his diagnosis: 
“I set my target to get back to work and that to me was 
important. Because that to me was normality, getting back 
to a normal thing because people used to say, “Why do 
you wanna go back to work? You should be retired at your 
age and that. And for me that was a big thing, it was a 
victory.”(Gus) 
For others, returning to work was too ‘big step’ that turned out to exceed their 
physical abilities. The consequences of resigning from ones job seemed to have 
tremendous impact on participants’ psychological well-being. Some participants 
(Steve, Gus) reported their job was ‘one of the major things’ that they missed 
after transplantation made them feel depressed and purposeless. The routine 
related to work appeared to protect their self-worth. Being deprived of their daily 
work rituals, seemed to mean for the participants a deprivation of normality, 
health and self-confidence. 
However, over time participants who did not return to work appeared to adapt 
strategies to keep themselves occupied. The job-related routine that was lost 
irreversibly seemed to be replaced by new tasks, consisting of small goals and 
targets, but nevertheless giving the participants a sense of purpose in everyday 
life. Engaging in these everyday activities appeared to release them from the 
entrapment and isolation that HCV had brought to their lives. It also evoked a 
sense of personal freedom and allowed spontaneity to re-enter their lives again: 
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“I just try to get up and go out every day. Like I say, I came 
out, let’s say November, no, it was October, after the good 
weather came I was out every day. But after the transplant 
I went out for my paper and things, going out, I managed 
to after a wee while be able to go for messages and 
things, and walked round to my family, so that’s what I’ve 
done rather than stay in, so that was good.”(Steve)  
When engaging in everyday routines, participants seemed to also apply 
downward comparison as a coping strategy. They compared themselves to less 
fortunate HCV patients and seemed to draw from it an additional motivation and 
energy: 
“I just thought to myself, “Listen, I got that, a lot of people 
have got that (new liver) and not been as lucky as me.”  A 
lot of people have what I had and waited, didn’t even make 
the liver transplant they were that ill, but I was that way, 
I’ve managed to get this liver transplant after three months, 
and I’ve got through it.  And thank god I did.  So you think 
of other people, that I was fortunate and how I came out, 
and I did come out on a Sunday.” (Steve) 
This account is peppered with a relief and gratitude for receiving an organ that 
saved Steve’s life. His words are also a nod to gravity and unpredictability of his 
former health status that is still other people’s faith. He seems to feel indebted to 
all those patients who had not received the new liver and obliged to attend 
worship and pray for them. The organ he received thus appeared to be a gift from 
God that others were deprived. Further, religious beliefs that helped him to get 
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through the journey of transplantation, now help him to cope with the guilt of 
survivor.   
Experience of medical and social support 
Resilience and an ability to cope with adversities related to HCV diagnosis and 
treatment could have been either enhanced by professional support or 
additionally challenged by their inadequacy. Participants’ reports about the 
medical care they received, oscillated in tone from great respect and praise to 
disappointment and reproach.  Negative emotions were expressed in relation to 
the side-effects of interferon treatment and an informational gap regarding the 
new sofosbuvir cure. Conversely, the acknowledgment of professional support 
was present when the procedure of liver transplantation was recalled.  
Participants felt strongly about not being informed about the side-effects of 
various treatments they had received. Participants seemed to be completely lost 
and ‘didn’t know what was going on’ when they were assigned to HCV treatments. 
They were unaware and unprepared for the consequences of treatment until they 
experienced the first associated side-effects. They seemed to be deprived of 
basic information as to what possible outcomes they could expect. This appeared 
to limit their opportunities to approach the treatment in a pro-active manner. In 
essence, they had no option but to react when they could have been pro-active:  
“Where, as if, they told me there was likely to be these 
things. Some of the things that could happen before it, 
then… I would have been prepared and I would have 
understood that this is all kicking in. There’ll have to be an 
adjustment. So they’re very bad that way. I would like to 
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know what the possibilities could be over the next few 
months. It’s not till it happens to you and they say: “Oh, 
yeah…” (laughter)…so…yeah.”(Gus) 
Like Gus’s, many other narratives reflected the participants’ sense of being 
abandoned by the medical profession, expressed as being ‘ditched onto 
transplant co-ordinators’ (Gus) and not receiving the care and information they 
deserved. Being deprived of an opportunity for a consultation with a doctor 
seemed to evoke strong feelings of disappointment and negligibility. 
Consequently, participants reported being perceived as not ‘high-category’ where 
pre-transplant patients receiving new treatment were considered to be more 
important.  
 Negative feelings regarding medical providers seemed to shift when participants 
left the discussion about the sofosbuvir treatment and reflected on the 
professional care they had received more generally. Participants reported a 
trusting and appreciative attitude towards all medical providers. They 
emphasized the availability and competency of transplant co-ordinators that were 
their main source of information: 
 “[…] they gave you quite a lot of support because it was 
quite – your clinic appointments are quite regular after it 
and then because the Hep C has still been bothering me – 
if I didn’t have that they would have been yearly, that’s the 
way it should be, but because of the Hep C it’s been more 
regular for me to come back here.  But the coordinators 
are great; if you’ve got any problems you just pick the 
phone up to them.  They are only a telephone call away if 
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you needed any help, any questions, they are always 
there.  If you want any information you ask them, you don’t 
ask the doctor.” (Eric) 
Although participants emphasized the ‘need to be looked after’ by their medical 
providers, they also indicated clearly that they never needed any medical ‘aids’ 
or additional physical support. Thus, they sought professional advice in terms of 
treatment and side effects while incorporating a self-sufficient approach to their 
physical care, relying only on their own determination to ‘build the strength up’ 
and necessary family support.  
In terms of emotional support, participants did not indicate the need for help from 
health care providers. Many of them reported contacting support groups or 
speaking to other HCV patients in order to find reassurance and help. They 
appeared to rely on this form of support and information provision more than on 
what they heard from their doctors. They seemed to be able to build clear 
expectations based on other patients’ accounts and gain greater insight regarding 
their treatment and its consequences: 
“Tell us what that guy that had it a year after me. After I 
spoke to him I was, ‘Yeah that’s made me feel…’ because 
I know it’s not just me it’s happening to. He’s gone through 
the same, so it must be a normal side effect of the 
operation or the medication and that’s what’s happening 
and that’s why it’s happening, but before it was because is 
what’s happening (…)” (Chris) 
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There was an ambiguous approach to meeting other patients and listening to their 
experience in the pre-transplant period. For some of them contacting post-
transplant patients before their own surgery was extremely important and 
reassuring, whereas for others it only reinforced the emotional burden and sense 
of isolation:  
“When I went there I was the only one that was on the list; 
they already had their transplants.”[…] we went away 
because it was upsetting Simone because he kept talking 
about how good it was. Okay, that’s good that you know 
what to expect but it’s not helping me really all that much 
I’m still waiting.”(Eric)   
Eric seems to emphasise a need for stage-appropriate support for HCV patients. 
People he had met at the support group meetings were at an advanced stage, a 
stage that he desired and perhaps a stage he feared he wouldn’t reach. A fear of 
unpredictability and uncertainty evokes a sadness and withdrawal.   
 
 
Theme 3: The experience of treatment 
Participants reported their journey through HCV treatment chronologically. Their 
experience of the various phases of medical interventions overlapped in many 
ways and evoked similar physical and psychological reactions. All participants 
started with a variety of pre-transplant treatments mostly containing interferon 
that induced several detrimental side-effects. Then, they described their 
experience of being on the transplant list and receiving the transplant. The new 
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organ was not, however, a guarantee of a full recovery and virus clearance. 
Therefore, participants found themselves searching for a new cure that could 
treat the recurrent virus and give them hope for an illness-free future. 
Trial and error- feeling “like a guinea pig” 
Participants in this study reported unique experiences of their pre-transplant 
treatment and indicated a number of detrimental physical and psychological side 
effects of some of the medical interventions. They all seemed to be unprepared 
for what was happening in the aftermath of the trials, however, they all decided 
to attend the treatment as anything is better than nothing. Subsequent treatments 
offered them hope when they were staring death in the face.  
However, a lack of information before and after treatment resulted in feelings of 
irritation and disappointment. According to the participants’ reports they seemed 
to confuse physical symptoms (e.g. sweating, cold, fever) with flu-like-symptoms 
or simply called them ‘complications’. These unspecified side-effects made them 
feel ‘not totally in control’ of their actions and emotional responses. Some 
participants reported outbursts of anger and frustration as a consequence of the 
interferon treatment. Their aggravated irritability caused them to be ‘dead-quick-
tempered’ and ‘snap’ at family members without any reasons. Reported mood 
swings ranged from aggravated anger to depression.  
The extent of the experienced side effects appeared to be difficult to define. 
Extreme physical and mental states seemed to change within seconds, not giving 
the participants the possibility to predict or control their bodily reactions and mood 
swings. There was no continuum of experienced symptoms, but highly disruptive 
physical and mental reactions that could not be controlled. This experience of a 
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total loss of control, however, did not provide Eric with a belief that he should not 
be blamed or be responsible for his actions or words. He seemed to be aware of 
what he had done to others and that it was inappropriate and out of character: 
“[…] the treatment itself was horrendous. You were sick, 
you were in depression, you were angry, and you didn’t 
want to talk to anybody. I stayed in my bed. The smallest 
little thing just set you off. . You were shouting at the kids, 
you were shouting at the wife, but you were up – 
sometimes you were up but the majority of the time you 
were down. You would feel as though you had a major flu 
attack. It was – you were sweating, you were cold. So it 
was really, really bad.” (Eric)  
 Eric’s extract here, suggests a deprivation of self-control over his mood and he 
seemed to be helpless in the face of the mood disturbances. He encountered a 
state where his mood could suddenly change from deep depression, to extreme 
anger and a manic state. In turn, this mania seemed to trigger social withdrawal 
as a defence mechanism to prevent angry outbursts towards loved ones and 
friends. 
Other participants reported decreased self-awareness when discussing 
aggressive reaction to treatments. They seemed to have great difficulty in 
comprehending what was happening to them. In this sense, they appeared to rely 
on reports from their friends and relatives, rather than on their own first-hand 
recollections. Most of the participants also struggled to identify themselves with 
the behaviour they displayed as a result of interferon treatment. They seemed to 
seek an escape from their past actions, by emphasising that it was not them who 
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acted so impulsively, because they were ‘not like that’. It was as if the treatment 
had completely taken over them: 
“there was difficult to understand what was happening to 
you, you know, but it wasn't something that was made 
you going to kill somebody, you know....nothing like that 
or go fighting or nothing, just felt not totally in control, 
which was an unusual thing for me.” (Gus) 
‘Horrendous’ side effects and unsuccessful treatment seemed not to stop 
participants from exploring other available drug trials. They appeared to perceive 
each treatment as a unique opportunity to overcome their debilitating condition. 
Subsequent treatments became a synonym of an opportunity that could not be 
missed, because it appeared to be a potential way out and gave them hope for 
the future: 
“One of them, one of the trials was very bad, but that was 
the one I was quite happy to, the new landing hospital was 
quite happy to go into these trials, because well sort of 
thing that was there was a chance, and also it was a way 
of moving forward to the next stage of trials etc.” (Gus) 
 Participants appeared to try anything and everything offered to them, even if that 
meant to go ‘on placebo’ treatment that could have caused no change in their 
health condition. It was notable that none of the participants seemed to express 
any strong emotions such as disappointment or frustration when describing 
treatment failures. In fact, one participant (Eric) emphasised that his ‘wife was 
more upset’ than he was, when the virus ‘came back’. Their non-responsiveness 
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and persistence in seeking new treatments might give a sense of how they 
attempted to make the poor treatment outcomes more bearable. They appeared 
to accept unquestioningly that ‘a dozen different tablets’ were ‘tried on’ them ‘in 
different combinations’ and that several treatments they attended appeared to be 
unsuccessful. Focussing on the future and not the past supported their 
determination and treatment adherence.  
Participants’ attitudes to the treatment and their adherence seemed to be, 
however, dependent on the trust they put in their medical providers. Many 
reported severe negligence from hospital staff that caused their confusion, 
disappointment and shock. They appeared to perceive themselves as being 
mistreated when they were extremely vulnerable and desperately needed 
support and reassurance. An unexpected medical error related to diagnosis was 
interpreted as yet another failure in patient care: 
“I was on a treatment for, I don’t know maybe five or six 
year ago. [] That was, I think it was just injections. I took 
that for a year and that was another shocker, because I 
went back to hospital to get bloods done and was told it’s 
cleared.  I thought, great. “But we want to see you again in 
a couple of months.” So I went back in a couple of months 
and they turned around and said, “We made a mistake” 
which was a kick in the teeth. You know, how can you 
make a mistake with that sort of thing?  To tell you it’s 
cleared and then all of a sudden, no. That was another 
where hospital let me down.” (Jimmy)  
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Jimmy has been humiliated by unfair treatment and negligence of the medical 
staff at a time when he needed their support most. People, his life depended on, 
disappointed him and made him suffer mentally after horrible mistake they made.  
In the end, however, participants appeared to accept their helpless position of a 
‘guinea pig’ in endless medical trials. They also accepted that they might not be 
informed about the potentially serious consequences of undertaking treatments 
and that these treatments might be just as unsuccessful as all of those they had 
tried in the past. Participants seemed to rely on medical doctors hoping that ‘they 
are trying to get rid of it (virus)’. Thus, on the one hand participants perceive 
themselves as ‘guinea pigs’, whereas on the other hand they accept their status 
of a trial subject. 
In summary, continuous participation in antiviral therapies seemed to disturb 
participants’ identity as healthy individuals.  A sense of helplessness was sensed 
here-they were placing all of their trust in the hands of a medical profession who 
had let them down so badly, so many times in the past. Consequently, they 
experienced concerns and frustration, but they also appeared to tolerate it and 
put their lives in the hands of others in the hope that subsequent treatments would 
free them from the burden of HCV. At times, they appeared desperate and 
extremely determined in their attempts to get the new cure and ‘get rid of the 
virus’. However, their attitude appears to be justified when the fear of dying and 
the increasing risk of not being able to survive another day became a reality.  
Living with uncertainty 
Uncertainty was further heightened by participants’ awareness of a rapid 
deterioration in their physical functioning, particularly a year before transplant. 
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Some of them just carried on with their lives until ‘it really took hold’, started 
slowing them down and interfered with their daily living. That was also the time 
when they had to confront the inevitability of a transplant that they attempted to 
repress in previous years. They seemed to delay facing reality, immersing 
themselves in a relatively stable health condition until such a time that their health 
could not afford them to delay no longer:  
“I suppose in a way you always wondered what would 
happen, how you would feel and everything. But I always 
took the attitude just get on with life. But then, when I 
started to go downhill after that, you know, they had 
mentioned you know a number of years before, you know 
this...I always knew there was always a transplant  at the 
end of it, even if they didn't work the treatments now, there 
is always a chance of transplant. I didn't go into, you know, 
what that meant really, until when I started go downhill 
2013.”(Gus) 
Further, when the transplant was considered as the only life-saving option, 
participants were then confronted with the related, subsequent challenges and 
uncertainties (e.g. expecting a place on the transplant list). None of the 
participants appeared to know how long it would take to receive the decision and 
if they got a positive one, how long they would have to wait for the transplantation. 
Awaiting the decision seemed to be ‘endless’, even the shortest period of time 
felt an eternity, when their life was at stake. They became impatient and 
expressed their frustration by questioning the meaning of keeping them on hold. 
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Uncertainty of what would happen to them in the near future evoked desperate 
indagation:   
 “Why is it taking so long? Why is it taking them two months 
to write this? Why am I not there?  Why is it taking so long?  
And when you think back it wasn’t that long but it’s long to 
me because it’s another two months down the line where 
I should have started two months. Who knows what 
lengths of time that you are going to be on the list? Nobody 
knows.” (Eric) 
Eric seemed to feel lost and abandoned, when all he needed was information 
provision and reassurance. Feeling alone, in this critical moment, when 
participants were so fragile and hanging in the balance, would determine their 
fate and a sense of helplessness and desperation.   
Some participants also did not know that considering their poor condition, there 
was a real possibility of not receiving the transplant. They appeared to be 
confused and deeply disappointed when they discovered the real purpose of pre-
assessment was to verify ‘whether or not they should go on the list’ and not as 
they assumed to understand how much they ‘needed to be looked after’. 
Paradoxically, their deteriorating health status that brought their cases to the 
stage of transplant consultation, could have also declined their chances of getting 
onto the transplant waiting list. Therefore, a feeling of relief, calm or joy 
accompanied the news that they were going on the list. The power of the long-
awaiting decision was for some participants and their partners extremely 
overwhelming causing a small breakdown and an awaking of future expectations:   
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“They told me, you’ve been accepted, you’re on the list and 
I just broke down, totally. I think, I’m going to start getting 
my life back here.  Then of course you don’t know how 
long you’ve got to wait, it’s just your luck I suppose.” 
(Jimmy)  
This happiness and relief was short lived and quickly replaced with worry, fear 
and eschatological thinking. Their hope appeared to be tinged with fear of not 
receiving the transplant after all. Two of the participants (Harry, Eric), reported 
that because of their very rare blood group, there was a real possibility of not 
finding a suitable donor in time. Therefore, the fear of dying before they could 
receive a transplant, seemed pronounced and very real. Participants were aware 
they could die ‘anytime’ whilst awaiting the transplant and feared that they would 
not live another year.  
This fear of dying did not dissipate them even when they had reached the 
transplant stage.  They were told by surgeons about possible fatal outcomes of 
the operation and about ‘the amount of people that died on the operating table’, 
which all heightened their pre-transplant anxieties. The information given to them 
prior the operation evoked eschatological thinking and an accelerated awareness 
of their own mortality. Uncertainty of the outcome made them feel extremely 
vulnerable and helpless. A matter of their survival and their faith appeared to be 
beyond their control:       
“They said, "You might die on the operating theatre.  Your 
liver might be rejected so you've got to go onto the super 
list, and that's a case of you first to get a liver." That's quite 
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scary as well, saying if I'm going for a liver transplant and 
that liver doesn't take, how am I going to survive until they 
get me a new one because I don't – you've not got that 
long to go. I don't know if it's a day or two days, I don't 
know. But it'd be a case of I'm first to get a liver in the 
United Kingdom and it's pretty scary.” (Ted) 
Uncertainty about survival of the transplant was expressed by all the participants. 
They were scared about dying on the operating table. They appeared to be 
particularly worried about the fact that they ‘might never see’ their relatives again 
and that their partners would have to deal with their death and its consequences. 
They tended not to share their fears with anyone to ‘not scare people’ with saying 
that they ‘might not be back’. Their priority became to protect their loved ones 
from despair by covering their own worries and uncertainty. A moment when the 
fear of dying accelerated and ‘kicked in’ was for the majority of the participants 
the point at which they were taken in to the operating theatre:  
“The worrying one is when you’re actually on your way 
there and – in your head, you know what to expect, but 
you don’t know.  And when you get taken down, on the 
way through it and when you’re getting taken down in that 
theatre, you think to yourself, is this it?  Is this my last 
breath sort of thing?”(Jimmy) 
Jimmy’s and some other participants in the current study, revealed stark 
realisation of their own mortality and how fragile their lives were at that moment 
in time. Everything appeared to be suspended here, fixed on this one moment of 
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liver transplantation where their life hangs beyond the balance and depends on 
others. 
Some participants reframed the seriousness of the situation they were in, by 
reassuring themselves that they were ‘strong enough to get through the 
operation’. Further, their irrational optimism also appeared to be expressed 
regarding the outcomes of the transplant. Some seemed to strongly believe that 
they would be able to survive the procedure, as if they were predestined to live 
and not to die. Conversely, others appeared to accept the worst scenario 
assigning the outcome to predestination, something that seemed to be beyond 
their control leaving them only with prayers and hope. By accepting the fact that 
their survival was beyond their control, they started to adopt a fatalistic approach: 
“So maybe something happened but I also said when it 
happened it happened. This is Allah brings, Allah, God so 
it’s happen it will happen but we’ll pray to God and 
something happen better for me. That was the only 
hope.”(Harry) 
Once more, the successful transplant that they prayed for and hoped for, did not, 
again, release their fears and uncertainties. HCV recurrence was ‘sort of hanging 
over’ them, like ‘a shadow, a thing on the new liver that did not let them forget 
that they would never fully recover or ‘get rid of their illness’. Despite all the efforts 
from the side of medical providers, a transplant gave the participants no 
guarantee of clearing the virus. However, knowing that there was a chance of 
recovery was enough:  
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“At first I thought, ‘Oh well one side of the transplant that 
will be my clear than clean’, but then I thought about it and 
I did ask the doctor and he says, ‘No it could re-infect you 
because they can’t take it all out’ even with a blood 
transfusion, he said, ‘Even that there could still be traces 
in that’ so I settled for that, but as long as I got the new 
liver.”(Chris) 
Finding out about virus recurrence after transplantation appeared to bring other 
participants to a realization that they were ‘on the downward slope again’ and that 
‘a continuous circle with the Hep C’ was never ending. Their way through illness 
and treatment appeared to be, at that point, an endless Sisyphean cycle. 
Consequently, the lack of positive outcomes made them to express their helpless 
position that there was no point of trying anymore, because it seemed that they 
were ‘not going to get anywhere’ despite the constant efforts. 
Feelings of helplessness in the face of reoccurring HCV appeared to be 
additionally enhanced by the unknown extent of HCV on the new liver. The 
majority of participants emphasized the aggressive, ‘attacking’ nature of the 
recurred virus that viciously ‘came back with a vengeance’. Participants seemed 
to make a deliberate attempt to humanize the recurrent infection and make the 
reflections very personal. It appeared to reveal their need for creating a tangible 
enemy that endangered their health and well-being, one that they were constantly 
battling against. 
Participants then began to turn their attention to their new organ, in particular, 
they focussed on preserving the new liver and protecting it as far as possible. 
Despite this, concerns of organ rejection was ‘could happen at any time’ (Gus).  
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New cure-“if they can get rid of it, I'll be over the moon.” 
Information about a new cure with the potential to clear the virus, formed a solid 
foundation of hope for HCV patients after transplantation. Participants seemed to 
associate new treatments with something that could only ‘improve things’ and 
prevent them from suffering ‘badly’. The cure regained and intensified a sense of 
future possibilities in their lives. Clearing the virus seemed to restore their positive 
attitude to life and brought back enjoyment and hope. It also appeared to have 
the potential to erase everything that made their lives a constant struggle: 
“So when I become healthy I can do a job. I can enjoy my 
life. It’s so… You know enjoy the world. I became good 
and so is there is no other complication, no problem.” 
(Harry) 
  The participants’ hopes for a disease-free life seemed to be slightly 
counterbalanced by fears of detrimental side effects of treatment. Most of the 
participants tended to look back and identify situations that were burdensome 
and prevented their adherence to the previous treatments and getting the virus 
clearance (as discussed previously). Participants were deeply concerned about 
possible side effects and worried about ‘what could go wrong’ in the course of the 
treatment. They recalled vividly symptoms like ‘sickness, dizziness, and 
sleeplessness’ that affected them in the past, and they appeared to fear liver 
rejection as a consequence of taking new treatment. However, no matter how 
detrimental were the effects of the past medical trials, and how the new cure could 
affect their new liver, they seemed to be desperate to receive it anyway and put 
themselves ‘forward for anything’: 
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“It depends how bad the side-effects were.  But if I thought 
I could with them then I would carry on, it’s only twelve 
weeks.  I mean it sounds a long time, but it’ll be worth it in 
the end I suppose.” (Jimmy) 
Most of the participants identified a number of factors that could stop them from 
attending the new sofosbuvir treatment, such as organ rejection, side effects or 
uncertainty about its effectiveness in post-transplant patients. However, all these 
fears and uncertainties that the novel therapy evoked, seemed to not only have 
a rational explanation. Participants appeared to identify obstacles and 
contraindications for the new therapy in order to protect themselves from 
disappointment and frustration that could result if the sofosbuvir treatment failed. 
This might also relate to the way they had learned to adjust to the challenges of 
living with HCV and a series of treatments they had undertaken over years.  
Two participants, who completed the sofosbuvir treatment and cleared the virus 
successfully, reported being seriously ill after receiving it. Here again, the sense 
of determination and hope of being ‘virus-free’ supported their adherence to the 
course of treatment. As participants who were still expecting the treatment, they 
started instilling hope that was not based on ‘much evidence’ or ‘exact science’, 
but they were still ‘hoping for the best’, and kept their ‘faith’ all along. When the 
treatment was considered successful, a sense of freedom was reported, giving 
birth to a new, healthy identity: 
“After it was clear I was a different person because that 
always hanging over me after the transplant. There’s a 
shadow, a thing on the new liver, the hepatitis C is 
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attacking it, once I got clear, different, great, so it was.” 
(Steve) 
 
In summary, this section showed how participants’ outlook on life and themselves 
had shifted diametrically as soon as they found out that they had cleared the virus 
or when they could just imagine themselves to be cured. A sense of determination 
and often desperation accompanied their need to be considered for the new cure 
and to ‘get rid of the virus’, which seemed to stand in their way to happiness and 
enjoying their lives fully. Hope appeared to strengthen their resilience in the light 
of uncertainty of possible side-effects and detrimental long-term consequences 
of sofosbuvir treatment. There seemed to be nothing that would stop them from 
becoming ‘a trial and error’ or ‘a guinea pig’ in the new treatment, as long that 
would mean to them ‘no need to go on the other stuff’ and saving the new liver.  
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Chapter Five: Discussion 
  This chapter will provide an overview of the findings from the current study and 
will discuss them in the wider context of the HCV literature. A reflection on the 
author’s personal experience of conducting this study will then follow. The 
strengths and limitations of the research will then be outlined and 
recommendations for future research will be made. 
 
  5.1 Summary of Findings 
  Three master themes and seven subordinate themes have emerged during the 
course of this study- as a result of using interpretative phenomenological analysis 
(IPA) in the process of data analysis. An interpretation of how participants had 
encountered their HCV diagnosis resulted in identification of: 1) various 
psychosocial aspects of being infected with the virus, and 2) how they initially 
learned about the illness. Being diagnosed with HCV was for most of the 
participants in this study, a powerful life event that brought about a immense 
sense of uncertainty and loss in their lives. Participants reported that their initial 
uncertainty relating to the diagnosis was mainly determined by a lack of 
information provision. Subsequent consequences of receiving diagnosis were 
recognized in terms of changes of participants’ social identity and their 
experience of stigma.  
  The second theme revealed different ways of managing the challenges and 
burden of living with HCV. Participants’ approaches towards the illness were 
found to be very pro-active and problem-focused. Resilience and seeking help 
from family members were two main strategies observed in dealing with 
adversities related to diagnosis. An emphasis was also put on the need for 
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professional medical support at the time of the uncertainties that were noted to 
accompany several antiviral treatments and post-transplant/virus recurrence 
related deterioration.  
  The third theme took the reader through a chronological journey of HCV 
treatment. This was again defined by uncertainty, unpredictability and insecurity. 
A lack of sufficient support and information provision, regarding endless medical 
procedures, evoked a disruption to participants’ identities. Their sense of self was 
reduced to the status of ‘a guinea pig’ that has to persistently pursue new 
treatments in order to survive. Their attitude towards those treatments appeared 
to be determination and hope driven. 
 
   5.1.1 The experience of encountering HCV 
   According to Bury (1982), a typical initial reaction to diagnosis is a feeling of 
uncertainty. Participants in this study repeatedly expressed their fear of the 
unknown, disbelief and shock due to lack of knowledge regarding HCV; 
observations which have been previously described in the literature (Tompkins et 
al., 2005; Suarez, 2010). However, although many of the participants reacted 
intensely to their diagnosis, not all of them did. Some of the participants in this 
study seemed not to be unaffected by receiving the news about their illness and 
carried on, with their daily routine uninterrupted. 
   Other patients, on the other hand, indicated a profound change in their quality 
of life. This detrimental effect was caused by labelling associated with the 
diagnosis itself; as previously recognized in the literature (Rodger et al., 
2003).Moreover, an illness that had been asymptomatic and had no impact on 
participants’ lives for years, unexpectedly started to significantly interfere with 
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their daily functioning. Also, participants’ perception of the worsening of their 
condition could have been determined to a great extent by their beliefs regarding 
the illness and attitudes towards it, rather than actual reactions to the presence 
of deleterious symptoms of liver disease (Castera et al., 2006).  
  A similar division in approach to diagnosis has been noted in previous research 
(Harris, 2009; Olsen et al., 2013). These differences demonstrate how the 
reaction to diagnosis can be dependent on the context. Those participants who 
contracted HCV through injected drug use reported that receiving HCV did not 
disrupt the structure of their everyday lives. Since it was recognised as an 
inevitable consequence of their actions. Also, due to high rates of HIV in this 
population, perhaps HCV was perceived as lesser of those two negative health 
outcomes. As previously recognized (Olsen et al., 2013), these individuals 
seemed to accept that the infection was incorporated in their identity of former 
drug users.   
  However, although some of the participants seemed to be unaffected by the 
diagnosis itself, it did change how others responded to them and treated them. 
This resulted in a disruption to their social identity. Poor knowledge about the 
infectiousness of HCV, and associating the disease exclusively with intravenous 
drug use, were found to fuel stigma against infected individuals (Butt et al., 2008; 
McCreaddie, Lyons, Horsburgh, Miller, & Frew, 2014; Hill, Pfeil, Moore, & 
Richardson, 2014). Feelings of social isolation and loneliness, as a direct 
consequence of stigmatisation, were also exposed in the majority of accounts- 
as also reported in the existing literature (Hill et al., 2014; McCreaddie et al., 
2011).  
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  This current study revealed that the stigma could also be related to strong 
emotional responses. According to previous findings (Tompkins et al. 2005), a 
diagnosis of HCV might raise considerable negative emotions that participants 
then appeared to direct against themselves (e.g. regret and shame) or towards 
others (e.g. blame and anger). Blame and anger, in terms of the stigma of HCV, 
can be understood as attempts to resist or reject the existing situation. These 
reactions were found to promote changes in a societal order and have the power 
to preserve positive self-identity (Stuenkel & Wong, 2009). Therefore, participants 
in the current study who reacted strongly to the diagnosis also indicated a very 
pro-active approach towards socio-political circumstances relating to HCV and 
appealed for their transformation.  
  Conversely, participants who were only focused on internalizing blame and 
regret in terms of contracting HCV (by injecting themselves), adopted a rather 
passive attitude towards general issues of HCV and indicated a tendency to 
isolate themselves from it. This reaction to stigma was found to be typical 
amongst affected individuals who often limited their contacts with society to 
enhance their feeling of normality (Camp, Finlay, & Lyons, 2002). The participants’ 
sense of normality and distancing themselves from the diagnosis, was, in addition, 
facilitated by the initial lack of symptoms typically associated with HCV. This 
‘invisibility’ of the stigma helped them to deny the salience of the diagnosis 
(Suarez, 2010).  
  The sense of stigmatisation was expressed differently by all participants in this 
study; which supports previous findings by Zickmund et al. (2003) who indicated 
that stigmatisation affects all infected individuals, despite their source of infection. 
However, as this current study has newly found, there are differences in terms of 
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how various groups of affected participants can react to diagnosis. Thus, it was 
shown that ‘victims’ of contracting the virus through blood transfusion tended to 
externalize their blame, whereas former drug users internalized blame. These 
new findings seem to consequently lead to differences in their approach to 
disclosure and coping (see Fig. 4). 
Fig.4. Differences of responsiveness to stigma and disclosure amongst participants in 
the current study. 
 
  Thus, a fear of stigma and rejection determined participants’ decision about the 
disclosure of their HCV status to their family, friends and society in general. One 
of the participants in the current study chose not to reveal his illness to relatives. 
This is a common reaction amongst HCV patients, previously supported in wider 
literature (Schafer et al., 2005). Fear of disclosure was also found to be an 
obstacle in building new romantic relationships or keeping previous contacts in 
other participants. Thus, diagnosis of HCV can lead to a long-term impact on 
patients’ ways of interacting with the family, friends and society, which is 
consistent with earlier findings (Tompkins et al., 2005). 
  This attitude seemed to be related to participants’ concerns about compromising 
the health and well-being of others- an observation that was also highlighted in 
previous research (Tompkins et al., 2005). This protective mode in approach to 
others often resulted in the limiting of participants’ contacts with friends and their 
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children, sometimes even in living in solitude. In this sense, findings in the current 
study extend those of the previous literature, by highlighting the inter- and 
intrapersonal consequences of HCV infection. 
     
  5.1.2 Managing the diagnosis of HCV 
  In this study, participants indicated resilient coping mechanisms in response to 
diagnosis with HCV, prolonged treatment and its severe side effects (Fig.5). The 
chronic disease that, until last year, was perceived as untreatable, constituted 
extreme hardship that could be maintained only if patients have a certain capacity 
to cope with it. This capacity can emerge from a range of external resources, 
including a caring family and wider social network, as well as from the strengths 
and resources that can be identified within individuals themselves. By successful 
recognizing, evaluating and applying these resources, people with chronic illness 
can enhance their resilience in stressful times this can have positive implications 
for their health and well-being (Tedeschi & Kilmer, 2005).  
Fig.5. Resilient coping model produced based on data in this study. 
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  When considering HCV as a chronic life adversity, resilient responses appeared 
to be a highly adaptive way of protecting and self-maintaining participants’ well-
being. Findings of this study revealed participants’ involvement in religious 
practices and fatalism. As previously supported in the extant literature (Bonanno, 
2004; Stoller et al., 2009; Pargament et al., 1998), spiritual meaning-making 
processes were identified in two patients’ accounts. One of the participants used 
his religious beliefs to decrease his stress reactivity towards the adversity of 
treatment (Steve) whereas another participant turned the illness over to God, 
interpreting his own outcome as being part of God’s plan (Harry).  
   The importance of establishing a healthy lifestyle was also found to be 
protective in the process of shaping participant’s resilience to HCV (Hopwood & 
Treloar, 2008). Accordingly, participants in this study utilized the positive health 
behaviours in order to effectively deal with uncertainties related to living with HCV. 
This strategy appeared not only to be a guarantee of physical improvement, but 
also gave them a sense of control over their condition, which was recognized in 
previous research (Hill et al., 2014). Participants did not only follow the dietary 
advice from medical staff by applying the new routine, but they also seemed to 
recognize for themselves food that prevented their recovery and compromised 
their relatively stable health status.   
   Hopwood and Treloar (2008) recognized that work and keeping occupied as 
were essential coping strategies in HCV patients. Consistent with their findings, 
participants in this study were found to emphasize the importance of being 
employed or engaged even in small everyday tasks. Adherence to a daily routine 
provided them with a sense of purpose in life and became a synonym of normality. 
When they were deprived of their daily activities and responsibilities, their social 
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identity was disrupted. The well-known structure of their everyday life and their 
self-concept had to be fundamentally reconsidered (Bury, 1982). Therefore, they 
were determined to stay employed or engaged in their daily tasks in order to 
maintain their sense of stability, self-worth and ‘normality’.  
   The pro-active, problem-focused coping that promoted a sense of control over 
their condition also enhanced their positive mental attitude. An applied positive 
approach can, in turn, enhance the development of their resilience in the face of 
chronic adversity (Bonanno, 2004; Tedeschi & Kilmer, 2005). As is typical with 
resilient people, who were found to be hopeful and optimistic even when facing 
chronic illness (Peterson, 2000), most of the participants in the study adopted 
positive overview of the illness and future treatment. Their optimistic approach to 
life in general facilitated their sense of improvement and ‘freed them’ from 
experiencing life through a narrow, illness-related lens. 
   Support from significant others and support groups were also found to be 
important variables in maintaining the physical and psychological consequences 
of HCV treatment (Hopwood et al., 2006). In this study, participants emphasized 
their need of support from family and friends for coping with adversities related to 
their treatment. Being aware of their own vulnerability and limited physical abilities 
following liver transplant or antiviral therapy, they acknowledged the invaluable 
role of their partners and children in their fight with HCV and recognized the need 
for support for their loved ones. These findings constitute an important indicator 
for potential primary carer-focused interventions (Chapman & McManus, 2012). 
   Participants also reported being trusting and appreciative of their medical 
supporters, recognizing their engagement and competence. However, the 
gratitude and general positive view of medical professionals was often 
counterbalanced with strong feelings of disappointment and negligibility at times. 
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An urgent need for more information about the sofosbuvir treatment, and for 
seeing a doctor regarding this treatment, facilitated their negative and doubtful 
attitude towards healthcare providers in general. This builds on previous research 
revealing a negative experience of receiving insufficient information and help 
from medical staff (Bailey, Armour, Kirk, & Jess, 2009) and how such 
insufficiencies can affect individuals’ sense of control over HCV (Hill et al., 2014).  
 
   5.1.3 The experience of treatment 
   The experience of the antiviral treatment that participants were receiving before 
transplantation, and often also after the operation, was described by them as 
highly detrimental- both in terms of physical and psychological side-effects. Their 
accounts are consistent with previous research investigating the side effects of 
interferon and ribavirin therapies (Rodis & Kibbe, 2010). Many participants 
reported outbursts of anger and frustration as well as sudden mood swings, and 
finally a number of physical debilitating symptoms.  
   These side effects not only had a huge impact on the patients themselves but 
also significantly affected their families and friends. Unexpected and 
misunderstood symptoms disturbed family dynamics and, often evoked a need 
for withdrawal and a sense of losing the control over their own lives. This feeling 
of a lack of control over their actions caused the majority of participants to 
experience symptoms of depression; which has often been reported in the 
previous literature (e.g. Ong & Younossi, 2004).  
   The lack of control was also a result of participants’ uncertainty regarding 
treatment for HCV and decision making related to it.  Sustained uncertainty about 
receiving, and effectiveness, of subsequent treatment for HCV has already been 
highlighted (Hopwood and Treloar, 2005; Sgorbini et al., 2009). This uncertainty 
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and lack of control over the process of treatment did not, however, stop 
participants in the current study in their determination and adherence to treatment. 
Despite an ongoing burden of unsuccessful treatments, the hope for a future cure 
was present in their accounts; an attitude also recognized in existing research 
(Hill et al., 2014). 
   As the current study included patients who were either before or after the new 
sofosbuvir therapy, certain differences were identified in their approach to 
treatment and future life. Uncertainty regarding decline of their health, as a 
consequence of virus recurrence, was an ongoing burden described by five pre-
treatment participants. This uncertainty was consequently reinforcing their lack of 
control over their lives and future. Conversely, two participants who had already 
received the new treatment and cleared the virus, experienced a sense of 
liberation and complete control over their future. Thus, this study has 
demonstrated how a limited framework of uncertainty, that is related to the 
diagnosis of a chronic illness (Bury, 1982), can suddenly shift towards a 
framework of possibilities and future certainty when a sense of healthy identity is 
regained through successful outcomes of treatment.   
 
  5.2 Clinical Implications 
  Participants in the current study highlighted the difficulties they were facing while 
undergoing pre-transplant anti-viral treatment, liver transplant and post-transplant 
therapy. The biggest issue at these stages of treatment seemed to constitute a 
lack of information provision and limited contact with medical doctors. The 
informational gap caused both participants and their family members to feel lost 
and confused when they experienced unexpected side effects or a sudden health 
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deterioration in their health following HCV treatment. Therefore, some 
participants argued that there is a need for being as informed and prepared as 
possible regarding the consequences of HCV treatment.  
  Learning more about the current and anticipated treatments would lessen a 
sense of being ‘a guinea pig’ in a set of experimental trials and help participants 
regain their sense of control over their illness. In addition, the possibility of 
receiving this information from medical doctors directly could resolve doubts and 
fears that seem to stigmatize participants’ post-transplant existence. As 
participants’ trust in medical providers had been challenged over the course of 
prolonged treatment, being seen by transplant doctors might also facilitate a 
successful attempt to rebuild a well-functioning patient-physician relationship.  
  In terms of implications for treatment, participants’ accounts revealed a need for 
interventions aimed at family counselling at each stage of living with HCV. 
Participants often indicated how HCV seriously affected their loved ones. 
Therefore, it is suggested that individual therapy should be provided for primary 
caregivers, who are otherwise not provided with any form of organized support. 
The important role of the family in the participants’ recovery also provides a 
rationale for counselling specifically focused on primary caregivers.  
  The fear of disclosure and engaging in sexual relationships that were recognized 
in this study, constitute an important implication for therapeutic interventions for 
both affected individuals and their current (or potential) partners. Attending a 
counselling session with loved ones would allow patients to explain their HCV 
status in a safe environment and help them to improve the communication in their 
relationships after disclosure. The fear of engaging in sexual relationships could 
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also be verified during the couple counselling and bring some clarity in terms of 
real and potential risks of sexual intercourse with people with HCV. 
5.3 Recommendations for future research 
   Although findings of the current research provided a rich and explanatory 
account of the experience of life with recurrent HCV from the patients’ own 
perspective, they also opened up several possibilities for future research. 
Reflecting upon changing medical circumstances of individuals currently being 
treated for HCV, present research constitutes an important fund of knowledge 
that could be elaborated upon and supplemented in the near future by 
subsequent qualitative or quantitative investigations. 
   First, some of the participants’ accounts revealed that HCV has not only a huge 
impact on those directly affected by the virus but also on their significant others. 
Therefore, it is recommended that an exploration is conducted upon the 
experience of HCV from the perspective of family members, who are usually the 
primary and the only caregivers of infected individuals. According to participants’ 
accounts, at times the diagnosis and consequences of HCV treatment affected 
the partners and children more than the participant. Paradoxically, loved ones 
were not offered any form of support, neither physical nor psychological. 
Therefore, through exploring primary caregivers’ experience of HCV, future 
research might recognize essential implications for intervention focused 
specifically on family members. Given the reluctance to disclose their HCV status 
to partners (or potential partners), the feasibility of family/couple counselling 
could be explored to: 1) improve interpersonal communication in relationships at 
the point of diagnosis; and 2) resolve ethical issue regarding not informing 
partners who could be at risk of infection. 
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   Second, the sample of this study was homogenous in terms of gender, 
consisting exclusively of male participants who, in addition, represented 
congenial age range. Thus, it would be interesting to explore the experience of 
HCV diagnosis and treatment from the female patients’ perspective. Considering 
that women were mainly identified as caregivers in the present research and are 
associated with this role in society in general, it may be of interest to explore their 
experience in the opposite role.   
  5.4 Strengths and limitations of the study 
  Several strengths and limitations have been identified throughout the process 
of conducting this qualitative research and will now be discussed in turn. 
 
   5.4.1 Strengths 
   This research provided an in depth exploration of a small, vulnerable clinical 
population living with an ongoing, potentially life-long, viral infection. It revealed 
valuable socio-political background information related to the context of virus 
contraction and vague diagnostics given in the 70s and 80s which, to a great 
extent, shaped patients’ lived experience of HCV. The group of patients that was 
introduced in this study has largely been overlooked by studies that mainly 
focused on HCV patients with a recent history of injected-drug-use.    
   Another strength of this study was the fairly homogenous sampling that allowed 
me to produce a detailed analysis of the lived experiences of a particular group 
of individuals with HCV. Consistent with Smith et al. (2009), my aim was not, 
however, to treat all the participants in this group as identical cases but to utilize 
the obtained uniformity of some basic social factors (e.g. family support, stigma) 
and theoretical indicators (e.g. the resilience theory) to identify psychological 
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variability (e.g., different coping strategies, attitudes to life with HCV) within the 
group. Consequently, I was able to achieve reasonable data saturation while 
reducing generalizability of the results.  
   An important advantage of this study constitutes its inherent flexibility and 
context sensitivity. Flexibility and sensitivity characterized all stages of this 
research: the data collection, analysis and definition of the findings. Use of semi-
structured interviews gave the participants the freedom to respond in their own 
way and enabled me, as a researcher, to explore anticipated and unanticipated 
areas of lived experience of HCV. Moreover, according to Patton (1990) who 
claimed that qualitative data is iterative, I could go back and forth between 
collected data, analysis and findings, allowing emergence and evolution of more 
aspects of the same phenomenon, which would not be possible if the design of 
the study had been rigidly predetermined. The experience of HCV amongst 
patients in this study would also not be fully understood if it had been extracted 
from the socio-political context associated with the contraction of the virus and 
from the family context that played a significant role in maintenance of the 
participants’ physical and mental well-being. 
   Yardley (2000) who has produced a set of guidelines for assessing the validity 
of qualitative research, emphasized the importance of applying following 
principles: sensitivity to the context; rigour and commitment with which the 
research is carried out; transparency and coherence; and the impact and 
importance of the research. I believe I demonstrated understanding and adhered 
to each of the principles. I have introduced the theoretical context, relevant 
literature background and socio-cultural factors that were relevant for the topic 
studied. In terms of the Yardley’s second principle, I demonstrated my 
commitment by my personal engagement in the process of data collection, that 
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is, when and where the interviews took place, as well as in my attentive listening 
to what participants had to say, and careful reflections on the participants’ 
statements. Furthermore, I was focused on idiographic engagement in data 
analysis, illustrating particularities of individual cases by using appropriate quotes, 
but I also emphasize the importance of shared experiences in terms of 
formulating the major themes. Finally, this study has a practical value for post-
transplant patients with recurrent HCV. It provides both the general public and 
the health professional with information about challenges that are a part of 
patients’ everyday reality and that reveal implications for future interventions. 
 
   5.4.2 Limitations 
   A major limitation of the current research is the reduced possibility for 
generalizing its findings beyond the seven individuals who were studied. In order 
to achieve generalizability of the results obtained in this study, further 
investigations involving larger population sampling and additional studies 
conducted in respect of the present topic would be required. Conducting more 
longitudinal studies, following individuals with recurrent HCV through their 
journey, would also be of great importance. These would provide reflections on 
the most recent experience of an illness that had been discovered only 
retrospectively in this study.   
   Other limitations of the current research included the confined accessibility to 
patients with HCV (exclusively gained through NHS clinics) and the low response 
rate to the project. As the contact with patients could only be initiated by the 
transplant co-ordinators during clinic visits or through the invitation letters, I had 
to completely rely on their actions and decision making. More participants could 
possibly have been obtained for this project if they had been recruited through 
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various support groups or through the transplant clinics, but by direct involvement 
of the researcher during the recruitment process.  Furthermore, the small pool of 
potential participants was additionally limited by concentrating this study 
exclusively on the HCV population in Scotland. 
      
  5.5 Reflection on the research  
   5.5.1 Reflection on the recruitment process  
   As I received an unconditional REC approval for my study in June 2014 (see 
Appendix 1), transplant co-ordinators in the Scottish Liver Transplant Unit at the 
RIE were provided with copies of the inclusion and exclusion criteria, twenty 
recruitment packs and a research protocol, so that they could identify, on my 
behalf, patients that were suitable for this research and send the Invitation Letter 
and the Participant Information Sheet to potential participants. Unfortunately, due 
to miscommunication within the transplant team and a busy period in the 
transplant unit, in the first two months of recruitment, no invitation letters were 
distributed to patients. As a result, recruitment was initiated in January 2015 by 
direct involvement of the Head Hepatologist and the Senior Research Nurse in 
the Transplant Unit. The response rate in the first two months after the first 
recruitment letters were sent was small (n=3) but relatively regular; approximately 
two patients a month expressed their interest and participated. However, despite 
fairly regular interviews in the first three months, in April 2015, I was not able to 
access any more patients who would meet my criteria. The number of patients 
who met my criteria and whom I had invited to my study by the end of March 2015 
was relatively small; approximately 23 individuals, of which only four had 
responded and been interviewed. Given the poor response rate and accessibility, 
the Senior Transplant Research Nurse, who guided me through the recruitment 
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process, advised me to open up the inclusion criteria from 6-18 months to 6-36 
months post-transplant. This amendment was approved by NHS ethics. Invitation 
packs were re-sent to participants who had been approached at the beginning of 
the recruitment period and three further participants were then reached. At this 
point, I decided to close recruitment as no further participants met the inclusion 
criteria and I had reached the anticipated end of the data collection period. The 
achieved sample was exemplary of recommendations by Smith et al. (2009) for 
a Master thesis. 
   According to the original research protocol, that was submitted to both ethics 
committees, I proposed to recruit between six and eight patients with HCV 
recurrence and between six and eight primary caregivers of those patients. It was 
my intention to widen the perspective on the infection diagnosis, recurrence and 
liver transplantation by introducing an in-depth account of caregivers’ 
experiences. However, none of the caregivers responded to the research 
invitation. Patients who were approached, in the first instance, with the 
recruitment pack, were also provided with a letter for their primary caregivers 
which was included in the patient’s envelope for them to pass on to their primary 
caregivers, if they wished to.  
  The reasons as to why the primary caregivers did not respond included: 1) non-
disclosure of HCV to loved ones (n=1); 2) partners considered too emotionally 
fragile by participants (n=2); 3) not fluent in English and unable to give a written 
consent (n=1); and 4) unknown (n=3). 
   5.5.2 Personal reflections 
   During the process of carrying out this study I became aware of a number of 
issues that can occur when investigating a clinical population in a medical setting. 
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The RIE, where the majority of interviews were conducted, was chosen firstly for 
the researcher’s and patients’ safety. It was also a place that all participants were 
familiar with, therefore, it was assumed they would feel more confident and 
natural while being interviewed there. However, despite my status as a research 
student being emphasized both in the Participant Information Sheet and upon 
meeting participants, some of the participants misinterpreted my role in the 
clinical setting, assigning me a status of a hospital employee. Whenever I noticed 
an indication of patients’ confusion regarding my role, this was explained and 
clarified again.  
   However, I often had the impression that participants still seemed to be 
somewhat unaware that the current study was not related to, and had no impact 
on, their recent medical treatment. For example, some participants appeared to 
expect a detailed explanation of the new antiviral therapy and possible 
professional advice. They seemed to have particular anticipations of the interview 
in terms of their participation in sofosbuvir treatment and perceived me as a 
mediator between them and the hepatology unit. Despite continuous clarification 
of the research being entirely independent from their medical care, these 
erroneous assumptions were often evident. 
   Using IPA as a method of investigation was a new (and at times challenging 
experience) as I had not previously conducted any qualitative research. I had to 
exert caution with the nature and type of questions I asked and seek clarifications 
on answers I received to ensure I was understanding participants experiences 
from their own perspective. As a novice qualitative researcher, I often sought 
feedback from my supervisors including ongoing feedback on the process of 
coding, analysis and the clustering of initial themes. As the project progressed, I 
gained confidence and independence as an analyst. 
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  5.6 Study Conclusions 
  The aim of this study was to gain an in-depth understanding of the experience 
of living with recurrent HCV following a liver transplant. I achieved this by 
exploring participants’ accounts that guided me through the subsequent stages 
of their life with a HCV diagnosis. The reports gave me an insight into several 
idiosyncrasies and similarities in patients’ attitudes and expectations, both prior 
to and after liver transplantation. Individual differences in the ways participants 
tried to manage the virus were identified, as well as a variety of resources utilised 
for coping. However, all participants were found to be strongly determined to fight 
HCV and were looking positively towards a virus-free future. Their resilience in 
the face of prolonged adversity of chronic disease accompanied them from the 
moment of the diagnosis, throughout the detrimental antiviral treatment, liver 
transplantation, and diagnosis of virus recurrence until the present moment, when 
they had either already cleared the virus or were still awaiting the new HCV cure.  
    Through exploring the experience of living with recurrent HCV, the current 
study made an important contribution to previous research addressing a unique 
journey of HCV re-diagnosis. It has explored intra-personal and inter-personal 
consequences virus recurrence and indicated potential implications for individual 
and couple/family therapy which should be adapted to the needs of patients and 
their loved ones at specific points in time. The periods of pre-and post-transplant 
antiviral treatment were found to be extremely challenging for both participants 
and their families, and therefore, should be further investigated and addressed in 
terms of mental support.   
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   In addition, a paucity of a clinical population with medically acquired HCV exists 
within the wider literature- this group constituted 70% of respondents in this 
current study. The socio-political context of their diagnosis seemed to be omitted 
in the scientific investigations in the U.K. as well as analyses of their unique social 
challenges and unique perspective on the diagnosis. Their approach to diagnosis 
and coping strategies differ from those applied by the participants who acquired 
HCV through intravenous drug use. Consistent with the work of Jacalyn Duffin 
(2005), who recognized ‘two diseases’- two forms of HCV- the first associated 
with ‘contaminated’ blood transfusion (‘innocent’) and the second acquired 
through IVDU (‘guilty’), this study recognized both forms of HCV. Further, the 
characteristics of these two groups were elaborated in the current study by 
identifying two new, distinct, patters between methods of virus acquisition, 
reactions to stigma and participants’ approaches to disclosure.   
   This project has also revealed significant shifts in patients’ attitudes following 
encountering the news of the new HCV cure or after successful completion of the 
treatment.  Hope and optimism about the future and regaining the ‘old’ healthy 
self were predominant in their responses. Thus, this research was the first 
qualitative study that has revealed the attitudes of people with recurrent HCV to 
the new antiviral therapy. Their experience and expectations were unique as, 
unlike individuals who have been recently diagnosed with HCV, they have had to 
live long years with the diagnosis and experimental treatments, in uncertainty and 
fear. For participants in this study, who either received or are expecting the new 
treatment, it is a life-saving and life-changing option that they have been 
desperately awaiting for decades.  
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   The implications of this study lie particularly in the potential for improvement in 
the quality of the lives of patients with recurrent HCV, who are still waiting to 
receive the ‘new cure’. Gaps in the knowledge about the new treatment, and the 
need for greater clarifications in terms of its side-effects and effectiveness, were 
indicated by some of the participants. In addition, considering the high level of 
psychological distress and the high prevalence of depression identified in patients 
with the poorer long-term quality of life after liver transplantation, it is argued that 
counselling and psychological intervention should be provided along with the 
post-transplant antiviral therapy. Also, according to participants’ accounts, 
additional care and support should be provided for their significant others who 
are, as primary caregivers, also significantly affected by numerous challenges 
related to the diagnosis and treatment of HCV.  
 
 
  
 
 
 
 
 
135 
 
References:  
 
Alonzo, A. A., & Reynolds, N. R. (1995). Stigma, HIV and AIDS: An exploration 
and elaboration of a stigma trajectory. Social Science and Medicine, 41, 303-315. 
 
Alonzo, A. A. (2000). The experience of chronic illness and post-traumatic stress 
disorder: the consequences of cumulative adversity. Social Science and 
Medicine, 50(10), 1475–1484.  
 
Anti-Discrimination Board of New South Wales. (2001). C-change: Report of the 
enquiry into hepatitis C-related discrimination. Sydney: Anti-Discrimination Board 
of New South Wales. 
 
Armstrong, F.L., Alter, M.J., McQuillan, G.M., & Margolis, H.S. (2000).The past 
incidence of hepatitis C virus infection: implications for the future burden of 
chronic liver disease in the United States. Hepatology, 31, 777-82. 
 
Australian Hepatitis Council and the Australian National Council on AIDS & 
Related Diseases (1999). Contact 99: Post-test information for hepatitis C 
[Booklet]. Canberra 
 
Backus, L.I., Boothroyd, D.B., Phillips, B.R., & Mole, L.A. (2007). Predictors of 
response of US veterans to treatment for the hepatitis C virus. Hepatology, 46, 
37–47. 
 
Bailey, R., Armour, K., Kirk, D., Jess, M., Pickup, I., & Sandford, R. (2009). The 
educational benefits claimed for physical education and school sport: an 
academic review. Research Papers in Education, 24, 1-27. 
 
Berenguer, M., Prieto, M., & Rayon, J.M. (2000). Natural history of clinically 
compensated hepatitis C virus-related graft cirrhosis after liver transplantation. 
Hepatology, 32, 852–858. 
 
136 
 
Boillot, O., Berger, F., Rasolofo, E., Mion, F., Chevallier, P., Gille, D., & Paliard, 
P. (1996). Effectiveness of early α-interferon therapy for hepatitis C virus infection 
recurrence after liver transplantation. Transplant International, 9(1), 202-203. 
 
Bonanno, G.A. (2004). Loss, trauma, and human resilience: Have we 
underestimated the human capacity to thrive after extremely aversive events? 
American Psychologist, 59, 20–28. 
 
Bonkovsky, H.L., Woolley, J.M., & the Consensus Interferon Study Group (1999). 
Reduction of health related quality of life in chronic hepatitis C and improvement 
with interferon therapy. Hepatology, 29, 264-270. 
 
Bourliere, M., Wendt, A., Fontaine, H., Hezode, C.,Pol, S., & Bronowicki, J.P. 
(2013). How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver 
International, 33(1), 46-55. 
 
Brashers, D.E., Neidig, J.L., Cardillo, L.W., Dobbs, L.K., Russell, J.A., & Haas, 
S.M. (1999). In an important way, I did die': uncertainty and revival in persons 
living with HIV or AIDS. AIDS Care, 12, 201–219.  
 
Braun, V. & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative 
Research in Psychology, 3, 77–101. 
 
Brown, P. (1995). Naming and framing: the social construction of diagnosis and 
illness. Journal of Health and Social Behavior, 35, 34–52. 
 
Bryman, A. (1988). Quantity and Quality in Social Research. London: 
Routledge. 
 
Burrows, B. & Bassett, B. (1996). Meeting the needs of people in Australia living 
with hepatitis C. Canberra: Commonwealth Department of Health and Family 
Services. 
 
137 
 
Bury, M. (1982). Chronic illness as biographical disruption. Sociology of Health 
and Illness, 4(2), 167-182. 
 
Butt, G., Paterson, B., & McGuinness, L.K. (2008). Living with the stigma of 
hepatitis C. Western Journal of Nursing Research, 30(2), 204-221. 
 
Callaly, T., Trauer, T., Munro, L., & Whelan, G. (2001). Prevalence of psychiatric 
disorder in a methadone maintenance population. Australian and New Zealand 
Journal of Psychiatry, 35, 601–605. 
 
Camp, D.L., Finlay, W.M.L. & Lyons, E. (2002). Is low self-esteem an inevitable 
consequence of stigma? An example from women with chronic mental health 
problems. Social Science and Medicine, 55, 823-34. 
 
Carithers, R.L., Sugano, D., & Bayliss, M. (1996). Health assessment for chronic 
HCV: 
Results of HQL. Digestive Diseases and Science, 41(12), 75-80. 
 
Castera, L., Constant, A., Bernard, P.H., Ledinghen, V.D., & Couzigou, P. (2006). 
Psychological impact of chronic hepatitis C: Comparison with other stressful life 
events and chronic diseases. World Journal of Gastroenterology, 12(10), 1545-
1550. 
 
Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R.J., Voigt, 
M., Riely, C., Martin, P., Teperman, L., Jiao, J., Lopez-Talavera, J.C., & Pegasys 
Transplant Study Group (2005). Interferon alfa-2a for hepatitis C after liver 
transplantation: two randomized, controlled trials. Hepatology, 41, 289–298. 
 
Chalfant, A. M., Bryant, R. A., & Fulcher G. (2004). Posttraumatic stress disorder 
following diagnosis of multiple sclerosis. Journal of Traumatic Stress, 17, 423–
428. 
 
Chapman, F., & McManus, A. (2012). Hepatitis C treatment-better outcomes 
through partner support. Australasian Medical Journal, 5 (11), 585-588. 
138 
 
  
Charmaz, K. (2006). Grounded theory. In: Ritzer, G. (Ed.), Encyclopedia of 
sociology. Cambridge, MA: Blackwell. 
 
Charney, D.S. (2004). Psychobiological mechanisms of resilience and 
vulnerability: implications for successful adaptation to extreme stress. American 
Journal of Psychiatry, 161(2), 195-216. 
 
Colaizzi, P. F. (1978). Psychological research as the phenomenologist views it. 
In: Valle, R.S. & King, M. (Eds.), Existential phenomenological alternatives for 
psychology (p. 48-71). New York: Plenum. 
 
Conrad, S., Garrett, L.F., Cooksley, W.G.E., Dunne, M.P., & MacDonald, G.A. 
(2006). Living with chronic hepatitis C means ‘you just haven’t got a normal life 
any more’. Chronic Illness, 2(2), 121–131. 
 
Constant, A., Castera, L., Quintard, B., Bernard, P.H., de Ledinghen, V., 
Couzigou, P., & Bruchon-Schweitzer, M. (2005). Psychosocial factors associated 
with perceived disease severity in patients with chronic hepatitis C: relationship 
with information sources and attentional coping styles. Psychosomatics, 46, 25–
33. 
 
Cordoba, J., Reyes, J., Esteban, J.I., & Hernandez, J.M. (2003). Labeling May 
Be an Important Cause of Reduced Quality of Life and Cognitive Function in 
Chronic Hepatitis C. American Journal of Gastroenterology, 98(1), 226-227. 
 
Crotty, M. (1998). The Foundations of Social Research: Meaning and Perspective 
in the Research Process. London: Sage. 
 
Crotty, M. (1996). Phenomenology and nursing research. Melbourne: Churchill 
Livingstone. 
 
139 
 
Davis, G.L. (2012). Epidemiology of HCV. In: M.L. Shiffman (Ed.), Chronic 
Hepatitis C Virus Advances in Treatment, Promise for Future (p. 3-12).New York: 
Springer. 
 
Davis, M., Rhodes, T., & Martin, A. (2004). Preventing hepatitis C: ‘Common 
sense’, ‘the bug’ and other perspectives from the risk narrative of people who 
inject drugs. Social Science and Medicine, 59, 1807-1818. 
 
Davis, G.L., Balart, L.A.,Schiff, E.R., Lindsay,K., Bodenheimer, H.C., Perrillo, 
R.P, Carey, M., Jacobson, I.M., Payne, J., Dienstag, J.L, Van Thiel, D.H., 
Tamburro, C., Martino, F.P., Sangvhi, B., &  Albrecht, J.K. (1994). Assessing 
health-related quality of life in chronic hepatitis C using the Sickness Impact 
Profile. Clinical Therapeutics, 16(2), 334-43. 
 
De Bona, M., Ponton, P., Ermani, M., Iemmolo, R. M., Feltrin, A., Boccagni, P. 
Gerunda, G., Naccarato, R., Rupolo, G., & Burra, P. (2000). The impact of liver 
disease and medical complications on quality of life and psychological distress 
before and after liver transplantation. Journal of Hepatology, 33, 609–615.  
 
Dempster, M. (2011). A Research Guide for Health and Clinical Psychology. 
London: Palgrave Macmillan. 
 
Department of Health, Review of Documentation Relating to the Safety of Blood 
Products 1970 – 1985 (Non A Non B Hepatitis), May 2007. Accessed from: 
www.gov.uk  
 
Department of Health, Self-Sufficiency in Blood Products in England and Wales: 
A Chronology from 1973 to 1991, February 2006. Accessed from: www.gov.uk 
 
De Waele, J‐P. & Harré, R. (1979). Autobiography as a psychological 
method.In: Ginsburg, G.P. (Ed.), Emerging strategies in social psychological 
research.  London: Wiley. 
 
140 
 
Di Bisceglie, A.M., Conjeevaram, H.S., Fried, M.W., Sallie, R., Park, 
Y., Yurdaydin, C., Swain, M., Kleiner, D.E., Mahaney, K., & Hoofnagle, J.H. 
(1995). Ribavirin as therapy for chronic hepatitis C: a randomized, double blind, 
placebo-controlled trial. Annals of Internal Medicine, 123, 897-903. 
 
Donahue, J.G., Munoz, A., Ness, P.M., Brown, D.E. Jr, Yawn, D.H., McAllister, 
H.A. Jr, Reitz, B.A., & Nelson, K.E. (1992). The declining risk of post-transfusion 
hepatitis C virus infection. The New England Journal of Medicine, 327, 369–373. 
 
Dudley, J. (1983). Living with stigma: The plight of the people who we label 
mentally retarded. Springfield, IL: Charles C. Thomas. 
 
Dudley, T., Chaplin, D., Clifford, C., & Mutimer, D.J. (2007). Quality of life after 
liver transplantation for hepatitis C infection. Quality of Life Research, 16 (8), 
1299.  
 
Duffin, J. (2005). Lovers and Livers: Disease Concepts in History. Toronto: 
Toronto Press Incorporated. 
 
Dwight, M.M., Kowdley, K.V., Russo, J.E., Ciechanowski, P.S., Larson, A.M., & 
Katon, W.J. (2000). Depression, fatigue, and functional disability in patients with 
chronic hepatitis C. Journal of Psychosomatic Research, 49, 311-7. 
 
Eriksson, M. & Svedlund, M. (2006). The intruder: spouses’ narratives about life 
with a chronically ill partner. Journal of Clinical Nursing, 15, 324–333. 
 
Feitelson, M.A (2002). Hepatitis C Virus: From Laboratory to Clinic. Cambridge: 
Cambridge University Press. 
 
Feray, C., Gigou, M., Samuel, D., Paradis, V., Wilber, J., David, M.F., Urdea, M., 
Reynes, M., Brechot, C., & Bismuth, H. (1994). The course of hepatitis C virus 
infection after liver transplantation. Hepatology, 20, p. 1137-43. 
  
141 
 
Feurer, I. D., Kelly Wright, J., Payne, J. L., Kain, A. C., Wise, P. E., Hale, P., 
Chapman, W.C., Speroff, T., & Pinson C.W. (2002). Effects of hepatitis C virus 
infection and its recurrence after liver transplantation on functional performance 
and health-related quality of life. Journal of Gastrointestinal Surgery, 6(1), 108–
115.  
 
Fife, B.L., (2005).The role of constructed meaning in adaptation to the onset of 
life-threatening illness. Social Science & Medicine, 61, 2132-2143. 
 
Forsberg, A., Backman, L., & Moller, A. (2000). Experiencing liver transplantation: 
A phenomenological approach. Journal of Advanced Nursing, 32(2), 327–334.  
 
Frank, C., Mohamed, M.K., Strickland, G.T., Lavanchy, D., Arthur, R.R., Magder, 
L.S., El Khoby, T., Abdel-Wahab, Y., Aly Ohn, E.S., Anwar, W., & Sallam, I. 
(2000). The role of parenteral antischistosomal therapy in the spread of hepatitis 
C virus in Egypt. Lancet, 355(9207), 887-91. 
 
Fraser, S. & Treloar, C. (2006). ‘Spoiled identity’ in hepatitis C infection: the binary 
logic of despair. Critical Public Health, 16, 99–110. 
 
Gadamer, H.G. (1976).Hegel’s Dialectic: Five Hermeneutical Studies. New 
Haven: Yale University Press. 
 
Giorgi, A. & Giorgi, B. (2003). Phenomenology. In: Smith, J.A. (Ed.), Qualitative 
Psychology: A practical guide to research methods (p. 25-50). London: Sage.  
 
Gane, E. (2003). The natural history and outcome of liver transplantation in 
hepatitis C virus-infected recipients. Liver Transplantation, 9, 28–34.  
 
Glaser, B.G. (1992). Emergence vs Forcing: Basics of Grounded Theory 
Analysis. Mill Valley, CA: The Sociology Press. 
 
Glaser, B. & Strauss, A. (1967).The Discovery of Grounded Theory: Strategies 
for Qualitative Research. Chicago: Aldine. 
142 
 
 
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. 
Englewood Cliffs, NJ: Prentice-Hall. 
 
Golden, J., M., O'Dwyer, A, & Conroy, R.M. (2005). Depression and anxiety in 
patients with hepatitis C: prevalence, detection rates and risk factors. General 
Hospital of Psychiatry, 27(6), 431-8. 
 
Hadziyannis, S.J., Sette, H. Jr, Morgan, T.R., Balan, V., Diago, M., Marcellin, 
P., Ramadori, G., Bodenheimer, H. Jr, Bernstein, D., Rizzetto, M., Zeuzem, 
S., Pockros, P.J., Lin, A., Ackrill, A.M., & PEGASYS International Study Group 
(2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic 
hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals 
of Internal Medicine, 140, 346–355. 
 
Harris, R.J., Ramsay, M., Hope V.D., Brant, L., Hickman, M., Foster, G.R., & De 
Angelis D. (2012). Hepatitis C prevalence in England remains low and varies by 
ethnicity: an updated evidence synthesis. European Journal of Public Health, 22, 
187–192. 
 
Harris, M., (2009). Troubling biographical disruption: narratives of unconcern 
about hepatitis C diagnosis. Sociology of health & illness, 31 (7), 1028-42. 
 
Harris, M., & Richters, J. (2006). Psychosocial aspects of living with hepatitis C 
virus. Social Research Briefs, 8, 1-4. 
 
Harris, M. (2005). Living with hepatitis C: The medical encounter. New Zealand 
Sociology, 20 (1), 4-19. 
 
Hassanein, T., Cooksley, G., Sulkowski, M., Smith, C., Marinos, G., Lai, M.Y., 
Pastore, G., Trejo-Estrada, R., Vale, A.H., Wintfeld, N., & Green, J. (2004). The 
impact of peginterferon alfa-2a plus ribavirin combination therapy on health-
143 
 
related quality of life in chronic hepatitis C. Journal of Hepatology, 40(4), 675 - 
681. 
 
Hassoun, Z., Willems, B., Deslauriers, J., Nguyen, B.N., & Huet, P. (2002). 
Assessment of fatigue in patients with chronic hepatitis C using the fatigue impact 
scale. Digestive Diseases and Sciences, 47(12), 2674-2681. 
 
Health Protection Agency, 2013. Hepatitis C in the UK: 2013 report. Available at: 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139502302  
[Accessed 08.11.1014] 
 
Health Protection Agency. Hepatitis C in the UK 2011. Harris H.E., Ramsay M.E. 
(Eds.). London: Health Protection Agency Centre for Infections, (p.1-97).   
Available at: 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1309969906418 
[Accessed 17.08.2014] 
 
Health Protection Scotland, NHS National Services Scotland. Surveillance of 
known hepatitis C antibody positive cases in Scotland: Results to 31 December 
2013. Health Protection Scotland Weekly report 2014. Report No. 48 2014/18. 
Available at: http://www.hps.scot.nhs.uk/documents/ewr/pdf2014/1418.pdf.   
[Accessed13.06.2014]. 
 
Heidegger, M. (1927/1962). Being and time. Oxford, UK: Basil Blackwell. 
 
Heidegger, M. (1967). What is a thing? South Bend, IL: Henry Regnery. 
 
Heimer, R., Clair, S., Grau, L.E., Bluthenthal, R.N., Marshall, P.A., & Singer, M. 
(2002). Hepatitis-associated knowledge is low and risks are high among HIV-
aware injection drug users in three US cities. Addiction, 97, 1277-1287. 
 
Hepworth, J. & Krug, G. J. (1999). A socio-cultural perspective on the effects of 
a new virus on a community’s health. Journal of Health Psychology, 4, 237–246. 
 
144 
 
Herek, G.M., Capitanio, J.P., & Widaman, K.F. (2003).Stigma, social risk, and 
health policy: Public attitudes toward HIV surveillance policies and the social 
construction of illness. Health Psychology, 22 (5), 533-540. 
 
Hickey, A., Bury, G., O'Boyle, C., Bradley, F., O'Kelly, F. D., & Shannon, 
W. (1996). A new short form individual quality of life measure (SEIQoL-DW) 
application in a cohort of individuals with HIV/AIDS. British Medical Journal, 313, 
29-33. 
 
Hill, R., Pfeil, M., Moore, J., & Richardson, B. (2014). Living with hepatitis C: a 
phenomenological study. Journal of Clinical Nursing, 24(3-4), 428-38. 
 
Hobfoll, S. E. (2002). Social and psychological resources and adaptation. Review 
of General Psychology, 6, 307–324. 
 
Holahan, C.J. & Moos, R.H. (1991). Life stressors, personal and social resources, 
and depression: A 4-year structural model. Journal of Abnormal Psychology, 100, 
31–38. 
 
Hoofnagle, J.H., Davis, G.L., Pappas, C., Hanson, R.G., Peters, M., Avigan, 
M.I., Waggoner, J.G., Jones, E.A., & Seeff, L.B. (1986). A short course of 
prednisolone in chronic type B hepatitis: report of a randomized, double-blind, 
placebo-controlled trial. Annals of Internal Medicine, 104, 12-17. 
 
Hopwood, M. & Treloar, C. (2008). Resilient coping: Applying adaptive responses 
to prior adversity during treatment for hepatitis C infection. Journal of Health 
Psychology, 13(1), 17-27. 
 
Hopwood, M.N., Treloar, C. & Redsull, L. (2006). Experiences of hepatitis C 
treatment and its management: What some patients and health professionals 
say. National Centre in HIV Social Research, The University of New South Wales, 
Sydney. 
 
145 
 
Hopwood, M., Treloar, C., & Bryant, J. (2006). Hepatitis C and injecting-related 
discrimination in New South Wales, Australia. Drugs: Education, Prevention & 
Policy, 13, 61-75. 
 
Hopwood, M. & Treloar, C. (2005). The experience of interferon-based 
treatments for hepatitis C infection. Qualitative Health Research, 15, 635-46. 
 
Hopwood, M. & Treloar, C. (2004). Receiving a hepatitis C-positive diagnosis. 
Internal Medicine Journal, 34, 526-531. 
 
House of Lords Debate, January 2011. Accessed from: 
researchbriefings.files.parliament.uk/.../SN05698.pdf  
 
Hunt, C.M., Dominitz, J.A., Bute, B.P., Waters, B., Blasi, U., & Williams, D.M. 
(1997). Effect of interferon-alpha treatment of chronic hepatitis C on health-
related quality of life. Digestive Diseases and Science, 42, 2482–2486. 
 
Husserl, E. (1900/2001). Logical Investigations. New York: Routledge. 
 
Husserl, E. (1936/1970). The Crisis of European Sciences and Transcendental 
Phenomenology. Evanston, IL: Northwestern University Press.  
 
Husserl, E. (1931). Ideas: General Introduction to Pure Phenomenology. New 
York: Collier. 
 
Janssen, H.L.A., Brouwer, J.T., van der Mast, R., Schalm, S.W. (1994). Suicide 
associated with alfa-interferon therapy for chronic viral hepatitis. Journal of 
Hepatology, 21, 241-243. 
 
Joachim, G. & Acorn, S. (2000). Stigma of visible and invisible chronic conditions. 
Journal of Advanced Nursing, 32 (1), 243-48. 
 
146 
 
Johnson, C. D., & Hathaway, D. K. (1996). The lived experience of end-stage 
liver failure and liver transplantation. Journal of Transplant Coordination, 6(3), 
130–133.  
 
Kalantar-Zadeh, K. & Unruh, M. (2005). Health related quality of life in patients 
with chronic kidney disease. International Urology and Nephrology, 37(2), 367-
378. 
 
Katz, J. (2001). Analytic Induction. In: N. Smelser & P.B. Baltes, 
(Eds.), International Encyclopedia of the Social and Behavioral Sciences. 
Amsterdam: Elsevier. 
 
Katz, I. (1979). Some thoughts about the stigma notion. Personality and Social 
Psychology Bulletin, 5(4), 447-460. 
 
Kausar, R. & Yusuf, S. (2011). State Anxiety and Coping Strategies Used by 
Patients with Hepatitis C in relation to interferon treatment. Pakistan Journal of 
Social and Clinical Psychology, 9, 57-61. 
 
Kia, L., Matkowskyj, K.A., & Levitsky, J. (2013). Hepatitis C in Liver 
Transplantation. In: D.Jensen & N. Reau (Eds.), Hepatitis C, (p. 71-82). New York: 
Oxford University Press. 
 
Koff, R.S. (1999). Impaired health-related quality of life in chronic hepatitis C: the 
how, but not the why. Hepatology, 29:277-279. 
 
Kraus, M.R., Schäfer, A., Faller, H., Csef, H., & Scheurlen, M. (2003). Psychiatric 
symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. 
Journal of Clinical Psychiatry, 64, 708-714. 
 
Lawitz, E., Lalezari, J.P., Hassanein, T., Kowdley, K.V., Poordad, F.F., Sheikh, 
A.M., Afdhal, N.H., Bernstein, D.E., Dejesus, E., Freilich, B., Nelson, 
D.R., Dieterich, D.T., Jacobson, I.M., Jensen, D., Abrams, G.A., Darling, 
J.M., Rodriguez-Torres, M., Reddy, K.R., Sulkowski, M.S., Bzowej, 
147 
 
N.H., Hyland, R.H., Mo, H., Lin, M., Mader. M., Hindes, R., Albanis, E., Symonds, 
W.T., Berrey, M.M., & Muir, A. (2013). Sofosbuvir in combination with 
peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with 
genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 
trial. Lancet Infectious Diseases, 13(5), 401–408. 
 
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, 
S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R., Jacobson, I.M., Kowdley, 
K.V., Nyberg, L., Subramanian, G.M., Hyland, R.H., Arterburn, S., Jiang, D., 
McNally, J., Brainard, D., Symonds, W.T., McHutchison, J.G., Sheikh, A.M., 
Younossi, Z., & Gane, E.J. (2013). Sofosbuvir for previously untreated chronic 
hepatitis C infection. The New England Journal of Medicine, 368(20), 1878-87. 
 
Leyendecker, B., Bartholomew, U., Neuhaus, R., Hordhold, M., Blumhardt, G., 
neuhause, P., & Klapp, B.F. (1993). Quality of life of liver transplant recipients. 
Transplantation, 56(3), 561-567. 
 
Lowe, D. & Cotton, R. (1999). Hepatitis C: A review of Australia’s response. 
Canberra: Department of Health and Aged Care. 
 
Luthar, S. S., Cicchetti, D., & Becker, B. (2000). The construct of resilience: A 
critical evaluation and guidelines for future work. Child Development, 71 (3), 543–
562. 
 
Luthar, S. S., & Zelazo, L. B. (2003). Research on resilience: An integrative 
review. In S. S. Luthar (Ed.), Resilience and vulnerability: Adaptation in the 
context of childhood adversities (p. 510-549). Cambridge, UK: Cambridge Press. 
 
Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, 
M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., & Albrecht, J.K. (2001). 
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin 
for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358, 958–
965.  
 
148 
 
Mantler , J., Schellenberg, E. G., & Page, J. S. (2003). Attributions for serious 
illness: Are controllability, responsibility, and blame different constructs? 
Canadian Journal of Behavioural Science, 35, 142-152. 
 
Markowitz, F.E. (1998). The Effects of Stigma on the Psychological Well-Being 
and Life Satisfaction of Persons with Mental Illness. Journal of Health and 
Social Behavior, 39(4), 336-347. 
 
Marks, D.F. & Yardley, L. (2004). Research Methods for Clinical and Health 
Psychology. London: Sage Publications. 
 
Masten, A. S. (2001). Ordinary magic: Resilience processes in development. 
American Psychologist, 53, 205-220. 
 
Mattingly, C. & Garro, L.C. (2000). Narrative and the Cultural Construction of 
Illness and Healing. Berkeley and Los Angeles: University of California Press. 
 
Maynard, M. (1994). Methods, practice and epistemology: the debate about 
feminism and research. In: M. Maynard & J. Purvis (Eds.), Researching women's 
lives from a feminist perspective (p.10-27). London: Taylor and Francis. 
 
McCorry, N., Dempster, M., Clarke, C., & Doyle, R. (2009). Adjusting to life after 
esophagectomy: The Experience of Survivors and Carers. Qualitative Health 
Research, 19(10), 1485-1494. 
 
McCreaddie, M., Lyons, I., Horsburgh, D., Miller, M., & Frew, J. (2014).  The 
isolating and insulating effects of hepatitis C: a substantive grounded theory. 
Gastroenterology Nursing, 34(1), 49-59. 
 
McHutchison, J.G., Ware, J.E., Bayliss, M.S., Pianko, S., Albrecht, J.K., Cort, S., 
Yang, I., Neary, M.P., & Hepatitis Interventional Therapy Group (2001). The 
effects of interferon alfa-2b in combination with ribavirin on health related quality 
of life and work productivity. Journal of Hepatology, 34, 140 –147. 
 
149 
 
McHutchison, J.G. & Hoofnagle, J.H. (2000). Treatment of hepatitis C virus. In: 
T.J. Liang & J.H. Hoofnagle (Eds.), Biomedical Research Reports, 2, 1-493. 
 
McNally, S., Temple-Smith, M., & Pitts, M. (2004). Making decisions about 
hepatitis C treatment. Melbourne: Australian Research Centre in Sex, Health and 
Society, La Trobe University. 
 
Miller, G. & Dingwall, R. (1997). Context and method in qualitative research. 
Milwaukee, USA: Dingwall Enterprises Ltd. 
 
Mohamed, M.K., Abdel-Hamid, M., Mikhail, N.N., Abdel-Aziz, F., Medhat, A., 
Magder, L.S., Fix, A.D, & Strickland, G.T. (2005). Intrafamilial transmission of 
hepatitis C in Egypt. Hepatology, 42, 683-687. 
 
Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. & Wiersma, S.T. (2013). Global 
epidemiology of hepatitis C virus infection: new estimates of age-specific 
antibody to HCV seroprevalence. Hepatology, 57 (4), 1333–42. 
 
Moore, G.A., Howley, D.A., & Bradley, P. (2008). Hepatitis C: studying stigma. 
Gastroenterology Nursing, 31(5), 346-352. 
 
National Institute for Health and Clinical Excellence (2015). Sofosbuvir for 
treating chronic hepatitis C. NICE technology appraisal guidance (T330).  
 
Ogden, J. (2004). Health Psychology: A Textbook (3rd Ed.). Maidenhead: Open 
University Press/ McGraw-Hill Education. 
 
Olsen, A, Banwell, C., & Dance, P. (2013). Reinforced biographies among women 
living with Hepatitis C. Qualitative Health Research, 23(4), 531-40. 
 
Ong, J.P. & Younossi, Z. (2004). Managing the hematologic side effects of 
antiviral therapy for chronic hepatitis C: anemia, neutropenia, and 
thrombocytopenia. Cleveland Clinic Journal of Medicine, 71(3), 17-21. 
 
150 
 
Pargament, K.I., Smith, B.W., Koenig, H.G., & Perez, L. (1998). Patterns of 
positive and negative religious coping with major life stressors. Journal for the 
Scientific Study of Religion, 37, p. 710–724. 
 
Paterson, B. L., Butt, G., McGuinness, L., & Moffat, B. (2006). The construction 
of hepatitis C as a chronic illness. Clinical Nursing Research, 15(3), 209-224. 
 
Paterson, D. L., Gayowski, T., Wannstedt, C. F., Wagener, M. M., Marino, I. R., 
Vargas, T., Laskus, T., Rakela, J., & Singh, N. (2000). Quality of life in long-term 
survivors after liver transplantation: Impact of recurrent viral hepatitis C virus 
hepatitis. Clinical Transplantation, 14, 48–54.  
 
Patton, M.Q. (1990). Qualitative evaluation and research methods (2nd Ed.). 
Newbury Park, CA: Sage. 
 
 
Poynard, T. (2005). Hepatitis C and B: Management and Treatment (2nd Edition). 
London and New York: Taylor and Francis. 
 
Poynard, R., Ratziu, V., Charlotte, R., Goodman, Z., McHutchison, J., & Albrecht, 
J. (2001). Rates and risk factors of liver fibrosis progression in patients with 
chronic hepatitis C. Journal of Hepatology, 34, 730-9. 
 
Public Health England (2014).Hepatitis C in the UK, 2014 report. Available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/3
37115/HCV_in_the_UK_2014_24_July.pdf 
 
Quelhas, R. & Lopes, A. (2009). Psychiatric problems in patients infected with 
hepatitis C before and during antiviral treatment with interferon-alpha: a review. 
Journal of Psychiatric Practice, 15, 262-81. 
 
Reicher, S. (2000). Against methodolatry: Some comments on Elliott, Fischer, 
and Rennie. British Journal of Clinical Psychology, 39(1), 1-6. 
 
151 
 
Remis, R. S. (2004). A study to characterize the epidemiology of hepatitis C 
infection in Canada 2002. Final report. Ottawa: Health Canada. 
 
Renault, P.F., Hoofnagle, J.H., Park, Y., Mullen, K.D., Peters, M., Jones, D.B., 
Rustgi, V., & Jones, A. (1987). Psychiatric complications of long-term interferon 
alfa therapy. Archives of Internal Medicine, 147, 1577–1580. 
 
Richardson, G.E. (2002). The metatheory of resilience and resiliency. Journal of 
Clinical Psychology, 58, 307-321. 
 
Ricoeur, P. (1981). Paul Ricoeur hermeneutics and the human sciences. New 
York: Cambridge University Press. 
 
Rimola, A., Navasa, M., Rodes, J., Elias, E., Neuberger, J., Lucey, M.R., & 
Shorrock, C. (1994). Specific indications: Parenchymal liver disease. In: J. 
Neuberger & M.R. Lucey (Eds.), Liver transplantation: Practice and Management 
(p. 34-104).London: BMJ Publishing Group. 
 
Robertson, G. (1999). Individuals’ perception of their quality of life following a liver 
transplant: An exploratory study. Journal of Advanced Nursing, 30(2), 497–505.  
 
Rodger, A.J., Jolley, D., Thompson, S.C., Lanigan, A., & Crofts, N. (1999). The 
Impact of Diagnosis of Hepatitis C Virus on Quality of Life. Hepatology, 30(5), 
1299-1301. 
 
Rodis, J.L. & Kibbe, P. (2010). Evaluation of medication adherence and quality 
of life in patients with hepatitis C virus receiving combination therapy. 
Gastroenterology Nursing, 33, 368–373. 
 
Rothe, J.P. (2000). Undertaking Qualitative Research. Concepts and Cases in 
Injury, Health and Social Life. The University of Alberta Press: Edmonton, 
Canada. 
 
152 
 
Rutter, M. (1990). Psychosocial resilience and protective mechanisms. In: J. Rolf, 
A.S. Masten, D. Cicchetti, K.H. Nuechterlein, S.Weintraub (Eds.). Risk and 
protective factors in the development of psychopathology (p. 181–214). New 
York: Cambridge University Press. 
 
Sabin, C.A., Phillips, A.N., Yee, T.T., Griffioen, A., & Lee, C.A (2005). Twenty five 
years of HIV infection in haemophilic men in Britain: an observational study. BMJ, 
331(7523), 997–998. 
 
Sachs, B.C. (1991). Coping with stress. Stress Medicine, 7. 61-63. 
 
Sarkar, S., Jiang, Z., Evon, D.M., Wahed, A.S., & Hoofnagle, J.H. (2012). Fatigue 
before, during and after antiviral therapy of chronic hepatitis C: results from the 
Virahep-C study. Journal of Hepatology, 57(5), 946-52. 
 
Satapathy, S.K., Sclair, S., Fiel, M.I, Del Rio, M.J, & Schiano, T. (2011). Clinical 
characterisation of patients developing histologically-proven fibrosis cholestatic 
hepatitis C post-liver transplantation. Hepatology Research, 41(4), 328-339. 
 
Scambler, G. (2004). Re-framing stigma: felt and enacted stigma and challenges 
to the sociology of chronic and disabling conditions. Social Theory and Health, 2, 
29 – 46. 
 
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., 
Foster, G.R., Kautz, A., Forton, D., & Pariante, C.M. (2012). Hepatitis C infection, 
antiviral treatment and Mental Health: A European Expert Consensus Statement. 
Journal of Hepatology, 57(6), 1379-90. 
 
Schafer, A., Scheurlen, M., Felten, M. & Kraus, M. (2005). Physicianpatient 
relationship and disclosure behaviour in chronic hepatitis C in a group of German 
outpatients. European Journal of Gastroenterology and Hepatology, 17, 1387–
1394. 
 
Searle, J. (1995). The Construction of Social Reality. New York: The Free Press. 
153 
 
 
Seeff, L.B., Miller, R.N., Rabkin, C.S., Buskell-Bales, Z., Straley-Eason, 
K.D., Smoak, B.L., Johnson, L.D., Lee, S.R., & Kaplan, E.L. (2000). 45-Year 
follow-up of hepatitis C virus infection in healthy young adults. Annual Internal 
Medicine, 132, 105-11. 
 
Seeff, L.B. (2002). Natural history of chronic hepatitis C. Hepatology, 36(5 Suppl. 
1), 35-46. 
 
Seligman, M.E.P., Steen, T.A., Park, N., & Peterson, C. (2005). Positive 
Psychology Progress: Empirical Validation of Interventions. American 
Psychologist, 60(5), 410-421. 
 
Sgorbini, M., O’Brien, L., & Jackson, D. (2009). Living with hepatitis C and 
treatment: the personal experiences of patients. Journal of Clinical Nursing, 
18(16), 2282-2291. 
 
Sharma, P., Marrero, J.A., Fontana, R.J., Greenson, J.K., Conjeevaram, H., Su, 
G.L., Askari, F., Sullivan, P., & Lok, A.S. (2007). Sustained virologic response to 
therapy of recurrent hepatitis C after liver transplantation is related to early 
virologic response and dose adherence. Liver Transplantation, 13, 1100–1108. 
 
Shergill, A., Khalili, M., Straley, S., Bollinger, K., Roberts, J.P., Ascher, N.A., & 
Terrault, N.A. (2005). Applicability, tolerability and efficacy of preemptive antiviral 
therapy in hepatitis C-infected patients undergoing liver transplantation. 
American Journal of Transplantation, 5(1), 118–124. 
 
Shiffman, M.L. (2011). Chronic Hepatitis C Virus: Advances in Treatment, 
Promise for Future. Richmond and Newport News, VA, USA: Springer. 
 
Singh, N., Gayowski, T., Wagener, M. M., & Marino, I. R. (1999). Quality of life, 
functional status, and depression in male liver transplant recipients with recurrent 
viral hepatitis C. Transplantation, 67(1), 69–72.  
 
154 
 
Skodol, A., (2010). The resilient personality. In: J. W. Reich , A. J. Zautra,  & J. 
S . Hall (Eds.), Handbook of adult resilience (p. 112–125). New York: Guilford 
Press. 
 
Sladden, T. J. Hickey, A. R., Dunn, T. M. & Beard, J. R. (1998). Hepatitis C virus 
infection: Impacts on behaviour and lifestyle. Australian and New Zealand Journal 
of Public Health, 22, 509–511. 
 
Smith, J. A. (1995). Semi-structured interviewing and qualitative analysis. In: J. 
A. Smith, R. Harre, & L. van Langenhove (Eds.), Rethinking methods in 
psychology (p. 9–26). London: Sage. 
 
Smith, J.A. (1996). Beyond the divide between cognition and discourse: using 
interpretative phenomenological analysis in health psychology. Psychology & 
Health, 11, 261-271. 
 
Smith, J.A. & Osborn, M. (2003). Interpretative phenomenological analysis. In: J. 
A. Smith (Ed.), Qualitative psychology: A practical guide to research methods (p. 
51-80). London: Sage.  
 
Smith, J.A. (2008). Qualitative Psychology: A Practical Guide to Research 
Methods (2nd Ed.). London: Sage.  
 
Smith, J.A., Flowers, P. & Larkin, M. (2009). Interpretative Phenomenological 
Analysis: Theory, Method, Research. London: Sage. 
 
Smith, J.A. & Eatough, V. (2012). Interpretative phenomenological analysis. In: 
G. Breakwell, J.A. Smith, & D.Wright (Eds.), Research Methods in 
Psychology.(4th Ed.). London: Sage. 
 
Soldan, K., Barbara, J.A., Ramsay, M.E., & Hall, A.J. (2003). Estimation of the 
risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus 
infectious donations entering the blood supply in England, 1993-2001. Vox Sang, 
84(4), 274–86. 
155 
 
 
Stewart, B., Mikocka-Walus, A., Morgan, J., Colman, A., Phelps, M., Harley, H., 
& Andrews, J. (2012). Anxiety and depression in Australian chronic hepatitis C 
outpatients: prevalence and predictors. Australasian Psychiatry: bulletin of Royal 
Australian and New Zealand College of Psychiatrists, 20(6), 496-500. 
 
Stoller, E.P., Webster, N.J., Blixen, C.E., McCormick, R.A., Hund, A.J., Perzynski, 
A.T., & Dawson, N.V. (2009). Alcohol consumption decisions among nonabusing 
drinkers diagnosed with hepatitis C: An exploratory sequential mixed methods 
study. Journal of Mixed Methods Research, 3, 65–86. 
 
Stuenkel, D. & Wong, V. (2009). Stigma. In: Larsen, P. & Lubkin, I. (Eds.), Chronic 
illness: impact and intervention (p.57). USA: Jones and Bartlett Publishers. 
 
Suarez, Alicia E. (2010). Racial Disparities in Knowledge of Hepatitis C Virus 
(HCV). In: J.J. Kronenfeld (Ed.), The Impact of Demographics on Health and 
Health Care: Race, Ethnicity and Social Factors (p.21-46). Bingley: Emerald 
Group Publishing. 
 
Sulkowski, M.S., & Thomas, D.L. (2003). Hepatitis C in the HIV-infected person. 
Annals of Internal Medicine, 138, 197–207. 
 
Sy, T. & Mazen Jamal, M. (2006). Epidemiology of Hepatitis C Virus (HCV) 
Infection. International Journal of Medical Sciences, 3(2), 41–46. 
 
Taintedblood, Government Announces another Inadequate Support Scheme for 
Contaminated Blood Sufferers, 10 January 2011. Available at: 
www.taintedblood.info/index.php 
 
Taylor, S.E., Kemeny, M.E., Aspinwall, L.G., Schneider, S.G., Rodriguez, R., & 
Herbert, M. (1992). Optimism, coping, psychological distress, and high-risk 
sexual behaviour among men at risk for acquired immunodeficiency syndrome 
(AIDS). Journal of Personality and Social Psychology, 63, 460–473. 
 
156 
 
Tedeschi, R.G. & Kilmer, R. (2005). Assessing Strengths, Resilience, and Growth 
to Guide Clinical Interventions. Professional Psychology Research and Practice, 
36(3). 
 
Teixeira, R., Pastacaldi, S., Davis, S., Dhillon, A.P., Emery, V.C., Rolles, K., 
Davidson, B., Patch, D., & Burroughs, A.K. (2000). The influence of 
cytomegalovirus virraemia on the outcome of recurrent hepatitis C after liver 
transplantation. Transplantation, 70(10), 1454-1458. 
 
The British Psychological Society (1993). Code of Conduct, Ethical Principles and 
Guidelines. 
 
The Penrose Inquiry Final Report, 2015. Available at: 
http://www.penroseinquiry.org.uk/finalreport/ 
 
The Penrose Inquiry Preliminary Report, 2010. Available at: 
http://www.penroseinquiry.org.uk/preliminary-report/ 
 
Thein, H.H., Yi, Q., Dore, G.J., & Krahn, M.D. (2008). Estimation of stage-specific 
fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis 
and meta-regression. Hepatology, 48, 418-31. 
 
Tine, F., Magrin, S., Craxi, A., & Pagliaro, L. (1991). Interferon for non-A, non-B 
chronic hepatitis: a meta-analysis of randomized clinical trials. Journal of 
Hepatology, 13, 192-9.  
 
Tompkins, C. N. E., Wright, N. M. J., & Jones, L. (2005). Impact of a positive 
hepatitis C diagnosis on homeless injecting drug users: a qualitative study. British 
Journal of General Practice, 55(513), 263-268. 
 
Toso, C., Cader, S., Mentha-Dugerdil, A., Meeberg, G., Majno, P., Morard, I., 
Giostra, E., Berney, T., Morel, P, Mentha, G., &  Kneteman, N.M. (2013). Factors 
predicting survival after post-transplant hepatocellular carcinoma recurrence. 
Journal of Hepato-Biliary-Pancreatic Sciences, 20(3), 342-7. 
157 
 
 
Unruh, M.L., Weisbord, S.D., & Kimmel, P.L. (2005). Health-related quality of life 
in nephrology research and clinical practice. Seminars in Dialysis, 18, 82–90. 
 
Valle, M. & Levy, J. (2008). Finding meaning: African American injection drug 
users' interpretations of testing HIV-positive. AIDS Care, 20, 130-138. 
 
Van Manen, M. (1990). Researching lived experience: Human science for an 
action sensitive pedagogy. New York: SUNY Press. 
 
Vinaixa, C., Rubin, A., Aquilera, V., & Berenguer, M. (2013). Recurrence of 
hepatitis C after liver transplantation. Annals of Gastroenterology, 26(4), 304-313. 
 
Ware, J.E. Jr, Bayliss, M.S., Mannocchia, M., Davis, G.L., & The International 
Hepatitis Interventional Therapy Group (2003).  Health-related quality of life in 
chronic hepatitis C: impact of disease and treatment response. Hepatology, 
30(2), 550-555. 
 
Wasley, A. & Alter, M.J. (2000). Epidemiology of hepatitis C: geographic 
differences and temporal trends. Seminars in Liver Disease, 20, 1-16. 
 
Williams, G. (1984). The genesis of chronic illness: Narrative reconstruction. 
Sociology of Health and Illness, 6(2), 175-199. 
 
Willig, C. (2008). Interpretive phenomenology. In: C. Willig (Ed.), Introducing 
qualitative research in psychology (2nd Ed., p. 50–69). Philadelphia: Open 
University Press. 
 
World Health Organisation. (2014). ICD-10 ICD-10: International Statistical 
Classification of Diseases and Health Related Problems. Geneva. World Health 
Organisation. 
 
Yardley, L. (2000). Dilemmas in qualitative health research. Psychology and 
Health, 15, 215–228. 
158 
 
 
Zautra, A.J., Davis, M.C., Reich, J.W., Nicassario, P., Tennen, H., Finan, P., 
Kratz, A., Parrish, B., & Irwin, M.R. (2008). Comparison of cognitive behavioral 
and mindfulness meditation interventions on adaptation to rheumatoid arthritis for 
patients with and without history of recurrent depression. Journal of Consulting 
and Clinical Psychology, 76, 408–421. 
 
Zickmund, S., Ho, E. Y., Masuda, M., Ippolito, L., & LaBrecque, D. R. (2003). 
“They treated me like a leper.” Stigmatization and the quality of life of patients 
with hepatitis C. Journal of General Internal Medicine, 18(10), 835-844. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
   Appendix 1 
W oSRES 
West of Scotland Research Ethics Service 
 
West of Scotland REC 3 
Ground Floor – The Tennent Institute Western 
Infirmary 
38 Church Street Glasgow 
G11 6NT www.nhsggc.org.uk 
 
Date 27th June 2014 
Miss Anna Krzeczkowska  Your Ref  
Our Ref  
Direct line 0141 211 2123 
Fax 0141 211 1847 
 E-mail WOSREC3@ggc.scot.nhs.
uk  
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virus infection recurrence after liver transplantation: an 
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REC reference: 14/WS/0122 
Protocol number: n/a 
IRAS project ID: 153106 
 
Thank you for your letter of 17 June 2014, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information was considered in correspondence by a Sub-Committee of the 
REC.
 
A list of the Sub-Committee members is attached. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date of 
this opinion letter. Should you wish to provide a substitute contact point, require further 
information, or wish to make a request to postpone publication, please contact, 
wosrec3@ggc.scot.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
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Appendix 2               
                                              
                                                                       
                               
                             GP Information Letter                                                                
 
                                                                                      <<Supervisor’s name and address>> 
                                                                           
 
<<insert GP’s Name>>  
<<Address>> 
<<Postcode>> 
 
Date:  
 
Dear Dr ...,, 
 
Re: (Patient name, age and DOB) 
 
Patient X has been in contact recently to express his/her intention to participate in a 
qualitative study exploring their personal experiences of recurrent hepatitis C virus 
following a liver transplant.  Together with Professor … , this study will be carried out 
by Anna Krzeczkowska (an MRes student at Edinburgh Napier University) and will be 
closely supervised by Dr… and myself.  
More specifically, Edinburgh Napier University and the Out-Patients Department (OPD4) 
for Gastrointestinal and Liver Disorders at the Royal Infirmary of Edinburgh, are 
interested in the personal experience, attitudes and expectations of hepatitis C virus 
infection recurrence after liver transplantation. This project is interested in learning more 
about what the diagnosis of virus recurrence and liver transplantation has meant for your 
patient. 
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Your patient will take part in an interview about his/her experience of hepatitis C virus 
infection recurrence after liver transplantation. The researcher will ask him/her to tell her 
about his experience of living with hepatitis C virus. 
We will arrange for the interviews to take place at the Welcome Clinical Research Facility 
at the RIE where we can book private and confidential rooms. If possible, we will arrange 
the interview on a day when your patient will be attending for a follow-up appointment 
with his/her hepatologist. 
The potentially sensitive nature of the interview questions may result in some individuals 
experiencing a degree of emotional distress. In the unlikely event that a participant/your 
patient becomes upset/distressed as a consequence of the interview, they will be 
encouraged to discuss any upsetting issues with the resident Clinical Psychologist at the 
Royal Infirmary of Edinburgh. A debrief sheet will also be provided for a participant 
detailing the contact details of the Chief Investigator (myself) and the Clinical 
Psychologist at the RIE whom he/she can contact should they experience any emotional 
problems as a result of the interview. The participant will be also be advised that he/she 
can withdraw from the research at any time and does not have to answer any question(s) 
that he/she does not wish to. 
Participation in the study will be completely confidential. However, confidentiality may 
be limited if the researcher (research student), who will be conducting the interview 
deems there to be a risk to the participant/your patient. In relation to someone becoming 
distressed or making a statement which gives cause for concern (e.g. expressing suicidal 
tendencies), the researcher as a certified Mental Health First Aider will provide initial 
help to the person. She will provide reassurance. The participant will then be informed 
that the researcher will contact an experienced member of staff within the liver transplant 
team. This individual would be contacted immediately and would remain with your 
patient while NHS protocol for suicidal patients was adhered to (e.g. contacting you as 
the patient’s GP, contacting the liaison Psychiatry team etc.). This would be discussed 
with the participant prior to the disclosure of information. Your patient will be informed 
of this within the participant information sheet and consent form. This procedure adheres 
to Section 7.1 of the British Psychological Society's Code of Conduct, Ethical Principle 
& Guidelines (2006). 
Patient X has consented for me to contact you to inform you about his/her participation 
in this study and is aware of the possibility that you might be contacted if there is a risk 
to his/her well-being. Please let me know if there is any reason why this patient of yours 
should not take part in a study of this sort.  
If a reply has not been received within 14 working days, confirming the patient’s 
suitability to take part in the study, then the patient will not be contacted. Please do not 
hesitate to contact me if you have any queries. 
 
Yours sincerely, 
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Appendix 3 
 
 
Liver Unit  
The Royal Infirmary of Edinburgh 
51 Little France Crescent 
Edinburgh EH16 4SA 
 
 
28 January 2014 
 
 
To whom it may concern 
 
Dear Sir or Madam 
 
I am happy to support the study of Ms Krzeczkowska in patients with recurrent hepatitis C post 
liver transplantation. The liver transplant coordinators and I will help in recruiting subjects for 
the study once all approval has been obtained 
 
Yours faithfully, 
Professor of Hepatology 
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Appendix 4 
                                     Letter of Invitation  
 
Experiences, attitudes and expectations of hepatitis C virus infection recurrence 
after liver transplantation: an interpretative phenomenological analysis. 
Edinburgh Napier University is working in collaboration with the Scottish Liver 
Transplant Unit at the Royal Infirmary of Edinburgh on a research study looking at 
experiences, attitudes and expectations of hepatitis C virus infection recurrence after liver 
transplantation. We are recruiting people who were diagnosed with hepatitis C virus 
infection recurrence after liver transplantation, and their primary caregiver to take part. 
We hope you will tell us what it is like to live with hepatitis C virus, from your own 
perspective. It is up to you to decide whether or not to inform your partner or family 
member about the project. Please bear in mind, that partaking of your caregiver is NOT 
a requirement of your participation in this study. We appreciate your personal view and 
do understand if you do not want to involve your caregiver in this project. However if 
you would be willing for your primary caregiver to take part in this study, please find an 
additional envelope and an invitation letter attached to this letter that you can pass on to 
your caregiver.     
This project will involve taking part in a one-to-one interview with the researcher. The 
interview is just like a chat with the researcher asking you about what is like to live with 
hepatitis C virus, how your life has changed after liver transplantation and the things you 
find most difficult about being diagnosed with virus recurrence. Although the researcher 
has some questions that she would like to ask you, we hope that you will just talk about 
what is important to you. The interview will last approximately 1-2 hours (but could be 
less or more). The interview will take place in private. The project is completely 
confidential. You will be given every chance to stop or withdraw from the project at any 
time without having to give a reason. Participation/non-participation/withdrawal from the 
study at any time will not affect your current/future care in any way. It is important that 
you understand that that there are no direct benefits for you in taking part. You will, 
however, play an important part in raising awareness of what it means to live with 
hepatitis C virus and to suggest improvements for future support/care. Please see the 
Personal Information Sheet attached to this letter that will give you full details about the 
study. 
Please note that you do not have to take part in this project if you do not want to. It is 
completely voluntary. 
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If you would like to know more about the study or are willing to take part in it, we would 
ask you to send us an e-mail or to return the reply-slip attached. Should you have any 
questions, please do not hesitate to contact the research team: 
 
Researcher’s name:                                                    Chief Investigator:                 
                                                                                     
 
                                    Thank you for reading this letter 
                                    Please see below for the reply slip 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _  
Please cut this reply-slip out and send it in an attached envelope to the researcher. 
Please tick (√)  appropriate box: 
1) I would like to know more about the study and I give you my consent for contacting 
me through contact details indicated below in order to discuss the project further; 
 
2) I would like to take part in the project and I give you my consent for contacting me 
through contact details indicated below: 
                           
Name  __________________________        Date ______________________________  
Telephone_______________________        
Email________________________________ 
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      Appendix 5                                                                                                
                                   Participant Information Sheet  
Study Title: Experiences, attitudes and expectations of hepatitis C virus infection 
recurrence after liver transplantation: an interpretative phenomenological analysis. 
1.  Invitation Paragraph 
 You are being invited to take part in a research study looking at the personal experience, 
attitudes and expectations of hepatitis C virus infection recurrence after liver 
transplantation. Before you decide whether or not to take part, it is important for you to 
understand why the research is being carried out and what it will involve. Please take time 
to read through the following information carefully and discuss it with others, if you wish. 
Please ask me if there is anything that is not clear or if you would like more information.  
2. What is the purpose of this study? 
Edinburgh Napier University and the Out-Patients Department (OPD4) for 
Gastrointestinal and Liver Disorders at the Royal Infirmary of Edinburgh, are interested 
in the personal experience, attitudes and expectations of hepatitis C virus infection 
recurrence after liver transplantation. This project is interested in YOUR experiences of 
living with hepatitis C virus. We are interested in learning more about what the diagnosis 
of virus recurrence and liver transplantation has meant for you.  
3. Why have I been invited? 
We are contacting patients who were diagnosed with hepatitis C virus infection 
recurrence following liver transplantation and who were treated at the RIE in order to ask 
you to take part in this study. 
4. Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you do decide to take part you 
will be read this information, have an opportunity to ask questions and then you will be 
asked to give your written consent. If you decide to take part, you are still free to withdraw 
at any time, without giving reason and without your rights or future care being affected. 
It is important that you understand that a decision not to take part (or a decision to 
withdraw at any stage) will not affect the standard of your care or any future care that you 
require. 
 
5. What will happen if I take part? 
If you decide that you would like to be involved, you will take part in an interview about 
your experience of hepatitis C virus infection recurrence after liver transplantation. I will 
ask you to tell me about your experience of living with hepatitis C virus. You can talk 
about any aspect of your life that you wish. Sometimes, I might ask you to elaborate on 
something that you have said previously. I might also ask you give me some examples. 
Please remember that you do not have to answer any questions that you do not want to. I 
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simply want to understand what the diagnosis of hepatitis C virus infection recurrence 
means for you. With your permission, I will record the interview on a digital voice 
recorder. This is just so that I can give you my full attention and so that I can type the 
interview up at a later date. This is a normal procedure for this type of project.  
6. Will direct quotations from my statements be published? 
We will publish direct quotes from you but these will be anonymised by the use of 
pseudonyms.  
7. Where and when will the interview take place? 
We will arrange for the interviews to take place at the Welcome Clinical Research Facility 
at the RIE where we can book private and confidential rooms. If possible, we will arrange 
the interview on the day when you will be attending for follow-up appointments with your 
hepatologist. However, if you prefer that your interview is carried out in a place that is 
more convenient and comfortable for you, this can be arranged. 
 
8. What are the possible disadvantages and risks of taking part? 
It is possible that you might become upset due to the sensitive nature of the questions. 
Please remember that you do not have to answer any questions that you do not wish to. If 
you do feel uncomfortable, embarrassed or upset at any time, please just ask me to stop. 
You are free to withdraw from the research at any time. 
9. What are the possible benefits of taking part? 
There are no direct benefits for you in taking part. However, we hope that by your 
participating, we will gain a better understanding and deeper insight into what it means 
to live with hepatitis C virus. 
10. What happens when the research stops? 
After all of the interviews have taken place, they will be analysed by a member of the 
research team. The results may then be published in scientific journals and presented at 
relevant conferences. It is important that you understand that your name and personal 
details will always remain confidential and your name will be encoded under a false name 
agreed in the beginning of the interview. Under no circumstances would they ever be 
revealed in journal articles or at a conference. 
 
11. What if something goes wrong? 
If you have a complaint about any part of the research project, you must express that 
complaint to either the researcher, to Dr … (Supervisor of the study), Dr … (Director of 
the study), Prof … (Professor of Hepatology at the RIE) or to the NHS Research Ethics 
Committee 3.  
12. Will my taking part in this study be kept confidential? 
No-one beyond the research team will receive any information about you or your 
participation. Before we begin the interview, you will be asked to give me a false name. 
We will refer to that name at all times. This is to protect your anonymity. The tape 
recording of your interview will remain within a locked filing cabinet at Edinburgh Napier 
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University until the researcher has typed it up. No-one but the researcher can access your 
data. It will then be deleted. The data gathered will be safely stored on a password-
protected PC at Edinburgh Napier University, to which only I will have access. All data 
will be kept until the end of the assessment process, which is due by June 2017, and then 
will be securely deleted.  
Confidentiality in this study may be limited if I will deem, while conducting the interview, 
there to be a risk to you. In the event that you will become distressed or make a statement 
which gives cause for concern, I will as a certified Mental Health First Aider provide 
initial help to you. I will also need to contact an experienced member of staff within the 
liver transplant team (The Transplant co-ordinator <name>) who would be allied in to 
remain with you and contact your GP in order to inform him about the situation. However, 
this would be discussed with you prior to the disclosure of information. 
 
13. Contact for further information: 
 
Researcher’s name: Anna Krzeczkowska 
E-mail:  
or  
Director of the study: Dr … 
Edinburgh Napier University 
Sighthill Court 
Edinburgh, EH11 4BN 
Tel. 
14.  Independent contact person for further information: 
 
If you would like to talk to someone who knows about this research project but who is 
not directly involved in it, please contact: 
<Name of the independent contact person> 
Edinburgh Napier University 
Sighthill Court 
Edinburgh 
EH11 4BN 
                                                             Thank you 
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Appendix 6                                                                                                           
CONSENT FORM 
 
Title of Project: Experiences, attitudes and expectations of hepatitis C virus 
infection recurrence after liver transplantation: an interpretative 
phenomenological analysis. 
 
 
Name of Researcher: Anna Krzeczkowska 
 
 
Please tick (√) appropriate box: 
 
 
1. I confirm that I have read and understand the Participant Information Sheet dated............ 
for the above study. I have had the opportunity to consider the information,  
ask questions and have had these answered satisfactorily.  
 
                                        YES                 NO 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason, without my medical care or legal rights being affected.  
 
                                        YES                 NO 
 
3.  I understand that relevant sections of my medical notes and data collected during the study,  
may be looked at by individuals from Edinburgh Napier University and from regulatory authorities, or  
where it is relevant to my taking part in this research. I give permission for these  
individuals to have access to my records.  
 
                                        YES                 NO 
 
4.  I agree to my GP being informed of my participation in the study. 
 
                                        YES                 NO 
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5.          I agree to an experienced member of staff within the liver transplant team to be contacted if the researcher 
deems there to be a risk to my health and safety. 
 
                                        YES                                   NO 
6.           I agree to having the interview audio-taped.        
 
 
                                        YES                 NO 
                                                            
7.           I agree to publication of direct quotations from the interview by maintaining  my anonymity. 
 
                                        YES                 NO 
 
8.  I agree to take part in the above study.                                
 
YES                     NO 
 
 
 
 
 
_____________________ ________________  __________________________  
Name of Patient   Date    Signature  
 
 
_____________________  ________________  __________________________  
Name of Person  
taking consent                Date    Signature  
 
 
 
                 Thank you for agreeing to take part in this research 
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Appendix 7                                     
   
                         Participant Debrief Sheet  
 
Experiences, attitudes and expectations of hepatitis C virus infection 
recurrence after liver transplantation: an interpretative 
phenomenological analysis.  
 
Thank you for participating in the project. I appreciate your time. If you have any 
questions, concerns or you would like to find out about the results of the study, after the 
assessment will be finished, please do not hesitate to contact  
The researcher of this project: 
Anna Krzeczkowska by email:  
 
The Director of the study:                                                          The independent advisor: 
 
 
 
 
Should you have any questions or concerns about anything you have discussed in the 
interview, please contact:  
<designated person at the The Royal Infirmary of Edinburgh> 
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or any of the organisations listed below: 
 
 
- Waverley Care, support service for patients with HIV and hepatitis C virus by 
telephone: 0131 558 1425 or by email: david.cameron@waverleycare.org. 
 
- C Plus, 22 Laurie Street, Edinburgh, EH6 7AB; Tel: 0131 478 7929; email: 
cplus@addaction.org.uk. 
 
- Hepatitis C Trust helpline: 0845 223 4424 or 020 7089 6221 (open 10.30am to 
4.30pm Monday-Friday); or contact the organisation by email: 
helpline@hepctrust.org.uk. 
 
- The Samaritans by email: jo@samaritans.org or by telephone: 08457909090. 
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Appendix 8 
                                                     
 
                                        Interview Schedule 
1. Tell me about how you were diagnosed with hepatitis C. What thoughts/feelings 
did you experience?  
 
2. What impact has the diagnosis had on your life?  
 
3. Tell me about your experience of hepatitis C virus. 
 
4. When you were told that you needed a transplant, what were your thoughts? 
Hopes? Fears? 
 
5. What were your expectations of the liver transplantation? In what ways have 
they been met/not met?  
 
6. In what ways were you prepared for what you experienced after the liver 
transplant?  
 
7. Tell me about your life after the surgery. How has life changed for you since? 
 
8. How did you feel when the hepatitis C recurred?  
 
9. What impact has the diagnosis of infection recurrence had on your life?  
 
10. In what ways were you prepared for being diagnosed with the infection 
recurrence? Were you given any information, prior or after liver transplant, 
about possible outcomes? 
 
11. What impact have the liver transplant and the diagnosis of the infection 
recurrence had on your relationships with others (e.g. partner, family, friends 
etc).  
12. In what ways have your relationships with others changed as compared to the 
period before liver transplantation? How does that make you feel? How do you 
cope with that? 
13. What has been the most challenging aspect of the recurrence? Why?  
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14.  Considering the whole experience since the liver transplantation, can you think 
of anything that you would describe as positive?  
 
 
15. What are, in your opinion, the major difficulties you have experienced since 
being diagnosed with the virus recurrence. What or who influenced how you 
coped with them? 
 
16. How would you describe your  experience of all your treatment  and support 
from health professionals you are currently receiving? To what extent have they 
met your expectations? 
 
17. Is there any form of support/medical care that you think would be helpful for 
you? If so, in what ways might it be helpful? 
 
18. What or who would you say are your primary sources of help/support? In what 
ways are they helpful/not helpful? 
 
19. What advice would you give others who are concerned about how they might 
cope after a liver transplant? 
 
20. Is there anything else that we have not covered that you feel is important for me 
to understand experience of hepatitis C virus infection recurrence after liver 
transplantation from your perspective? 
 
 
 
